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ABSTRACT 
 
The gonadotropin-releasing hormone receptor (GnRHR), a member of the G protein-coupled receptor 
(GPCR) family, is a central regulator of reproductive function in all vertebrates. A central question in 
the field is to identify which hormones regulate the GnRHR gene, the signalling pathways that are 
activated, the transcription factors involved in mediating responses to various signals, and the 
complex interplay between all these factors. This study investigated the mechanisms of regulation of 
transcription of the mouse GnRHR gene in the mouse pituitary gonadotrope LßT2 cell line by GnRH 
and dexamethasone (dex). Real-time PCR showed that both dex and GnRH increase transcription of 
the endogenous mouse GnRHR gene. Chromatin immunoprecipitation (ChIP) assays revealed the 
presence of the activating protein-1 (AP-1) proteins c-Jun and c-Fos on the mouse GnRHR promoter 
under basal as well dex- and GnRH-stimulated conditions. Furthermore, recruitment of the 
glucocorticoid receptor (GR) to the AP-1 element in response to dex was established by ChIP and 
interestingly, treatment with GnRH also resulted in recruitment of the GR in the absence of steroid. 
Knockdown of GR levels by small interference RNA decreased the dex- and GnRH-induced 
upregulation of the GnRHR gene revealing a requirement for the GR for both the dex and GnRH 
response. ChIP and immunofluorescence assays provided evidence that both GnRH and dex 
upregulate the GnRHR gene via nuclear translocation and interaction of the GR with the AP-1 region 
on the mouse GnRHR promoter. It was also shown that GnRH activates the unliganded GR by rapid 
phosphorylation of the GR at Ser-234 in a GnRHR-dependent fashion to transactivate a GRE-reporter 
gene in LßT2 and COS-1 cells. Using kinase inhibitors a direct link was established between GnRH-
induced protein kinase C and mitogen-activated protein kinase activation, leading to unliganded GR 
phosphorylation at Ser-234 and transactivation of the glucocorticoid-response-element (GRE). 
Furthermore it was shown that GnRH and dex synergistically activate the endogenous GnRHR 
promoter in LßT2 cells, via a mechanism involving SRC-1 recruitment to the GnRHR AP-1 region. The 
results suggest a novel mechanism of rapid non-genomic cross talk between the hypothalamic-
pituitary-gonadal and hypothalamic-pituitary-adrenal axes via GnRHR-dependent phosphorylation and 
activation of the unliganded GR in response to GnRH.  
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THESIS OUTLINE 
 
Please note that sections of this study have been accepted for publication in Molecular Endocrinology 
(MS # ME-08-0464): 
GENOMIC AND NON-GENOMIC CROSS TALK BETWEEN THE GONADOTROPIN-RELEASING 
HORMONE RECEPTOR AND GLUCOCORTICOID RECEPTOR SIGNALLING PATHWAYS  
Andrea Kotitschke, Hanél Sadie-Van Gijsen, Chanel Avenant, Sandra Fernandes, Janet P. Hapgood  
 
 
This thesis contains the following sections:  
1.  A short introduction will outline the main field of the present study. 
2. A summary of the general hypotheses and aims of the study. 
3. Chapter 1: Literature review. This chapter gives a detailed overview of the current literature, 
with a focus on the expression and transcriptional regulation of the mouse GnRHR, the GR 
mechanism of action, non-classical GR action and GPCR cross talk. 
4.  Chapter 2: Materials and Methods. This chapter gives details regarding the experimental 
protocols used to obtain the results presented in chapters 3 to 5. 
5. Chapter 3: Results. In the first part of this study homologous- and GC-mediated 
transcriptional regulation of the mouse GnRHR gene was investigated in the mouse 
gonadotrope LßT2 cell line. A brief introduction the specific aims and the results will be 
presented in this chapter.  
6. Chapter 4: Results. The second part of the study was further investigating the ligand-
independent activation of the GR by GnRH which was found in Chapter 3, as well as the 
signalling pathways involved in dex- and GnRH-mediated transactivation. A short 
introduction will give an overview on the current knowledge in the field and specific aims are 
formulated. 
7. Chapter 5: Results. The 3rd results chapter contains results of an extensive study on the 
synergistic effect of dex plus GnRH on gene transcription. The chapter includes a brief 
introduction, aims and all the results obtained. 
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8. Chapter 6: Discussion and Conclusions. In this final chapter, the results presented in 
previous chapters 3 to 5 are discussed. This chapter also contains proposed models which will 
be discussed in context with the results obtained. In addition, some perspectives about future 
research are included. 
9. Addendum A: This addendum contains additional results from the study not presented in 
chapters 3 to 5. 
10. Addendum B: Results obtained by previous students in Prof. Hapgood’s laboratory are 
shown, which are relevant for the present study.  
11. Addendum C: This addendum contains sequences of all primers used in this study.  
12. Addendum D: This addendum contains information regarding buffers and solutions used in 
the experimental protocols.  
13.  The Bibliography contains a list of all the references used throughout the thesis in 
alphabetical order. 
14. Thereafter follows a copy of the publication “Genomic and non-genomic cross talk between 
the gonadotropin-releasing hormone receptor and glucocorticoid receptor signalling pathways” 
(2009) Kotitschke A, Sadie-Van Gijsen H, Avenant C, Fernandes S, Hapgood JP. Mol 
Endocrinol 23(11):1726-1745. 
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INTRODUCTION 
 
 
Gonadotropin-releasing hormone (GnRH) is the central endocrine regulator of reproduction. GnRH is 
a hypothalamic decapeptide synthesized by hypothalamic neurosecretory cells and released in a 
pulsatile fashion into the portal circulation (Fink, 1988). After binding to its cognate receptor (GnRHR) 
on pituitary gonadotropes, the hormone stimulates the biosynthesis and secretion of the 
gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn regulate 
gonadal steroidogenesis and gametogenesis in both sexes (Fink, 1988). The GnRHR is a member of 
the plasma membrane G-protein coupled receptor (GPCR) family (Bockaert and Pin, 1999) and is 
primarily expressed in the anterior pituitary in gonadotrope cells (Hyde et al., 1982). The expression of 
the GnRHR in various extra-pituitary tissues including the ovary, breast, placenta as well as hormone 
dependent tumors has been reported (Emons et al., 1989). Thus it has become evident that GnRH is 
a potentially important autocrine and/or paracrine regulator of local cellular functions in some extra-
pituitary tissues (Cheng and Leung, 2005; Hapgood et al., 2005).  
 
The responsiveness of the pituitary to GnRH is dependent on receptor numbers expressed on the cell 
surface which is in part regulated by GnRHR gene expression (Kaiser et al., 1993; Marian et al., 1981; 
Norwitz et al., 1999a; Savoy-Moore et al., 1980; Yasin et al., 1995). GnRH has been identified as a 
potent regulator of GnRHR gene expression in vivo (Kaiser et al., 1993; Wu et al., 1994; Yasin et al., 
1995) and in vitro. (Kaiser et al., 1993; Loumaye and Catt, 1982; Young et al., 1984). Although 
regulation of expression of GnRHR has been shown to occur at the transcriptional, translational and 
post-translational level, the underlying molecular mechanisms including signalling pathways and 
transcription factors involved have not been fully investigated.  
 
In addition to GnRH, other hormones have been shown to regulate GnRHR gene expression, 
including gonadal steroids such as estradiol and progesterone (Cheng et al., 2001), activin 
(Fernandez-Vazquez et al., 1996; Pernasetti et al., 2001) and pituitary adenylate cyclase-activating 
peptide (PACAP) (Cheng and Leung, 2001; Pincas et al., 2001). Furthermore, glucocorticoids (GCs) 
have also been shown in some cases to regulate GnRHR gene expression in vertebrates, although 
the underlying mechanisms are not well defined. Although chronic stress and GCs appear to 
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predominantly suppress gonadotropin secretion and reproduction, the effects of transient or acute 
stress are variable and the effects may depend on species and physiological status (Brann and 
Mahesh, 1991; Tilbrook et al., 2000). Clearly further work is required to determine the target cells, 
target genes, GC-receptors involved and mechanism of action of GC-mediated regulation of GnRHR 
gene expression. It is possible that a combination of one or all of these mechanisms may be involved, 
resulting in different responses.  
 
It is becoming increasingly clear that multiple signalling pathways are simultaneously activated in the 
same cell and these pathways cross talk to affect biological responses thereby possibly fine-tuning 
biological responses. The GnRHR may be a potential target facilitating cross talk between 
neuroendocrine-, stress- and immune-responses. Unravelling the molecular mechanism of this 
complex interplay between several hormones might add another level towards understanding receptor 
physiology and may be of great relevance to drug design since both GCs and GnRH are administered 
as therapeutic drugs.  
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AIMS AND HYPOTHESES 
 
The project was based of the following hypotheses: 
 
I) That the mouse GnRHR gene is transcriptionally upregulated by dexamethasone (dex) and 
 GnRH in LßT2 cells; 
II) That the activator-protein 1 (AP-1) regulatory element in the GnRHR promoter plays an 
 important role in GnRH- and dex-mediated regulation of the GnRHR due to binding of the  
 AP-1 proteins c-Jun and c-Fos to the promoter in intact LßT2 cells; 
III) That the glucocorticoid receptor (GR) is recruited to the AP-1 site in the GnRHR promoter as 
 an essential transcriptional factor mediating transcriptional regulation of the GnRHR gene 
 expression in response to dex in LßT2 cells; 
IV) That cross talk between the GnRHR and the GR results in rapid post-transcriptional 
 modifications of the GR, nuclear translocation of the receptor and transcriptional 
 activation of a glucocorticoid response element (GRE) in the absence of a GR ligand; 
V)  That mitogen-activated-protein kinases (MAPKs), protein kinase C (PKC), protein kinase A 
 (PKA) and tyrosine kinase (c-src) are important signalling pathways mediating transcriptional 
 effects of dex and GnRH in LßT2 cells; 
VI)  That dex synergistically enhances the GnRH-induced GnRHR gene expression in LßT2 cells; 
 
The aim of the first part of this study was to unravell the molecular mechanism of homologous and 
dex-mediated GnRHR gene regulation in LßT2 cells. In particular the project focused on the 
involvement of the AP-1 proteins c-Jun and c-Fos as well as the glucocorticoid receptor (GR) in 
mediating basal, GnRH-, and dex-mediated transcriptional regulation of the GnRHR gene. Therefore 
the protein expression levels as well as in vivo binding of these proteins to the AP-1 regulatory 
element in the GnRHR promoter were investigated. Furthermore a requirement for the GR in GnRHR 
gene expression was established by using GR specific siRNA. The second part of the study aimed to 
follow up and further investigate ligand independent activation of the GR by GnRH. Several steps of 
the classical GR mechanism of action were investigated including nuclear translocation, 
phosphorylation and transactivation. Furthermore, the signalling pathways activated in response to 
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dex and GnRH and their potential involvement in mediating transcriptional effect were investigated in 
this part of the study. In particular the three major MAPKs namely c-Jun N-terminal Kinase (JNK), 
extracellular regulated Kinase (ERK) and p38 as well as PKC, PKA and c-src were investigated in 
LßT2 cells. The last part of the study investigated the effect of dex plus GnRH on GnRHR gene 
expression. The underlying mechanism was investigated. More specific aims are presented in the 
relevant chapters. 
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CHAPTER 1 
LITERATURE REVIEW 
 
1.1 G-PROTEIN COUPLED RECEPTOR FAMILY 
1.1.1 G-protein coupled receptors  
Among membrane bound receptors G-protein coupled receptors (GPCR) form the largest and most 
diverse family of cell surface molecules that detect extracellular stimuli and activate intracellular signal 
transduction pathways and, ultimately, cellular responses (Bockaert and Pin, 1999). The wide array of 
stimuli that activate these receptors includes hormones, light, pheromones, peptides, 
neurotransmitters, lipids and ions. GPCRs share a common central core domain comprised of 7 
membrane spanning α-helices which are connected by 3 intracellular and 3 extracellular loops, as well 
as a carboxyl (C)-terminal intracellular domain and an amino (N)-terminal extracellular domain 
(Bockaert and Pin, 1999). These distinct domains confer specific properties to the GPCRs and 
contribute to ligand recognition, activation of the receptor, effector molecule binding and initiation of 
downstream signalling events (Bockaert and Pin, 1999; Millar et al., 2004). GPCRs are desensitized 
by sustained stimulation with ligand followed by internalization of the receptor. These processes 
require serine/threonine phosphorylation in the C-terminal tail (Carman et al., 1998; Liggett et al., 
1989; McArdle et al., 2002). 
 
GPCRs mediate signal transduction of extracellular stimuli through interaction of their intracellular 
domains with heterotrimeric G-protein. They consist of the Gα-subunit associated with GDP and the 
tightly associated Gβγ-subunits. More than 20 Gα-subunits are known and can be divided into four 
major classes of Gα-subunits: Gαs, Gαi, Gαq/11, and Gα12/13 (Kraus et al., 2001). Agonist binding to the 
GPCR induces a conformational change in the receptor that allows the exchanges of GDP for GTP on 
the Gα subunit. This exchange triggers the dissociation of the Gα-subunit, now bound to GTP, from the 
receptor and the Gβγ dimer. Both Gα-GTP and Gβγ can then activate different signalling cascades to 
regulate key biological functions (Ostrom et al., 2000). Depending on the class of G-protein to which 
the GPCR is coupled, a wide variety of downstream effector proteins and signalling pathways can be 
activated (Marinissen and Gutkind, 2001; Neves et al., 2002). The Gαs-subunit exerts its action by 
Un
ive
rsi
ty
of 
Ca
e T
ow
n
 2 
activating adenylyl cyclase (AC) which in turn increases intracellular levels of the second messenger 
cyclic adenosine monophosphate (cAMP) and results in activation of protein kinase A (PKA) (Beebe, 
1994; Birnbaumer, 1992). In contrast, the Gαi-subunit inhibits adenylyl cyclase but has been shown to 
be involved in activation of ion channels and phospolipases (PLs) (Birnbaumer, 1992; Naor et al., 
2000). The α-subunit of Gq activates primarily PLC which increases the second messengers 
diacylglycerol (DAG) and inositol (1,4,5)-triphosphate (IP3) leading to Ca2+ mobilization and activation 
of protein kinase C (PKC) (Naor et al., 2000; Ostrom et al., 2000). In addition it has become clear that 
ßγ-subunit dimers can mediate signal transduction pathways including activation of phosphoinositide-3 
kinase (PI3k), molecules in the MAPK pathways and PLC (Hur and Kim, 2002; Luttrell et al., 1995; 
Naor et al., 2000; Stephens et al., 1997). The combination of interactions of a GPCR with several G-
proteins may confer increased diversity and specificity of complex signalling pathways (Hur and Kim, 
2002). Because of the diverse array of ligands, the diversity of G-proteins and effector molecules, 
GPCRs regulate most biological functions including cell proliferation and growth, metabolism, cell 
survival and differentiation (Marinissen and Gutkind, 2001). 
 
 
 
Figure 1.1: The G-protein coupled receptor (GPCR) signaling network. Activation of the GPCR by 
ligand leads to the dissociation of the GDP-bound Gα-subunit and the tightly associated Gβγ-subunit 
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which are able to interact with a diverse array of effector molecules involved in signal transduction 
pathways to regulate key biological responses (Marinissen and Gutkind, 2001). 
 
1.1.2 The gonadotropin-releasing hormone receptor 
The gonadotropin-releasing hormone receptor (GnRHR) is a member of the plasma membrane G-
protein-coupled receptor (GPCR) family (Bockaert and Pin, 1999) which is primarily expressed in 
gonadotrope cells in the anterior pituitary (Hyde et al., 1982). The interaction of gonadotropin-
releasing hormone (GnRH) and its receptor initiates transduction of hormone signals across the cell 
membrane which is a crucial event in endocrine signalling. GnRH is a decapeptide secreted in a 
pulsatile fashion from the hypothalamus from where it travels through the hypophysial portal to the 
anterior pituitary (Fink, 1988). Upon binding of GnRH to its cognate receptor (GnRHR) on pituitary 
gonadotropes, a broad range of signalling cascades is activated leading to synthesis and secretion of 
the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) (Fink, 1988). The 
release of these two hormones stimulates gametogenesis and steroidogenesis in both sexes (Cheng 
and Leung, 2005). Changes in frequency and amplitude of GnRH pulses have differential effects on 
the synthesis rate of LHβ and FSHβ in the gonadotropes (Shupnik, 1996) and result in a differential 
secretion pattern of these hormones thereby regulating the synthesis and release of sex hormones in 
the gonads (Fink, 1988; Millar et al., 2004). In turn, sex hormones such as androgens and estrogens 
regulate GnRH responsiveness via positive and negative feedback loops to the hypothalamus and the 
anterior pituitary (Gharib et al., 1990). 
 
The first primary structure of the mammalian GnRHR was determined by sequencing of the receptor 
cDNA isolated from an immortalized murine gonadotrope cell line (αT3-1 cells) (Reinhart et al., 1992; 
Tsutsumi et al., 1992). Subsequently, the sequences of GnRHRs from several mammalian species 
including rat (Eidne et al., 1992), sheep (Brooks et al., 1993), human (Chi et al., 1993), bovine (Kakar 
et al., 1993), pig (Weesner and Matteri, 1994) as well as non-mammalian vertebrates have been 
described (Millar et al., 2004). These receptors were all designated as type I GnRHRs. The 
mammalian type I GnRHR lacks a C-terminal tail setting it apart from non-mammalian GnRHRs and 
other GPCRs, and appears not to undergo agonist-induced receptor desensitisation and thus 
internalizes slowly (Kaiser et al., 1997; McArdle et al., 2002).  
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At least two isoforms of the peptide hormone GnRH (GnRH I and GnRH II) have been found in most 
vertebrates, however only type I GnRHR proteins have been identified in pituitary as well as extra-
pituitary tissues and cell lines from several mammalian species (Millar, 2003; Pawson et al., 2003; van 
Biljon et al., 2002). Although type II GnRHR transcripts have been detected in most vertebrates, 
expression of a functional type II GnRHR protein has not been conclusively shown and its precise role 
remains to be elucidated (Millar et al., 2004; Morgan et al., 2003; Neill, 2002; van Biljon et al., 2002) 
 
1.1.3 Tissue distribution and physiological function of the GnRHR  
The GnRHR was first identified exclusively in pituitary gonadotropes (Fink, 1988; Hyde et al., 1982; 
Kaiser et al., 1997). Here, binding of GnRH to its receptor activates intracellular signal transduction 
pathways to affect the synthesis of the heterodimeric glycoprotein hormones composed of the 
common subunit α and the specific ß-subunits LHβ and FSHβ (Gharib et al., 1990; Hamernik, 1995). 
The pulsatile release of these gonadotropins regulates development, growth, pubertal maturation, and 
reproductive processes by the release of sex steroids. Naturally-occuring mutations of GnRHR have 
been associated with a condition named hypogonadotropic hypogonadism with symptoms such as the 
absence of secondary sexual characteristics, delayed onset of puberty or low sex steroid levels (Millar 
et al., 2004; Seminara et al., 1998) demonstrating a crucial role of the receptor in the physiology of 
reproduction (Naor, 2009). GnRHR agonists and antagonists have been widely used in clinical 
applications such as treatment of infertility, hormone-dependent diseases and cancers (Conn and 
Crowley, 1994; Neill, 2002). 
 
In addition to its established endocrine role in gonadotropin regulation in the pituitary, there is 
accumulating evidence in the literature showing that the GnRHR is widely expressed in various extra-
pituitary mammalian tissues and cells including reproductive tissues and non-reproductive tissues 
suggesting a functional role for GnRH and its receptor as an important autocrine and/or paracrine 
regulator in diverse extra-pituitary tissues (Cheng and Leung, 2005; Hapgood et al., 2005). In female 
reproductive tissues GnRH, acting via the GnRHR, has been shown to be involved in regulation of the 
menstrual cycle (Raga et al., 1998), ovarian steroidogenesis (Guerrero et al., 1993), embryo 
implantation and maintenance of pregnancy (Rama and Rao, 2001). In male reproductive tissues 
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GnRH and its cognate receptor have been shown to play a role in testis and sperm development 
(Cheung and Hearn, 2003) as well as sperm oocyte interaction (Morales, 1998). 
 
Functional GnRHR has been detected in a wide range of the carcinomas and tissues originating from 
the endometrium, ovary, breast and in tumors not related to the reproductive system such as 
melanoma (Imai et al., 1994; Imai and Tamaya, 2000; Limonta et al., 2003). The expression of the 
receptor in cancer tissues implies that GnRH may have a direct regulatory role in cell proliferation 
(Imai and Tamaya, 2000). It is well known that GnRH analogues can inhibit proliferation in human 
malignant tumors (Cheng and Leung, 2005; Grundker et al., 2002). The anti-tumor effects appear to 
be mediated via inhibition of gonadotropins and gonadal steroids and modulation of growth factor or 
cytokine expression (Cheng and Leung, 2005). However the intracellular mechanisms mediating the 
antiproliferative effects are not yet fully understood (Pawson et al., 2003). 
 
A few studies support an active role for GnRH in regulating immune responses. GnRH has been found 
to interact directly with T-cells and stimulate adhesion, migration and homing of normal T-cells into 
specific organs (Chen et al., 2002). In addition GnRHRs have been identified in the spleen and thymus 
in mice and the expression of the receptor was increased in response to GnRH in immune cells 
(Jacobson et al., 1998).  
 
1.1.4 GnRHR signalling pathways  
The nature of the intracellular signalling pathways initiated by the GnRHR has been shown to vary 
between cell types. It was proposed that the GnRHR may exert its various effects by interacting with 
several G-proteins (Liu et al., 2002b; Stanislaus et al., 1998). By contrast, GnRHR may interact with a 
single G-protein leading to activation of different downstream signalling cascades (Grosse et al., 2000; 
Naor, 2009). It was reported that the GnRHR interacts mainly with Gq/11 in αT3-1 pituitary gonadotrope 
cell lines (Grosse et al., 2000; Hsieh and Martin, 1992; Naor et al., 1986) while other investigators 
show that the GnRHR can couple to Gq/11, Gi and Gs in rat pituitary cell cultures (Hawes et al., 1993; 
Stanislaus et al., 1998) and LßT2 cells (Knollman and Conn, 2008; Kraus et al., 2001; Liu et al., 
2002b; Yokoi et al., 2000). 
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Several reports in the literature have further unravelled the downstream kinase pathways in 
gonadotrope cell lines. In pituitary derived αT3-1 cells GnRH activates PLCß which enhances the 
turnover of phosphoinositide, leading to increased levels in DAG and IP3 and activation of various 
PKC subspecies (Harris et al., 1997). GnRH can induce mobilization of intracellular Ca2+ and influx of 
extracellular Ca2+ which are important triggers for GnRH-mediated secretion of LH and FSH (Naor, 
1990; Stojilkovic and Catt, 1995). In addition GnRH stimulation was shown to elevate intracellular 
cAMP level in rat pituitary cultures (Borgeat et al., 1972) and LßT2 cells (Lariviere et al., 2007), but not 
in αT3-1 cells (Horn et al., 1992; Kanasaki et al., 2002) which is consistent with the finding that the 
GnRHR couples exclusively to Gq/11 in αT3-1 cells (Grosse et al., 2000) whereas the receptor couples 
to both Gs and Gq in LßT2 cells (Liu et al., 2002b). Activation of a number of mitogen-activated protein 
kinases (MAPK) by GnRH in pituitary cells has been demonstrated and appears to depend on the cell-
context (Dobkin-Bekman et al., 2006; Kraus et al., 2001; Naor, 2009; Yokoi et al., 2000). MAPK 
kinases (MKKs) catalyze the phosphorylation of MAPK and thereby increase their activity (Johnson 
and Lapadat, 2002). Inversely, phosphatases dephosphorylate MAPKs and return them in an inactive 
state. The MAPK family is composed of four major subfamilies of kinases: extracellular-regulated 
kinases (ERK1,2) also known as p42/p44; ERK5 (big MAPK), the c-Jun-N-terminal kinases 
(JNK1/2/3), and p38 (α,β,β2,γ,δ) (Harris et al., 2002; Johnson and Lapadat, 2002; Liu et al., 2002a; 
Liu et al., 2002b; Pearson et al., 2001; Yokoi et al., 2000). An important characteristic of MAPKs is 
their ability to translocate to the nucleus and activate gene transcription (Naor et al., 2000; Pearson et 
al., 2001). Upon stimulation of the GnRHR extracellular signal-regulated kinase (ERK), c-Jun-N-
terminal kinase (JNK) and p38 are activated in both αT3-1 and LßT2 cells, by both protein kinase A 
(PKA) - and protein kinase C (PKC) -dependent and -independent pathways (Bonfil et al., 2004; Liu et 
al., 2002a; Liu et al., 2003; Mulvaney et al., 1999; Roberson et al., 1999; Sundaresan et al., 1996). In 
addition, GnRH activates phosphoinositide-3-kinase (PI3K) and src-tyrosine kinase (c-src) in LßT2 
cells (Bonfil et al., 2004; Kanasaki H, 2006).  
 
1.1.5 Mammalian GnRHR gene structure 
Cloning of the GnRHR gene from mouse (Zhou and Sealfon, 1994), human (Fan et al., 1995), pig 
(Jiang et al., 2001), sheep (Campion et al., 1996) and rat (Reinhart et al., 1997) reveals that the gene 
contains two introns and three exons (Fan et al., 1994; Kakar, 1997). Exon 1 encodes the 5’- 
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untranslated region (UTR), the transmembrane (TM) domains I to III and a portion of TMD IV. Exon 1 
is separated by a 4,2 kb intron from exon 2 which encodes the remainder of the TMD IV, TMD V and 
part of the intracellular loop 3. Exon 3 is followed by a 5 kb intron and encodes the remaining 
sequence of the open reading frame which includes TMD VI, VII and the 3’-UTR (Chi et al., 1993; 
Kakar, 1997; Kakar et al., 1992). Location of all exon-intron boundaries are perfectly conserved 
amongst the different species (Cheng and Leung, 2005). The GnRHR gene exists as a single copy 
gene and encodes a 327 to 328-amino acid protein (Cheng and Leung, 2005; Fan et al., 1994).  
 
 
 
Figure 1.2: Structural organization of the human GnRHR I gene  
Exons (I, II and III) are illustrated as boxes, with portions of exons containing coding sequences shown 
in black and untranslated regions in white. Sizes of coding portions are indicated above in 
kilobasepairs. The sizes of the introns separating the exons are indicated below. (Hapgood et al., 
2005) 
 
1.1.6 Mouse GnRHR promoter characterization 
The 5’–flanking region of the mouse GnRHR gene has been cloned and the major transcriptional start 
site has been identified 62 nucleotides upstream of the translational start site (Albarracin et al., 1994). 
While several minor transcriptional start sites were found to be present further upstream in the 
promoter, TATA or CAAT sequences were found to be absent from the promoter region (Albarracin et 
al., 1994). Albarracin et al. further demonstrated in transient transfection studies that a 1.2 kb mouse 
GnRHR genomic fragment fused to luciferase reporter gene appears to be sufficient to direct high 
levels of transcription in αT3-1 cells. This region appears to be pituitary- and gonadotrope-specific 
since considerably lower reporter expression occurred in transfected rat somatolactotropic GH3 cells 
Un
ive
sit
y o
f C
ap
e T
ow
n
 8 
and only very low expression levels were found in the transfected placental cell line JEG-3 and the 
kidney fibroblast cell line CV-1 (Albarracin et al., 1994; Kaiser et al., 1997). Sequencing analysis 
revealed a consensus activator protein-1 (AP-1) element at position -336/-330 relative to the 
translational start site as well as a gonadotrope-specific element (GSE)-like sequence at position -15/-
7 (Albarracin et al., 1994; Kaiser et al., 1997). The latter has been identified as a binding site for the 
orphan nuclear receptor steroidogenic factor-1 (SF-1) (Duval et al., 1997a). Clay et al. showed that 
elements residing between -500 and -400 bp relative to translational start site of mouse GnRHR 
promoter confer cell-specific expression (Clay et al., 1995) and other investigators identified an 
tripartite enhancer element that regulates cell specific expression comprised of a binding site for SF-1 
at -244/-236 bp (Duval et al., 1997a), a consensus AP-1site at -336/-330 bp and an element referred 
to as GnRHR activating sequence (GRAS) at -391/-380 bp relative to translational start site (Duval et 
al., 1997b). GRAS was found to contain overlapping functional elements and binding sites for SMAD, 
AP-1 and FoxL2 proteins (Ellsworth et al., 2003a; Norwitz et al., 2002b). In addition a region 
designated Sequence-underlying Responsiveness to GnRH-1 (SURG-1) has been identified including 
binding sites for Oct-1 and nuclear factor Y (NF-Y) (Kam et al., 2005). Furthermore a region termed 
DARE (down-stream activin regulatory element) was found to contain binding sites for LHX2 a 
member of the LIM homeodomain family (Cherrington et al., 2005), as well as an ATTA element 
located at -360 bp in the proximal GnRHR promoter where LHX3 was shown to bind in vitro and in 
vivo (McGillivray et al., 2005).  
 
 
 
Figure 1.3: Functional elements in the mouse GnRHR promoter 
Functional cis-elements that have been characterized are shown as black boxes. Transcription start 
sites (arrows) and the translation start site (ATG) are indicated. Abbreviations: SF-1 = steroidogenic 
factor-1 binding site; CRE = cAMP response element; AP-1 = activator protein 1 binding site; Oct-1 = 
octamer transcription factor-1 binding site; GRAS = GnRH receptor activating sequence; DARE = 
downstream activin response element; SURG = sequence underlying responsiveness to GnRH; NF-Y 
= nuclear factor-Y binding site (Hapgood et al., 2005). 
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1.2 TRANSCRIPTIONAL REGULATION OF THE GnRHR GENE 
1.2.1 Homologous regulation of GnRHR gene expression 
The responsiveness of the pituitary to GnRH is dependent on receptor numbers expressed on the cell 
surface which is in part regulated by GnRHR gene expression (Kaiser et al., 1993; Marian et al., 1981; 
Norwitz et al., 1999a; Savoy-Moore et al., 1980; Yasin et al., 1995). Several hormones including 
GnRH regulate GnRHR gene expression in vivo (Kaiser et al., 1993; Wu et al., 1994; Yasin et al., 
1995). Studies in rats showed that pulsatile administration of GnRH upregulated GnRHR expression 
while continuous stimulation with GnRH did not increased pituitary GnRHR mRNA levels (Yasin et al., 
1995). In contrast, continuous GnRH administration in sheep reduced GnRHR mRNA and protein 
levels (Wu et al., 1994). 
 
Early reports indicate that continuous administration of low doses of GnRH increased GnRHR 
numbers in cultured rat pituitary cells (Loumaye and Catt, 1982; Loumaye and Catt, 1983; Young et 
al., 1984). However, another study in rat pituitary primary cultures showed that continuous GnRH 
treatment had no effect on GnRHR mRNA levels, but that pulsatile GnRH administration increased 
GnRHR mRNA levels (Kaiser et al., 1993). 
 
In the incompletely differentiated αT3-1 cell line changes in receptor numbers without changes in 
mRNA levels have been reported after short term (20 min) stimulation with 0,1 nM or 1 nM GnRH 
(Tsutsumi et al., 1993). In a later study by the same group it was found that continuous stimulation 
with 1 µM GnRH over 24 h decreased GnRHR numbers without any effect on GnRHR mRNA levels 
(Tsutsumi et al., 1995). In contrast to these findings, GnRHR mRNA levels were found to increase 
after 4 h of stimulation with 100 nM GnRH and only decreased after longer incubations in αT3-1 cells 
(Norwitz et al., 1999a). Consistent with these results, mouse GnRHR promoter-reporter constructs 
transfected into αT3-1 cells responded significantly after 4 h to continuous treatment with 100 nM 
GnRH (Norwitz et al., 1999a; Sadie et al., 2003; White et al., 1999). Responsiveness to GnRH was 
localized to two sequences namely SURG-1 and SURG 2 (Norwitz et al., 1999a). SURG-2 as 
described earlier contains the consensus AP-1 binding site which is a critical component in regulation 
of the mouse GnRHR gene by GnRH in αT3-1 cells (Norwitz et al., 1999a). Homologous regulation via 
SURG-2 appears to be mediated by increased binding of AP-1 proteins in a PKC- and JNK-dependent 
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fashion in αT3-1 cells (Ellsworth et al., 2003b; Norwitz et al., 1999a; White et al., 1999). A later study 
by Norwitz et al. demonstrated that GnRH-mediated transcriptional activation of the mouse GnRHR is 
in part mediated by increased binding of SMAD and AP-1 protein complexes to an overlapping 
GRAS/SBE (SMAD-binding-element) element of the promoter (Norwitz et al., 2002b). In addition 
GnRH-mediated increase in binding of the nuclear proteins Oct-1 and NF-Y to SURG-1 in vivo has 
been proposed to direct expression of the mouse GnRHR gene (Kam et al., 2005).  
Very few reports have been published on homologous regulation of GnRHR gene expression in the 
more differentiated gonadotrope cell line LβT2. Turgeon et al. found that GnRHR mRNA levels are 
upregulated in response to pulsatile GnRH administration after 3 days of treatment (Turgeon et al., 
1996), and another study demonstrated that pulsatile GnRH stimulation for 10 h increased 
transcriptional activity of a transfected mouse GnRHR promoter construct as well as receptor levels on 
the cell surface (Bedecarrats and Kaiser, 2003). By contrast, in the same study Bedecarrats et al. 
found that continuous GnRH treatment had little effect on GnRHR-reporter activity in LßT2 cells and 
receptor levels appeared to be downregulated after 10 h of continuous stimulation (Bedecarrats and 
Kaiser, 2003). 
 
1.2.2 Regulation of GnRHR gene expression by gonadal steroid hormones 
In early studies estradiol was found to increase GnRHR numbers in vivo (Crowder and Nett, 1984; 
Savoy-Moore et al., 1980; Wu et al., 1994) and in primary pituitary cultures (Gregg et al., 1990; Laws 
et al., 1990) suggesting that augmented receptor numbers may contribute to increased pituitary 
sensitivity to GnRH during preovulatory LH surge. Although it has been proposed that the estradiol-
mediated increase in receptor numbers is mediated at the transcriptional level (Duval et al., 2000; Wu 
et al., 1994), in pituitary derived cell lines it was found that estradiol either downregulates GnRHR 
numbers in αT3-1 cells (McArdle et al., 1992) or had little effect on endogenous GnRHR mRNA in 
LβT2 cells (Turgeon et al., 1996).  
Several studies suggest a negative regulatory effect of progesterone on GnRHR expression in the 
pituitary since high levels of progesterone were found to correlate with reduced GnRH sensitivity of the 
pituitary (Marrs et al., 1981; Reyes et al., 1976; Rubinstein et al., 1978; Sowers et al., 1978). 
Consistent with this hypothesis GnRHR numbers were found to decrease during the luteal phase of 
the estrous cycle (Crowder and Nett, 1984). In addition further studies revealed that GnRHR mRNA 
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levels were decreased in the presence of progesterone in primary ovine pituitary cultures (Sakurai et 
al., 1997; Wu et al., 1994), further supporting a direct effect of progesterone on GnRHR expression in 
the pituitary. Recent results with the transfected human GnRHR promoter in αT3-1 cells show that 
progesterone decreased GnRHR promoter activity via direct transcriptional effects through binding of 
the PR to a putative GRE-PRE in the human GnRHR promoter (Cheng et al., 2001).  
Similarly, testosterone was found to exhibit a negative effect on GnRHR transcription since mRNA 
levels appeared to decrease in the presence of the steroid hormone (Kaiser et al., 1993; Zapatero-
Caballero et al., 2003). Consistence with these findings GnRHR numbers were found to decrease in 
primary pituitary cultures from male rats after treatment with α-dihydrotestosterone (DHT) (Tibolt and 
Childs, 1985). However, a study by Curtin et al. demonstrated that stimulation with DHT resulted in 
upregulation of GnRHR mRNA levels in LßT2 cells (Curtin et al., 2001). 
 
1.2.3 Regulation of GnRHR gene expression by glucocorticoids 
In addition to sex steroids, glucocorticoids (GCs) have also been shown to regulate GnRHR gene 
expression in mammals, although the underlying mechanisms are not well defined. It has been 
reported that GCs play an important role in modulating GnRHR levels as part of a feedback 
mechanism from the adrenal to the pituitary (Breen and Karsch, 2004; Daley et al., 1999; Rosen et al., 
1991; Tilbrook et al., 2000). Rosen et al. have shown that GCs augmented GnRH-induced increase in 
GnRHR numbers in rats (Rosen et al., 1991). In contrast another study in sheep showed that cortisol 
resulted in decreased GnRHR protein levels while the mRNA levels remained unchanged (Daley et 
al., 1999). Similarly, cortisol was found to decrease responsiveness to GnRH in the pituitary 
independent of changes in GnRHR gene expression (Breen et al., 2008). There is evidence for direct 
effects of GCs on GnRHR transcription in gonadotrope cells of the pituitary, with dexamethasone (dex) 
upregulating expression of both the endogenous GnRHR gene and a transfected mouse GnRHR 
promoter-reporter construct in LβT2 cells (McGillivray et al., 2007; Turgeon et al., 1996). These results 
are consistent with those of Maya-Nunez et al. showing that GCs can upregulate activity of the mouse 
GnRHR promoter in the somatolactotrope GGH3 cell line expressing exogenous GnRHR (Maya-Nunez 
and Conn, 2003). Furthermore, the authors suggest that the GC-activated glucocorticoid receptor 
(GR) interacts with AP-1 proteins to increase GnRHR transcription, although the they do not provide 
experimental evidence for this mechanism (Maya-Nunez and Conn, 2003). 
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1.3 EFFECTS OF STRESS ON REPRODUCTION 
Chronic and acute stress have been implicated in regulation of reproduction in mammals although the 
underlying mechanisms are not well defined and the results are contradicting. While chronic stress 
appears to predominantly suppress gonadotropin secretion and reproduction, the effects of acute 
stress have been found to either inhibit or enhance reproductive function (Brann and Mahesh, 1991; 
Tilbrook et al., 2000). The effects of stress on reproduction are mediated by GCs from the adrenals as 
part of a cross talk mechanism between the hypothalamic-pituitary-adrenal (HPA) and hypothalamic-
pituitary-gonadal (HPG) axes (Rivier and Rivest, 1991). 
The inhibitory effects of stress on reproduction were shown to be mediated by corticosterone- or 
cortisol-mediated inhibition of LH secretion in rat primary pituitary cultures (Kamel and Kubajak, 1987) 
or ovariectomized ewe respectively (Breen and Karsch, 2004). The latter study suggested that cortisol 
suppresses pulsatile LH secretion by inhibiting pituitary responsiveness to GnRH rather than by 
suppressing hypothalamic GnRH release (Breen and Karsch, 2004). Evidence for direct effects of 
GCs on the pituitary comes from reports in the literature showing that cortisol inhibits GnRH-induced 
LH release from bovine and porcine pituitary cultures (Li, 1994; Padmanabhan et al., 1983). In 
addition, cortisol was found to inhibit the estrogen-induced increase in GnRHR mRNA and protein 
suggesting a suppressive effect of GCs on GnRHR gene expression (Adams et al., 1999). In contrast, 
an early study found that pulsatile administration of GnRH increased GnRHR mRNA levels in rat 
pituitary cells, and the effect was further increased by dex (Rosen et al., 1991). These results suggest 
a stimulatory effect on reproduction of GCs via increasing GnRHR (Rosen et al., 1991). Furthermore, 
in cultured rat pituitary cells (Baldwin et al., 1991; Brann and Mahesh, 1991; Kilen et al., 1996; 
McAndrews et al., 1994) and rat pituitary fragments (D'Agostino et al., 1990) GC stimulation increased 
FSHβ synthesis and secretion, while having no effect or decreasing LH levels. The GnRH-stimulated 
secretion of FSH was also enhanced in pituitaries from both male and female rats after in vitro 
incubation with either corticosterone or cortisol (D'Agostino et al., 1990).  
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1.4 STEROID HORMONE RECEPTORS 
1.4.1 The glucocorticoid receptor 
Steroid hormone receptors such as the glucocorticoid receptor (GR), the androgen receptor (AR), the 
mineralocorticoid receptor (MR), the progesterone receptor (PR) and the estrogen receptor (ER) are 
members of the nuclear receptor subfamily 3 (Evans, 1988; Griekspoor et al., 2007; Gronemeyer et 
al., 2004; Mangelsdorf et al., 1995). These receptors are modulator proteins sharing a common 
structural organization that contains distinct functional regions including a divergent N-terminal 
transactivation domain (NTD), a highly conserved central zinc-finger DNA-binding domain (DBD) and 
a less conserved C-terminal ligand-binding domain (LBD). The NTD of the GR harbours a region 
known as the activation function-1 (AF-1) domain which has been shown to interact directly with 
components of the basal transcription machinery and many cofactors involved in transcriptional 
regulation (Dahlman-Wright et al., 1995; Heitzer et al., 2007; McEwan et al., 1993). The central DBD 
contains two zinc-finger motifs where each zinc atom is coordinated in a tetrahedral arrangement by 
four cysteins. The amino acids of the first zinc-finger enable the receptor to bind specific DNA 
sequences in target promoters and those of the second zinc-finger are important for receptor 
dimerization with another GR monomer (Dahlman-Wright et al., 1991). A variable hinge region is 
adjacent to the DBD. This region enables the receptor to change conformation and contains a nuclear 
localization sequence (NLS) (Picard and Yamamoto, 1987). A second activation function domain (AF-
2) is present at the LBD at the C-terminal end of the receptor.  
 
 
 
 
Figure 1.4: Functional domains of the glucocorticoid receptor 
GR functional domains include the DNA-binding domain (DBD), ligand-binding domain (LBD), the 
hinge region (h) and two transactivation domains (AF1 and AF2) and are indicated in the boxes 
(Kassel and Herrlich, 2007). 
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The human GR was first cloned in 1985 (Hollenberg et al., 1985) and is a ubiquitously expressed 
protein found in almost all cell types and tissues (Gross et al., 2009). Since then, five GR protein 
subtypes arising from alternative splicing have been identified, namely GRα, GRβ, GRγ, GR-A and 
GR-P. GRα is known as the classic, functional receptor and consists of 777 amino acids. The shorter 
GR isoform GRß, made up of 742 amino acids, shares an identical NTD with GRα and can be 
distinguished from GRα by a differential C-terminal end. In addition alterative translation initiation 
results in more diverse GR proteins, i.e. GRα-A, GRα-B, GRα-C1, C2, D1, D2 and D, respectively. All 
the translational GR isoforms were detected in mouse and rat; however the expression levels were 
found to be different to human tissues (Lu and Cidlowski, 2005). The existence of several GR isoforms 
may represent one mechanism for modulating differential cellular responsiveness to glucocorticoids 
(GCs). 
The endogenous ligands of the GR, cortisol and corticosterone in humans and rodents respectively, 
are synthesized in the adrenal cortex (Liberman et al., 2007). The release of GCs is under the control 
of the hypothalamic-pituitary-adrenal axis. Corticotropin-releasing hormone (CRH) is secreted in the 
hypothalamus triggering the release of adrenocorticotropin hormone (ACTH) which in turn stimulates 
the synthesis of steroids in the adrenal cortex (Chrousos, 1995). The GR and GCs play a crucial role 
in control of homeostatic and adaptive processes including metabolic, immune, neural, and 
behavioural mechanisms (Bloom et al., 1982; De Kloet et al., 1998; Wiegers and Reul, 1998). Given 
the essential role of GCs they are extensively applied as therapeutics in many immune and 
inflammatory diseases including acute and chronic asthma, rheumatoid arthritis as well as in cancer 
treatment (Barnes, 2006; Rhen and Cidlowski, 2005). 
 
1.4.2 GR mechanism of action  
GCs are highly lipophilic and are either transported bound to corticosteroid-binding-globulin (CBG) or 
diffuse across the plasma membrane (Hammes et al., 2005). In the absence of hormone the GR is 
localized mostly in the cytoplasm in a multiprotein complex associated with multiple chaperones such 
as heat-shock proteins (hsp) 90, 70 or 40 and co-chaperones like the immunophilins FKBP 51 and 
FKBP 52, cyclophilin 40 or protein-phosphatase 5 (Cheung and Smith, 2000; Pratt et al., 1996; Pratt 
and Toft, 1997). The LBD of the GR contains a sequence to facilitate protein-protein interaction with 
hsp90. This interaction enables proper folding of the receptor and maintains the GR in a conformation 
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that prevents DNA binding in the absence of hormone (Griekspoor et al., 2007). In the classical 
cascade of events ligand binding induces rearrangements of the GR heteroprotein complex resulting 
in dissociation from the cytoplasmic chaperones and the exposure of its nuclear localization 
sequences (NLS) (Zhou and Cidlowski, 2005). These signals are recognized by nuclear translocation 
proteins such as importins (Freedman and Yamamoto, 2004) which actively shuttle the GR into the 
nucleus where the ligand-activated GR interacts at regulatory promoter regions of target genes to 
either enhance/initiate transcription (transactivation) or down regulate transcription (transrepression) 
(Newton and Holden, 2007). 
 
It has become apparent from many studies that the GR can modulate gene expression by interacting 
with other regulatory transcription factors (Kassel and Herrlich, 2007). The activated GR initiates the 
assembly of distinct multiprotein complexes on the promoter that include co-activator proteins, 
chromatin remodelling factors and other transcription factors involved in transcriptional regulation to 
enhance or repress transcription according to the composition of the complex (Hayashi et al., 2004; 
Newton and Holden, 2007). In fact many factors determine the outcome of the transcriptional 
response mediated by the GR. It has been proposed that modulation of the receptor through specific 
ligands, post-transcriptional modifications of the receptor, the specificity of the promoter architecture in 
the target promoter as well as the availability of specific cofactors and other transcription factors 
significantly contribute to the diverse effects of the GR (Chinenov and Rogatsky, 2007). 
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Figure 1.5: GR-mediated transcriptional regulation 
Upon ligand binding the cytosolic GR dissociates from the multiprotein complex and translocates to 
the nucleus where the receptor modulates gene transcription via direct interaction with specific DNA-
elements (a), cross talk at the promoter elements without GR binding sites such as AP-1 or NF-κB (b) 
or at composite sites (c). GCs = Glucocorticoids, GR = glucocorticoid receptor, Hsp = heat shock 
protein, GTM = general transcription machinery, TF = transcription factor.  
 
 
1.4.2.1 Control of gene expression by DNA binding of the GR 
The classical model of GR function involves a number of steps including transformation of the receptor 
to an active form upon ligand binding, homodimerization (Griekspoor et al., 2007) followed by binding 
of the liganded receptor to specific palindromic DNA consensus sequence (Nordeen et al., 1990; 
Strahle et al., 1987) termed the glucocorticoid response elements (GRE) located within regulatory 
promoter regions of GC-responsive gene and modulation of gene expression of target genes. Genes 
positively regulated by the GR contain GREs consisting of two conserved 6-base pair half-sites 
separated by three nonconserved bases: 5’-GGTACAnnnTGTTCT-3’ (Nordeen et al., 1990; Strahle et 
al., 1987). However, gene sequences recognized by the GR have been found to deviate from the 15 
bp consensus sequence but maintain specific functional groups on critical nucleotides within each half 
site (Heitzer et al., 2007; So et al., 2007). The GR has been shown to bind to the GRE as a 
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homodimer whereby the dimerization occurs via distinct hydrophobic motifs within the ligand binding 
domain and is stabilized by interactions in the DNA binding domain of each GR molecule (Bledsoe et 
al., 2004; Luisi et al., 1991). When bound to the DNA the GR serves as a platform for recruitment of 
transcription factors and in addition the GR itself was found to interact with several members of the 
transcriptional machinery like the transcription factor TFIIB or TATA-box binding protein (TBP) to 
induce transcription (Ford et al., 1997; Horwitz et al., 1996). Another group of co-activators are 
components of large complexes such as thyroid receptor associated proteins (TRAP) and vitamin D 
interacting proteins (DRIPS) (Heitzer et al., 2007). The GR has been shown to interact with BRG1, a 
component of the SWI-SNF chromatin remodelling complex, and this interaction leads to improved 
accessibility of the promoter region for several cofactors and the basal transcription machinery (BTM) 
(Fryer and Archer, 1998). Furthermore, the GR can interact with other co-regulatory factors at both 
activation domains of the GR in a ligand-dependent fashion (Gronemeyer et al., 2004; Rosenfeld et 
al., 2006). CREB-binding protein (CBP) and p300, which serve as co-activators for a wide variety of 
transcription factors including the GR, posess histone acetyltrasferase activities and are able to 
remodel chromatin structure and promote transcription (Heitzer et al., 2007; McKenna et al., 1999). 
Chromatin modification is considered to be an essential mechanism of regulating gene expression to 
generate coordinated responses to environmental changes (Eberharter and Becker, 2002). Some co-
activators are implicated in assisting in the assembly of the pre-initiation complex formation allowing 
access of RNA-polymerase (Spiegelman and Heinrich, 2004). Acetylation of histones relaxes the 
chromatin structure which facilitates easier binding of transcription factors and increases efficiency in 
transcription (Eberharter and Becker, 2002).  
The most well studied co-activators are members of the steroid receptor co-activator (SRC) family, 
also known as the p160 family of co-activators, which includes SRC-1 (or NcoA-1), SRC-2 (also 
known as TIF-2 or GRIP-1, NcoA-2) and SRC-3 (also known as RAC3, ACTR, AIB1,P/CIP and TRAM) 
(Griekspoor et al., 2007; Perissi and Rosenfeld, 2005; Rosenfeld et al., 2006; Xu and O'Malley, 2002). 
All members of the p160 family interact with nuclear receptors through an LxxLL motif in the nuclear 
receptor interaction domain (NID) (Heery et al., 1997; Le Douarin et al., 1996; Savkur and Burris, 
2004; Torchia et al., 1997). The N-terminus harbours a bHLH/PAS domain, which was shown to 
interact with several secondary co-activators (Kim et al., 2003; Lee et al., 2004) while the C-terminus 
was found to recruit arginine methyltransferases CARM1 and PRT1 and histone acetyltransferases 
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CBP/p300 and pCAF (Chen et al., 1999a; Lee et al., 2005; Lee et al., 2002; Voegel et al., 1998). 
Furthermore, SRC-1 (Spencer et al., 1997) and SRC-3 (Chen et al., 1997) are known to possess 
histone acetylase (HAT) activity, leading to disruption of nucleosomes (Edwards, 2000; Kleiman and 
Tuckermann, 2007). In addition GRIP-1 has been shown to possess HAT-activity in vitro (Goel and 
Janknecht, 2004). Unlike other members of the p160 family GRIP-1 possesses a repressor domain 
which mediates ligand-dependent repression of AP-1 and NF-κB (Rogatsky et al., 2002; Rogatsky et 
al., 2003). 
The mechanism of transcriptional regulation by the GR has only been fully described for a few 
promoters such as the phosphoenolpyruvate carboxykinase (Hanson and Reshef, 1997) and a recent 
study by Ronacher et al. demonstrates a direct correlation between GRE-transactivation mediated by 
the GR and GR binding of GRIP-1 (Ronacher et al., 2009). However for most GC-regulated genes the 
precise mechanism remains unknown.  
 
1.4.2.2 Modulation of transcription factor function by the GR 
The GR can interfere with the activities of other transcription factors through cross talk with several 
transcription factors (Kassel and Herrlich, 2007). Often the modulation of the transcriptional activity is 
bidirectional and can be enhancing or inhibitory. Depending on the composition of the target promoter 
cross talk can occur at composite response elements, at overlapping response elements or at 
response elements lacking binding sites for the modulating transcription factor (Kassel and Herrlich, 
2007).  
In the first mode of cross talk both GR and other transcription factors can bind to the promoter in target 
genes containing binding sites for both transcription factors and modulate the transcriptional response 
either positively or negatively (Diamond et al., 1990). Composite binding sites do not contain 
conventional binding sites for either factor and transcriptional regulation involves protein-protein 
interactions as well as protein-DNA interactions (Kassel and Herrlich, 2007). For example the GR may 
function as a monomer at these composite sites, forming heterocomplexes with other transcription 
factors (Chinenov and Rogatsky, 2007). An interaction between the GR and these other transcription 
factors can either result in enhancement or repression of gene transcription. For example, GCs 
enhance phosphoenolpyruvate carboxykinase (PEPCK) (Imai et al., 1993) and somatostatin gene 
transcription (Liu et al., 1994) via protein-protein interactions of the GR with the cAMP response 
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element (CRE) binding protein (CREB). Similarly, the GR and the octamer-binding transcription factor 
(Oct-1) activate transcription at a composite response element in the mouse mammary tumor virus 
(MMTV) promoter (Bruggemeier et al., 1991; Miksicek et al., 1987) while binding of both the GR and c-
Jun/c-Fos heterodimers to a composite site in the promoter results in repression of mouse proliferin 
gene transcription (Diamond et al., 1990). 
At overlapping response elements the GR interferes with binding of other transcription factors thereby 
blocking transcription (Kassel and Herrlich, 2007). In the human osteocalcin gene the GRE overlaps 
with the TATA box in the promoter. GR binding to the GRE prevents binding of transcription factor IID 
(TFIID) to the promoter and results in repression of gene transcription (Stromstedt et al., 1991). 
Another mode of cross talk between the GR and other transcription factors occurs at response 
elements without binding sites for the GR mostly resulting in transcriptional repression (Kassel and 
Herrlich, 2007; Yamamoto et al., 1998). In this case the GR can interfere with transcriptional function 
of other transcription factors by physically interacting directly or indirectly with other proteins. This 
mode of cross talk is described as a tethering mechanism and has been show to occur for pro-
inflammatory transcription factors such as AP-1 (Jonat et al., 1990; Schule et al., 1990; Yang-Yen et 
al., 1990), NF-κB (Mukaida et al., 1994; Ray et al., 1991; Scheinman et al., 1995b), SMAD3/4 (Song et 
al., 1999), Oct-1/2 (Kutoh et al., 1992; Wieland et al., 1991) and STAT6 (Biola et al., 2001). The DNA-
binding domain but not the dimerization-domain of the receptor appears to be essential for the 
interaction suggesting that transcriptional repression is a function of GR monomers (Heck et al., 
1994). The physiological importance of the dimerization-independent repressor function of the GR was 
demonstrated in a few reports showing that transcriptional regulation via GREs was impaired while 
AP-1 and NF-κB repression was fully active in GRdim knockout mice containing a dimerization deficient 
receptor (Reichardt et al., 1998; Reichardt et al., 2001; Tuckermann et al., 1999). Numerous models 
have been proposed for a transrepression mechanism via tethering of the monomeric GR to other 
transcription factors including prevention of co-activator (De Bosscher et al., 1997) or corepressor 
binding or interaction with RNA-polymerase II (Nissen and Yamamoto, 2000). In addition the GR can 
indirectly antagonise transcription factor activity by inducing the synthesis of inhibitory factors such as 
IκB (Auphan et al., 1995; Scheinman et al., 1995a). It was proposed that GCs induce the synthesis of 
IκB which binds to NF-κB in the cytoplasm and thereby preventing NF-κB-mediated gene transcription. 
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There are only a few reports demonstrating enhanced transcriptional activity when GR interacts with 
transcription factors at promoters lacking GR binding sites. Stoecklin et al. showed STAT5 response 
elements in the promoter are sufficient for GR to enhance STAT5-induced transcriptional activity 
(Engblom et al., 2007; Stoecklin et al., 1997). Lerner et al. reported that the ligand-activated GR can 
associate with an enhanceosome that constitutively contains c-Jun and OCT-1 as well as IL-6 induced 
STAT3 on the α2-macroglobulin (α2-M) promoter to enhance transcription (Lerner et al., 2003). While 
all of these factors contain transcription activation domains only STAT3 was shown to be required for 
the observed transcriptional increase of the α2-macroglobulin gene (Lerner et al., 2003). Another 
study demonstrated that transactivation of COUP-TFII regulated genes containing only a response 
element for COUP-TFII could be synergistically increased by the ligand-activated GR (De Martino et 
al., 2004).  
 
1.4.2.3 Modulation of activator protein-1 function by the GR 
AP-1 is a sequence-specific transcription factor containing a basic region required for dimerization and 
a basic region involved in recognition of DNA motifs (Angel and Karin, 1991). AP-1 is composed of 
members of the Jun family (c-Jun, JunB, and JunD), the Fos family (c-Fos, FosB, Fra1, and Fra2) 
(Angel and Karin, 1991) or the CREB/ATF family (Cohen et al., 1989; Zerial et al., 1989). It has been 
reported that AP-1 plays an important role in several cellular functions such as development, 
differentiation and cell growth (Angel and Karin, 1991). Activation of AP-1 is induced by mitogens, 
cytokines, and stress agents such as ultraviolet (UV) light. JNK was shown to mediate phosphorylation 
of c-Jun at Ser-63 and Ser-73 resulting in enhanced transcriptional activity (Smeal et al., 1991). While 
Jun family members can form homodimers or heterodimers with other AP-1 proteins, the Fos leucine 
zipper is incapable of forming homodimers (Turner and Tjian, 1989). Depending on the composition of 
the AP-1 dimer, different sequence elements are recognized; Jun/Fos dimer preferentially bind to 
heptameric TPA responsive elements (TRE) (De Cesare et al., 1995) while Jun/ATF dimer bind to the 
octameric cAMP responsive elements (CRE) (Hai and Curran, 1991).  
Cross talk between AP-1 and the GR appears to be mutual and involves complex formation of both 
transcription factors (Jonat et al., 1990; Wissink et al., 1997). It was suggested that GCs interfere with 
AP-1 via direct or indirect interaction of the GR with c-Fos and c-Jun (Jonat et al., 1990; Schule et al., 
1990; Touray et al., 1991; Yang-Yen et al., 1990) while a study by Kerppola et al. demonstrated that c-
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Fos is the primary target for GR inhibition of AP-1 in vitro (Kerppola et al., 1993). GR binding to AP-1 
does not depend on the presence of a GR binding site in the promoter (Teurich and Angel, 1995) and 
was shown not to alter the occupancy at the AP-1 site at the collagenase-1 promoter by in vivo foot 
printing experiments (Konig et al., 1992) and ChIP assays (Kassel et al., 2004). Similarly, Rogatsky et 
al. showed that GCs do not decrease binding of c-Jun and c-Fos proteins to the collagenase-3 
promoter in vivo (Rogatsky et al., 2001). Furthermore, for genes containing a composite element, such 
as the proliferin gene, the composition of the AP-1 dimer appears to determine whether cross talk with 
the GR is positive or negative whereby it can be inhibitory for the Jun/Fos heterodimer, but stimulatory 
for the Jun homodimer (Diamond et al., 1990; Hoeppner et al., 1995; Miner and Yamamoto, 1992; 
Teurich and Angel, 1995). A recent study by Rani et al. in PC12 cells identified a 7 bp region of the rat 
tyrosine hydrolase (TH) gene promoter which has no similarities with any known GRE but resembles 
an AP-1 binding site as the sole regulatory region for the dex-mediated increase in transactivation 
(Rani et al., 2009). In addition, the authors found that the GR as well as several AP-1 proteins 
including c-Fos, FosB, JunD and JunB but not c-Jun bind to that region designated as a novel TH-
GRE/AP1 sequence in intact cells. In addition cross talk between AP-1 and the GR occurs indirectly. 
For example, GCs were shown to inhibit JNK resulting in failure to phosphorylate c-Jun and thereby 
reducing AP-1 activity (Caelles et al., 1997). Furthermore GCs induce the synthesis of the 
transcription factor glucocorticoid-inducible leucine zipper (GILZ) which inhibits AP-1-driven reporter 
constructs via a mechanism involving direct interference with AP-1 DNA binding to its target promoters 
(Mittelstadt and Ashwell, 2001).  
 
1.4.3 Post-translational modifications of the GR 
Several reports in the literature have postulated that post-translational modifications of the GR play an 
important role in GR transcriptional activity, receptor stability, subcellular localization and protein-
protein interactions (Faus and Haendler, 2006). 
Besides the well described acetylation of lysine residues in the N-terminus of histones (Kouzarides, 
2000) a variety of transcription factors are known to be directly acetylated resulting in enhanced or 
decreased transcriptional activity. Ligand-dependent acetylation of the GR has recently been shown to 
occur at several lysine residues within the DBD (Ito et al., 2006). Ito et al. further report that 
deacetylation of the GR by histone deacteylase-2 (HDAC-2) enables NF-κB repression of target 
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genes. Ubiquitylation, another post-translational modification usually targets proteins for degradation 
via the proteasome pathway, while ubiquitylation has also been shown to affect subcellular localization 
or protein-protein interaction (Faus and Haendler, 2006). A potential target residue for ubiquitylation 
has been identified in the degradation motif of the human GR and the authors further suggested a 
potential role of the ubiquitin-proteasome pathway in regulating GR protein degradation (Wallace and 
Cidlowski, 2001). Sumoylation leads to attachment of small ubiquitin-modifier (SUMO) chains onto 
lysine residues and has been implicated in fine tuning steroid receptor function (Faus and Haendler, 
2006). Recent in vitro studies have identified the GR as a potential target protein since 3 different 
lysine residues have been found to be acceptor residues for SUMO (Zhou and Cidlowski, 2005). 
Sumoylation of the GR has been reported to affect protein stability and transcriptional function, 
however reports in the literature are controversial and it has yet to be established if the endogenous 
GR is a target for sumoylation.  
Early findings suggest that the GR is constitutively phosphorylated under physiological conditions and 
undergoes agonist-induced hyperphosphorylation (Housley and Pratt, 1983; Orti et al., 1989; Singh 
and Moudgil, 1984). Several phosphorylation sites have been identified, most of which are serine 
residues located at the N-terminal end of the receptor, and have been shown to be highly conserved 
amongst species (Bodwell et al., 1991; Ismaili and Garabedian, 2004). Solid phase sequencing of the 
mouse GR demonstrated that Ser-212, Ser-220, and Ser-234 are situated in the AF-1 domain of the 
receptor and that phosphorylation at these specific residues is required for full transcriptional activity 
and thus a role of phosphorylation in GR-mediated transactivation has been suggested (Bodwell et al., 
1991). While Ser-203 and Ser-226 of the human GR were found to be phosphorylated in the absence 
and presence of hormone, Ser-211 phoshorylation was only observed in the presence of a GR agonist 
in human U2O2 ostecarcinoma cells (Wang et al., 2002) and rat hepatoma cells (Blind and 
Garabedian, 2008). The role of GR phosphorylation in receptor function is controversial. While single 
or multiple phosphorylation site mutations of the mouse GR at Ser-203, Ser-211 and Ser-226 
(equivalent to the human GR Ser-203, Ser-211 and Ser-226) were found to result in a modest 
reduction in transcriptional activity of a mouse mammalian tumor virus (MMTV) promoter in COS-1 
cells (Mason and Housley, 1993; Webster et al., 1997) others reported an increase in transcription in 
HCT116 cells (Kino et al., 2007) or a significant decrease of the MMTV-promoter activity in COS-1 
cells with the equivalent human GR mutant constructs (Avenant, 2009). Ligand-induced 
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transactivation of a GRE-reporter was shown to be abolished when these specific phospho-sites were 
mutated in the mouse GR (Webster et al., 1997) or the human GR (Avenant, 2009) in COS-1 cells. 
Furthermore, phosphorylation has been implied to affect cellular distribution of the GR. In U2OS cells 
the ligand-activated human GR, phosphorylated at Ser-211 was predominately found in the nucleus 
while GR isoforms phosphorylated at Ser-203 remain mainly in the cytoplasm (Wang et al., 2002). 
However, other groups reported that mutation of various phosphorylation sites of the mouse GR 
(Webster et al., 1997) or the human GR (Avenant, 2009) had no effect on ligand induced nuclear 
translocation in COS-1 cells (Avenant, 2009; Webster et al., 1997).  
Webster et al. demonstrated that ligand-induced GR protein degradation was abolished when several 
serine residues of the mouse GR were mutated and thus proposed that phosphorylation plays a role in 
receptor trunover (Webster et al., 1997). However, a recent study showed that single mutations or 
combinations of serine mutations had no affect on agonist-induced degradation of human GR 
(Avenant, 2009). In addition it has been shown in the literature that the phosphorylation status of the 
GR dictates protein-protein interaction with other transcription factors like components of the mediator 
complex such as TSG101 (Ismaili et al., 2005), or the vitamin D receptor interacting protein 150 
(DRIP150) (Hittelman et al., 1999), or cofactors such as p300/CBP (Galliher-Beckley et al., 2008), or 
GRIP-1 (Avenant, 2009) thereby regulating GR transcriptional activity.  
Taken together the studies above suggest that agonist-induced phosphorylation modulates GR 
transcription at various levels. Although ligand-induced phosphorylation has been linked to subcellular 
localization, protein degradation, protein-protein interaction and modulatory effects on target gene 
expression, it appears that cell-, promoter- and possibly even species-specific effects play a role in the 
mechanism. 
 
1.5 RAPID STEROID ACTION  
1.5.1 Rapid non-genomic effects of steroid receptors 
According to the classical model for genomic steroid action, steroid hormones bind to specific 
receptors which interact at the regulatory regions of their primary target genes to either enhance or 
repress transcription (Beato, 1989). These effects are characterized by a specific delay and sensitivity 
towards inhibitors of transcription and translation since gene transcription and protein synthesis are 
required (Falkenstein et al., 2000). In contrast to delayed genomic steroid actions, rapid non-genomic 
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effects are characterized by their rapid onset of action (usually within minutes), their insensitivity 
towards transcriptional or translational inhibitors as well as rapid activation of signalling cascades to 
ensure the fast effects (Stellato, 2004). Rapid actions of steroids do not fit in the classical genomic 
model of steroid action and might reflect that the steroid receptors have an alternative mechanism of 
transcriptional regulation that runs in parallel to the classical genomic pathway via reciprocal cross talk 
between various receptors and signalling pathways (Tasker et al., 2006). Rapid signalling has been 
found for virtually all groups of steroids and their receptors including the ER, AR, PR and the GR 
(Falkenstein et al., 2000). The existence of plasma membrane-associated receptors for steroid 
hormones such as estrogen, GCs and aldosterone has been proposed (Falkenstein et al., 2000). 
However, the functional role and identity of these membrane-associated receptors is under intense 
investigation and both genomic- and non-genomic effects appear to be involved in activation of such 
receptors.  
17ß-estradiol has been demonstrated to rapidly stimulate endothelial nitric-oxide synthase (eNOS) 
and the effect was blocked with the specific ER antagonists tamoxifen but not with the transcription 
inhibitor actinomycin D, indicating that the nuclear ER is capable to activate eNOS in a novel, 
nongenomic manner (Chen et al., 1999d; Kim et al., 1999; Lantin-Hermoso et al., 1997). Furthermore, 
another study linked MAPK pathways to the rapid activation of eNOS by 17ß-estradiol (Shaul, 1999). 
Several groups have reported evidence for the existence of a membrane ER structurally similar to the 
intracellular ER (Falkenstein et al., 2000). Plasma membrane-impermeable BSA-conjugated estradiol 
was found to stimulate eNO release and the ER antagonist ICI 182,780 completely blocked this effect, 
indicating that the site of estradiol action is on the plasma membrane. The binding of estradiol to the 
membrane was confirmed using FITC-labelled estradiol coupled to BSA (Kim et al., 1999). Additionally 
the cytoplasmic ER has been shown to associate with the plasma membrane of endothelial cells via 
caveolae further supporting the proposal that rapid non-genomic 17ß-estradiol effects are mediated by 
a membrane form of the ER which is structurally similar to the cytoplasmic ER (Razandi et al., 2002; 
Razandi et al., 1999). Rapid non-genomic effects of progesterone have been found in spermatozoa 
(Baldi et al., 1998; Blackmore, 1998) oocytes (Morrill and Kostellow, 1999) as well as in rat 
hepatocytes (Waldegger et al., 1995) and natural killer cells (Mandler et al., 1993) involving increase 
in Ca2+ influx and activation of phospholipase C (PLC) and phospholipase A (PLA) (Falkenstein et al., 
2000). Recently the existence of a membrane-bound PR has been identified in seatrout (Zhu et al., 
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2003b) and humans (Thomas et al., 2007; Zhu et al., 2003a) with characteristics of a GPCR possibly 
mediating non-genomic effects in various tissues including T-lymphocytes and Jurkat cells (Dosiou et 
al., 2008; Thomas et al., 2007). Similarly, rapid non-genomic signalling induced by androgens mostly 
involves Ca2+ signalling and phosphorylation and activation of MAPK (Falkenstein et al., 2000). 
 
1.5.2 Rapid GC-mediated effects 
In the literature there is accumulating evidence for rapid non-genomic GC actions including modulating 
general cellular functions, brain and neurophysiological functions as well as behavioural responses 
(Makara and Haller, 2001; Orchinik et al., 1994). Some rapid non-genomic effects of GCs have been 
shown to be mediated by alteration of the physiocochemical property of cell membranes (Song and 
Buttgereit, 2006). It has been proposed that GCs interact with cellular membranes such as the plasma 
or mitochondrial membrane and ultimately altering cellular function by modifying cation transport 
through the plasma membrane or by increasing the proton leak of the mitochondria (Song and 
Buttgereit, 2006). In human bronchial epithelial cells it was shown that treatment with low 
concentrations of dex (0,1 nM to 1 µM) results in decreased Cl- secretion and Ca2+ levels via a non-
genomic mechanism that is independent of the classical GR and involves a ATPase, adenylate 
cyclase and PKA signalling (Urbach et al., 2002). In addition, rapid GC effects can be mediated via the 
classical cytoplasmic GR or a membrane-bound GR (Gross and Cidlowski, 2008; Lowenberg et al., 
2008; Moutsatsou and Papavassiliou, 2008; Song and Buttgereit, 2006) as described below in detail. 
 
1.5.2.1 Cross talk of the membrane-bound GR  
In early studies membrane receptors for corticosterone were characterized in neuronal plasma 
membranes of the amphibian Taricha granulosa (Moore and Orchinik, 1994; Moore et al., 1995). The 
corticosterone-binding receptor was found to be enriched in neuronal plasma fractions with an 
estimated molecular weight of 63 kDa and appears to be distinct from the classical cytosolic GR 
(Breuner and Orchinik, 2002; Evans et al., 2000; Falkenstein et al., 2000). Consistent with this report 
other groups showed that the membrane-associated GR exhibits distinct differences in cell 
localization, molecular size, and binding characteristics from the cytosolic GR (Gametchu et al., 1999; 
Powell et al., 1999). On the other hand similarities between the membrane-associated GR and the 
cytosolic GR such as shared epitope recognition for antibodies directed against the cytosolic GR, a 
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similar phosphorylation pattern, and similar heat shock protein binding properties, have also been 
described, to support the hypothesis that the membrane GR is a modified form of the cytosolic GR 
(Stellato, 2004). 
The presence of the GR in several types of immune cells provides evidence for the hypothesis that 
non-genomic GC signalling is involved in modulating immune function (Lowenberg et al., 2008). It was 
shown that a subset of the GR population resides in the plasma membrane of human leukemic cells 
(Gametchu et al., 1999; Gametchu et al., 1993) mouse monocytes and B-cells (Bartholome et al., 
2004) and S-49 mouse lymphoma cells (Chen et al., 1999b; Chen et al., 1999c; Powell et al., 1999). 
Recent studies provide molecular insight into the functional role of non-genomic GC action in T-cells 
(Lowenberg et al., 2005; Lowenberg et al., 2006b). The unliganded GR was shown to be an essential 
part of a plasma-membrane T-cell receptor-linked multiprotein complex containing hsp90, LCK, FYN 
and ZAP-70 (Bartis et al., 2007; Bartis et al., 2006; Lowenberg et al., 2006b). Short-term GC treatment 
induced disruption of that protein complex resulting in impaired T-cell receptor signalling as a 
consequence of cellular redistribution and abrogated activation of LCK and FYN (Lowenberg et al., 
2006b). Similarly, Bartis et al. reported rapid GC-induced GR-dependent phosphorylation of ZAP-70 in 
Jurkat cells thereby facilitating non-genomic GC action in T-cells (Bartis et al., 2007; Bartis et al., 
2006; Lowenberg et al., 2006b) and Löwenberg et al. show that short-term GC treatment inhibited 
insulin signalling through a GR-dependent and transcription-independent mechanism in adipocytes 
and T-lymphocytes (Lowenberg et al., 2006a). 
 
1.5.2.2 Cross talk of the classical GR with intracellular signalling proteins 
The classical cytosolic GR appears to cross talk with various intracellular signalling pathways to 
mediate rapid effects. Jain et al. presented a study showing the presence of the classical cytosolic 
GR, hsp90 and STAT3 in caveolae-containing low-density detergent-resistent membranes (DRM) 
derived from liver cells (Jain et al., 2005). This study further provides evidence for a functional 
contribution of the GR associated with these membrane rafts towards transcription since the presence 
of a raft disrupter, filipin III, significantly inhibited dex-induced GRE-transactivation (Jain et al., 2005). 
In addition, it has been reported that liganded GR can directly interact with a member of the MAPK 
family, namely JNK (Bruna et al., 2003). This protein-protein interaction results in repression of AP-1 
regulated genes since GC-mediated inhibition of JNK activity decreases the phosphorylation of c-Jun 
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(Caelles et al., 1997). Croxtall et al. demonstrated that epidermal-growth factor (EGF) stimulated PLA 
activation and subsequent release of arachidonic acid (AA) can be inhibited by dex in a GR- and 
MAPK-dependent, but transcription independent fashion in A549 cells supporting the hypothesis of 
non-genomic GR-mediated mechanism (Croxtall et al., 2000). A study by Solito et al. further suggests 
that GCs induce rapid serine phosphorylation and membrane translocation of ANXA1 via a non-
genomic GR-dependent mechanism that requires MAPK, phosphatidylinositiol 3-kinase (PI3K), and 
PKC pathways in folliculostellate cells (Solito et al., 2003). 
Interestingly, GCs have also been reported to rapidly activate p38, JNK and ERK in PC12 cells and 
cultured hippocampal neurons (Di and Tasker, 2004; Li et al., 2001; Qi et al., 2005; Tasker et al., 
2006). The activation of these downstream messengers might provide a novel mechanism whereby 
GCs signal rapidly from the plasma membrane to the nucleus via the cytosolic GR (Tasker et al., 
2006). Similarly, rapid activation (phosphorylation) of MAPK and PKB/Akt by GCs has been shown in 
ovarian follicular cells (Sasson et al., 2003). The authors propose that rapid GC effects may either 
involve a non-genomic mechanism via interaction with a putative membrane-bound receptor or 
alternatively specific interaction of GC with the cytosolic GR resulting in the release of associated 
proteins from the multi-protein complex (Sasson et al., 2003). In support of the latter, proteins from the 
GR-associated multi-protein complex consisting of heat shock proteins, chaperones and co-chaperone 
as well as kinases may have a potential role in rapid modulation of intracellular signalling after 
dissociation from the ligand activated GR. Evidence for this hypothesis comes from a study by Croxtall 
et al. showing that GC-induced activation of lipocortin I and inhibition of AA release is in fact 
independent of GR nuclear translocation and appears to be mediated via release of src-kinase from 
the cytoplasmic GR multi-protein complex (Croxtall et al., 2000). This implies that GCs may 
orchestrate a broad and complex signalling cascade beyond the GR-dependent genomic pathways. 
 
1.5.2.3 Cross talk of the classical GR with GPCRs 
There is increasing evidence that rapid GC effects are in part mediated by membrane-bound GPCRs 
(Tasker et al., 2006). Iwasaki et al. proposed a possible involvement of Gi in rapid GC-mediated 
inhibition of ACTH in AT20 cells (Iwasaki et al., 1997) and Malcher-Lopez et al. found that a Gs-
coupled receptor is involved in rapid GC-induced synthesis and release of endocannabiniods from 
neuroendocrine cells (Malcher-Lopes et al., 2008). Another study reported an inhibitory effect of 
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corticosterone on nicotine-mediated Ca2+ influx involving a G-protein-PKC-dependent pathway in 
PC12 cells (Qiu et al., 1998). In addition these effects were also observed in the presence of BSA-
conjugated corticosterone, implying the possible contribution of a membrane GC receptor (Qiu et al., 
1998). 
Interestingly, Kino et al. demonstrated that the liganded cytosolic GR directly interacts with G-protein-β 
and the proteins comigrated to the plasma membrane after activation of the somatostatin receptor, a 
GPCR, by somatostatin in HCT116 cells. Thus, it is likely that G-protein associated GR might explain 
some of the non-genomic effects of GCs at the plasma membrane (Kino et al., 2005). 
 
1.6 GPCR CROSS TALK: FINE-TUNING OF MULTIPLE RECEPTOR SIGNALLING 
PATHWAYS 
GPCR’s utilize complex signalling pathways to transmit signals from the plasma membrane to the 
cytoplasm and the nucleus. The complexity is highlighted by the fact that several G-proteins, 
interacting receptors, and effector proteins are usually simultaneously expressed in the same cell. In 
addition, GPCRs can affect signalling of members of another receptor family via pathways interacting 
at mutual cellular regulatory proteins resulting in numerous points of cross talk (Hur and Kim, 2002).  
 
1.6.1 Microdomains as a functional complex to facilitate cross talk 
The classical theory of GPCR signalling is based on random collisions between proteins in the plasma 
membrane (Hur and Kim, 2002). However, there is accumulating evidence in the literature suggesting 
that receptors, G-proteins and effector molecules are much less diffuse than expected and rather 
organized in distinct specialized microdomains. Caveolae and lipid rafts are such microdomains and 
have been shown to contain many proteins including GPCRs (Bliss et al., 2007; Dobkin-Bekman et al., 
2009; Haasemann et al., 1998; Navratil et al., 2003; Roberson et al., 2005), G-proteins (Moffett et al., 
2000), adenylyl cyclases, nitric oxidase synthase and protein kinase C (Dobkin-Bekman et al., 2009; 
Hur and Kim, 2002; Lisanti et al., 1994; Shaul and Anderson, 1998). The significance of the 
association of signalling molecules in microdomains is not clear and it needs to be determined 
whether they are required to facilitate cross talk of the downstream signalling cascade or if the 
specialized domains rather reduce the functional activity of the molecules through interactions with 
caveolin (Hur and Kim, 2002). De Weerd et al. showed that treatment with B2-receptor agonist 
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bradykinin resulted in the recruitment of the B2-receptor and the receptor-coupled Gα-subunits to 
caveolae in smooth muscle cells (de Weerd and Leeb-Lundberg, 1997). The results suggest that 
GPCR agonists enable the association of their receptors and coupled G-proteins with caveolae (de 
Weerd and Leeb-Lundberg, 1997). In contrast, another study demonstrated that the ß2-adrenergic 
receptor was restricted to caveolae structures in its basal inactive state in rat cardiomyocytes since the 
the presence of receptor was found to be decreased in caveolae upon agonist stimulation (Rybin et 
al., 2000). Similarly, Engelman et al. show that caveolin-1 expression can inhibit signal transduction 
from the p42/44 MAPK cascade both in vitro and in vivo, suggesting an inhibitory role for caveolae in 
signal transduction (Engelman et al., 1998). This is in agreement with a recent study by Dobkin-
Bekman et al. demonstrating that a signalling complex including the GnRHR, c-src, FAK, caveaolin-1, 
PKC and ERK is pre-formed in the absence of ligand while GnRH stimulation results in re-structuring 
of that complex and the release of ERK in LßT2 cells (Dobkin-Bekman et al., 2009). The authors 
suggest that the signalling complex has a restrictive role for ERK nuclear translocation and signalling 
in these cells.  
 
1.6.2 Scaffolding proteins as mediators of GPCR cross talk 
Scaffolding proteins can facilitate the association of different proteins to enhance or ensure specificity 
of cellular responses (Hall and Lefkowitz, 2002). GPCRs can associate with scaffolding proteins via 
intracellular loops or via their intracellular C-termini thereby bridging the GPCR directly to effector 
molecules in the cytoplasm and enabling cross talk with other pathways (Hall and Lefkowitz, 2002). In 
support of this, activation of the AT1 receptor has been shown to trigger the Jak/STAT signalling 
pathway which is usually activated by cytokine or growth factor receptors but not by GPCRs (Bhat et 
al., 1994; Marrero et al., 1996; Sayeski et al., 2001). The activation of the Jak/STAT pathway has 
been found to be dependent on direct interaction between the C-terminal tail of AT1 and Jak, resulting 
in Jak-induced recruitment, phosphorylation and activation of STAT1. A recent study by Maudsley et 
al. demonstrates that a calcium-dependent proline-rich tyrosine kinase 2 (Pyk2) is a scaffold for a focal 
adhesion/cytoskeleton-dependent complex containing c-src, Grb2, and mSos. The complex was 
further shown to be involved in GnRH-mediated ERK translocation to the nucleus in the gonadotrope 
cells αT3-1 and LßT2 (Maudsley et al., 2007). 
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ß-arrestins were originally discovered as cytosolic regulator, adaptor and scaffolding proteins in the 
context of GPCR desensitization, internalization and signalling (Lefkowitz et al., 2006). More recently 
these proteins have been implicated in regulating non-seven-membrane-spanning receptor pathways 
and facilitating protein-protein interactions of various proteins enabling a broad variety of cross talk 
from the plasma membrane to the cytoplasm. In addition, ß-arrestins have been shown to link GPCRs 
to signalling pathways such as MAPKs (Lefkowitz et al., 2006). For example, Ahn et al. demonstrate 
that ß-arrestin-dependent activation of ERK results in accumulation of the kinase in the cytoplasm in 
HEK-293 cells (Ahn et al., 2004a; Ahn et al., 2004b). The authors suggest that ß-arrestin-activated 
ERK mediates phosphorylation of cytosolic proteins in contrast to nuclear ERK which is known to 
phosphorylate transcription factors (Yoon and Seger, 2006). Furthermore, reports in the literature 
identified ß-arrestin 2 as a MAPK scaffold for the activation of JNK3 (McDonald et al., 2000) or p38 
(Sun et al., 2002) or as a mediator in assembling a RAF/MEK/ERK multiprotein complex to enable 
receptor-specific signalling (Luttrell et al., 2001). 
Moreover, ß-arrestin was implicated to be involved in immune responses since it was shown to inhibit 
NF-κB-mediated gene expression by interacting directly with the NF-κB-inhibitor Iκ-B (Witherow et al., 
2004). Similarly, ß-arrestins directly interact with TNF receptor-associated factor 6 (TRAF6) after 
activation of TLR-IL-1R thereby preventing activation of NF-κB and AP-1 (Wang et al., 2006).  
Interestingly, Kang et al. proposed a novel role for ß-arrestin as a messenger in GPCR signalling from 
the cell membrane to the nucleus through histone modification (Kang et al., 2005). Stimulation of the 
GPCR delta-opioid receptor induces nuclear translocation of ß-arrestin 1 followed by enrichment of ß-
arrestin 1 at specific promoters such as that of p27 and c-fos, where it facilitates the recruitment of 
p300, resulting in enhanced histone acetylation and transcription of these genes (Kang et al., 2005).  
 
1.6.3 Cross talk between GPCRs by heterodimerization 
In contrast to other families of cell surface receptors GPCRs were thought to function as monomers 
(Hur and Kim, 2002). However, it has been proposed that receptor dimerization and oligomerization is 
required for GPCR signal transduction in a similar fashion to that known for RTKs and growth 
hormone receptors (Bockaert and Pin, 1999; Bouvier, 2001; Milligan, 2001; Salahpour et al., 2000). 
Furthermore it has been postulated that activation of one particular signalling pathway by one GPCR 
can reduce or augment the effects of another GPCR by homo-and hetero-oligomerization of these 
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receptors (Hur and Kim, 2002). A study by Suh et al. demonstrated that ß-adrenergic receptor-
mediated elevated cAMP levels were found to decrease upon activation of the P2Y2 receptor via Gi in 
PGT-3 cells (Suh et al., 2001). In contrast another study proposed that formation of a heterodimer 
consisting of the AT1 receptor and the B2 receptor resulted in enhanced activation of Gαq and Gαi 
proteins, the two major Gα-proteins coupled to the AT1 receptor (AbdAlla et al., 2000). Furthermore, 
Rocheville et al. reported that formation of a functional heterodimer of the dopamine D2 receptor and 
the somatostatin SSTR5 receptor results in enhanced dopaminergegic and somatostatinergic effects 
(Rocheville et al., 2000a). In addition the authors show in a subsequent study that functional hetero-
oligomer D2R/SSTR5 receptor units are formed in cells expressing both receptor types (Rocheville et 
al., 2000b). The authors suggest that hetero-oligomerization generates a novel receptor with 
enhanced functional activity. It is likely that similar functional hetero-oligomers could be formed 
between many potential pairs of GPCR family members when they are expressed in the same cell 
thereby adding a further level of complexity to the concept of receptor cross talk.  
 
1.6.4 Cross talk of the GnRHR with other receptors  
As mentioned earlier cross talk between cell surface receptors including the GnRHR is a mechanism 
of generating signal diversity. Cross talk between the GnRHR and the epidermal growth factor (EGF) 
receptor (EGFR) has been described in the literature and can either result in GnRH-induced 
transactivation of the EGFR or attenuation of EGFR signalling (Cheung and Wong, 2008). It has been 
demonstrated that the GnRHR antagonizes EGF-induced mitogenic signalling and cell proliferation by 
interfering with the stimulatory effects of the EGFR in human prostate (Moretti et al., 1996), ovarian 
and endometrial cancer cells (Grundker et al., 2001). The ligand activated GnRHR was shown to 
mediate this negative mode of cross talk via activation of phosphotyrosine phosphatases thereby 
reducing the EGF-induced autophosphorylation of the EGFR (Grundker et al., 2001; Moretti et al., 
1996). Similarly, negative cross talk has been reported for the GnRHR and the insulin-like growth 
factor (IGF) receptor (IGFR) in human prostate cancer cells (Marelli et al., 1999; Montagnani Marelli et 
al., 2007). These studies show that GnRHR agonists interfere with the IGF-signalling by inhibiting 
IGFR protein expression and tyrosine-phosphorylation thereby inhibiting the downstream IGF-
mediated phosphorylation and activation of Akt (Montagnani Marelli et al., 2007). The ligand-activated 
GnRHR has also been shown to interfere with other signalling pathways such as cytokine signalling 
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via cross talk with intracellular non-receptor targets. Grunker et al. demonstrated GnRHR-induced 
activation and nuclear translocation of NF-κB via Gαi thereby inhibiting apoptosis in ovarian cancer 
cells (Grundker et al., 2000) while another study showed that GnRH suppressed IL-8 expression by 
inhibiting TNFα-mediated NF-κB activation in endometrial stromal cells (Sakamoto et al., 2003). 
Furthermore, in a recent study Naor et al. describe reciprocal cross talk between the GnRHR and the 
prostaglandin receptor in LßT2 cells (Naor et al., 2007). GnRH was shown to induce synthesis of 
prostanoids which in turn inhibit GnRH-induced GnRHR gene expression. The authors suggest that 
inhibition of the GnRHR by PGF2α and PGI2 is mediated by inhibition of phosphoinositide turnover 
possibly resulting in altered protein assembly at the AP-1 site in the GnRHR promoter (Naor et al., 
2007). 
The GnRHR has further been shown to affect sex steroid hormone receptor function. In HEK293 cells 
GnRH induced nuclear translocation of the AR mediated by c-src and Hic5 but in contrast to 
testosterone GnRH did not transcriptionally activate the receptor (Maudsley et al., 2006). In addition it 
was found that GnRH can activate the PR in the absence of progesterone in rat anterior pituitary cells 
(Turgeon and Waring, 1994) resulting in transcription of a transfected progesterone-response element 
(PRE)-reporter constructs as well as the gonadotropin-alpha subunit gene and FSHß gene in αT3-1 
cells (An et al., 2006) and LßT2 cells (An et al., 2009), respectively. Similarly, a recent study by Chen 
et al. demonstrated that GnRH activates the ER in LßT2 cells in a GnRHR-dependent pathway leading 
to transactivation of ERE-containing genes (Chen et al., 2009). 
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Compounds and antibodies 
GnRH, dexamethasone (dex) and Mifepristone (RU486) were purchased from Sigma-Aldrich, South 
Africa. Antibodies to GR (H-300, sc-8992), c-Jun (sc-44 and sc-1694), c-Fos (sc-253), PR (sc-539), 
AR (sc-13062), MR (sc 14112), p300 (sc-32244) and SRC-1 (sc-8995) were obtained from Santa Cruz 
Biotechnology, USA. Antibodies to β-actin (#4967), SAP/JNK (#9252), phospho-SAPK/JNK (#9251), 
p44/42 (#9102), phospho-p44/42 (9101), p38 (#9212) and phospho-p38 (#9211) were purchased from 
Cell Signaling, South Africa and the rabbit HRP conjugate (NA934VS) from AEC Amersham, South 
Africa. The GRIP-1 antibody (G8970-10) was obtained from United States Biological, USA. The 
fluorescent labeled secondary antibody AlexaFluor®488 (#A21206) was obtained from Molecular 
Probes, USA. The anti-phospho-serine 226-GR and anti-phospho-serine 211-GR antibodies 
(corresponding to Ser-220 and Ser-234 in mouse, respectively) were a generous gift from Dr. M. J. 
Garabedian (New York University, School of Medicine, USA). See table 2.2 for dilutions of all the 
primary antibodies. 
The GnRHR antagonist Antide (A8802) and the JNK (SP600125), PKA (Dihydrochloride, H89), ERK 
(PD98059) and p38 (SB230580) inhibitors were purchased from Merck chemicals, South Africa. The 
c-src inhibitor PP2 was purchased from Calbiochem, UK, and the PKC inhibitor Bbisindolylmaleimide x 
Hydrochloride (# B 3931) (synonym Ro 31-8425, from now on referred to as BIM) was obtained from 
Sigma-Aldrich, South Africa.  
 
2.2 Incubation with test compounds 
Dex and RU486 were diluted in 100% EtOH to a final concentration of 100 µM. GnRH was purchased 
as lyophilized salt and dissolved in H2O to a final concentration of 100 µM. Antide was obtained as a 
lyophilized product and dissolved in H2O to a final concentration of 100 µM. All kinase inhibitors were 
dissolved in DMSO to a final concentration of: 10 mM for SP600125 (from now on referred to as JNK 
inhibitor), SB230580 (from now on referred to as p38 inhibitor) and PP2 (c-src inhibitor), 50 mM for 
PD98059 (from now on referred to as ERK pathway inhibitor), 1 mM for H89 (PKA inhibitor) and 100 
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µM for BIM (PKC inhibitor). All test compounds were added to cells as 1/1000 dilution in culture 
medium unless stated otherwise in the figure legends. Vehicle controls were either culture medium 
alone, or culture medium containing 0,1% DMSO or 0,1% EtOH depending on test compounds added. 
For kinase inhibitor studies cells were pre-incubated for 30 min with the c-src inhibitor PP2 or for 15 
min with the p38, JNK or ERK pathway inhibitor before adding the test compound. 
 
2.3 Plasmids 
Wild type HA-tagged human GR (pCMV-HA-human GR) expression vector was obtained from Prof. M. 
J. Garabedian. The pTAT-GRE-E1b-luc plasmid was a gift from Dr G. Jenster at Erasmus University of 
Rotterdam, Netherlands and the pCMV-ß-galactosidase plasmid was a gift from Dr. G. Haegeman 
(University of Gent, Belgium). The pSV-hARo was a kind gift from Frank Classens Catholic University 
of Leuven, Belguim, the pRS-hMR expression plasmid was obtained from Prof. R.M. Evans (University 
of California, USA) and the pMT-PR-B was kind gift from Prof. S. Okret (Karolinka Institute, Sweden). 
The pAP-1 luc plasmid (containing seven copies of a consensus AP-1 site) was obtained from 
Stratagene, USA. The expression construct R10, containing the full-length (1.2 kb) mouse GnRHR 
cDNA (Tsutsumi 1992) in the pcDNA1 expression vector, was obtained from Dr. S.C. Sealfon, Mt 
Sinai Medical School, New York, USA. The MMTV-luciferase plasmid was a kind gift from Gordon L. 
Hager (National Cancer Institute, USA). The expression plasmid pSG5-hERα were obtained gift from 
F. Gannon (EMBL, Germany) and the ERE.vit2-luc was a kind gift from K. Korach (National Institute of 
Environmental Health Science,USA). The promoterless luciferase expression vector pGL2-basic was 
purchased from Promega (Promega Corp., USA). The pLG luciferase reporter plasmid containing 580 
bp of the mouse GnRHR gene (-579 to +1 relative to the translation start site) has been previously 
described (Sadie et al., 2003). The pLGmAP1 expression plasmid was constructed by Dr. Hanel Sadie 
by site-directed PCR mutagenesis using the pLG expression vector as template, as described (Sadie 
et al., 2003), using primers containing the underlined mutated AP-1 promoter sequence in the anti-
sense (PCRmAP1a 5’CTGATGTCGAAAGgaAtTCcTAATATCATCCAATT3’) and sense (PCRmAP1s 
5’AATTGGATGATATTAgGAaTtcCTTTCGACATCAG 3’) orientation (mutated bases are indicated in 
lowercase). Isolated plasmids were sequenced to confirm the presence of the correct insert.  
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2.4 Transformation of bacterial cells and plasmid preparation 
Plasmids were transformed into Escherichia coli DH5α cells by heat shock transformations according 
to Sambrook et al. (Sambrook et al., 1989). Briefly, 100 µl competent cells were mixed with 10 ng 
DNA. The mixture was put on ice for 30 min, followed by 2 min incubation at 42°C and 2 min 
incubation on ice (Sambrook et al., 1989). Immediately after transformation, cells were mixed with 900 
µl SOC medium (2% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.05% (w/v) NaCl, 2.5 mM KCl, 10 mM 
MgCl2 and 20 mM glucose; (Sambrook et al., 1989)) and incubated for 1 h at 37°C while shaking at 
200 rpm. Cells were subsequently plated out on LB agar plates (1% (w/v) tryptone, 0.5% yeast extract, 
1% NaCl and 1,5% agar, (Sambrook et al., 1989)) containing 50 µg/ml ampicillin (Sigma-Aldrich, 
South Africa) and allowed to grow overnight at 37°C. The following day, colonies were picked and 
grown in 50 ml LB medium (1% (w/v) tryptone, 0.5% yeast extract and 1% NaCl; (Sambrook et al., 
1989)) containing 50 µg/mL ampicillin for at least 8 h at 37°C while shaking. For glycerol stocks 500 µl 
80% (v/v) glycerol was mixed with 500 µl of the cell suspension and stored at -80°C. For plasmid 
preparations, LB medium containing ampicillin 50 µg/mL ampicillin was inoculated and allowed to grow 
overnight at 37°C while shaking. The next day the p lasmid DNA was purified with the PUREYIELD 
plasmid maxiprep kit from Promega (Promega, Madison, WI, USA), according to the manufacturer’s 
protocol. The integrity and purity of the plasmids were tested by restriction digestion and agarose gel 
electrophoresis. 
 
2.5 Cell culture 
LβT2 mouse pituitary gonadotrope cells were kindly provided by Dr. P.Mellon from the University of 
California, San Diego, USA. COS-1 monkey kidney fibroblast cells were purchased from American 
Type Culture Collection (ATCC, USA). The cells were maintained in high glucose Dulbeccos’s 
Modified Eagles Medium (DMEM, Sigma-Aldrich, South Africa) supplemented with 10% fetal calf 
serum (Delta Bioproducts, South Africa), 50 IU/ml penicillin and 50 µg/ml streptomycin (Gibco-BRL 
Life Technologies, UK), unless stated otherwise. Cultures were maintained in 75 cm2 culture flasks 
(Greiner Bio-one International, Austria) at 37°C, in an atmosphere of 90% humidity and 5% CO2. LßT2 
cells and COS-1 cells were passaged with 0.25% trypsin / 0.1% EDTA in calcium- and magnesium-
free PBS (Highveld Biologicals, South Africa) once or twice a week, respectively. LßT2 cells were very 
sensitive to overtrypsinizing, and were therefore not incubated in the trypsin solution for longer than 3 
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min. Both cell lines were regularly tested for mycoplasma infection by means of Hoechst staining 
(Freshney, 1987), and only mycoplasma-negative cells were used in experiments.  
 
2.6 Transient transfections 
Cells were plated in 24-well culture plates (Nunc, Denmark) at a density of 1 X 105 or 5 X 104 cells per 
well for LßT2 cells or COS-1 cells, respectively, in 500 µl DMEM supplemented with 10% fetal calf 
serum and antibiotics as described above. Twenty-four h after plating, medium was replaced with 
fresh medium and cells were transfected with 250 ng pTAT-GRE-E1b-luc, MMTV-luciferase construct 
or pAP-1-luc promoter-reporter constructs, or cotransfected with 125 ng pCMV-HA-human GR and 6 
ng R10 GnRHR expression vector. In order to correct for transfection efficiency, 25 ng pCMV-ß-
galactosidase were co-transfected. All transfections were performed according to the FuGENE 6 
(Roche Applied Science, South Africa) product protocol, at a ratio of 1µg DNA : 2 µl FuGENE 6. At 
least 24 h after transfection, the medium was replaced with serum-free medium. Incubations were 
performed with test compounds as indicated in the figure legends. Cells were harvested in 50 µl 
reporter lysis buffer (Promega Corp., USA) per well. The luciferase assays (Luciferase Assay System, 
Promega, USA) and β-galactosidase assays (Galacto-Star, Tropix Inc, USA) were carried out with 10 
µL cell extract in white 96-well plates in a Modulus microplate reader (Turner Biosystems, USA). 
Luciferase values were normalized to corresponding β-galactosidase values and expressed relative to 
vehicle control values. The constituitive CMV promoter of the pCMV-ß-galactosidase expression 
vesctor was found not to be regulated under experimental conditions and therefore chosen in the 
present study.  
 
2.7 RNA interference 
LßT2 cells were plated in 12-well plates (Nunc, Denmark) at a density of 2 X 105 cells per well in 1 ml 
DMEM supplemented with 10% fetal calf serum and antibiotics as described above. After 24 h cells 
were transfected with siRNA using HiPerfect transfection reagent (Qiagen, USA) according to the 
manufacturer’s protocol. Briefly, GR siRNA (Mn_Nr3c_3, Mn_Nr3c_4, Mn_Nr3c_5, Mn_Nr3c_6, 
GeneSolution siRNA Cat no.1027416, Qiagen, USA) or scrambled siRNA as non-silencing control 
(Negative Control siRNA Cat no 1027310, Qiagen, USA) were diluted in 50 µl Opti-
MEM+GlutaMAXTM-I (Gibco-BRL Life Technologies, UK) and 3,5 µl transfection reagent was added to 
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the diluted siRNA. The mixture was incubated for 10 min at RT and added drop-wise to the cells to 
obtain a final concentration of 20 nM for the GR siRNA or the scrambled siRNA per well. After 96 h, 
transfected cells were either harvested and the efficiency of the gene silencing determined by Western 
blotting, or treated with compounds for a further 8 h in serum-free medium for real-time PCR analysis. 
Using increased amounts of siRNA oligos or transfection reagent, longer incubation times, or 
transfecting twice with siRNA oligos did not further decrease the GR protein levels. In addition, the use 
of 3 different GR siRNA oligos resulted in the same extent of GR knockdown. 
 
2.8 Isolation of total RNA 
LβT2 cells were plated in 12-well culture plates (Nunc, Denmark) at a density of 4,5 X 105 cells per 
well in 1 ml medium. Forty-eight h after plating, medium was replaced with fresh medium containing 
test compounds. Total RNA was isolated with Trizol reagent (Sigma-Aldrich, South Africa) according 
to the manufacturer’s protocol. Briefly, 400 µl Trizol reagent was added per well and incubated at RT 
for 5 min. Thereafter cell lysates were transferred into microcentrifuge tubes and centrifuged for 10 
min at 12 000 g (4°C). The supernatant was transferred into new microcentrifuge tubes and 80 µl 
chloroform was added to each sample and the samples were vortexed vigorously for 15 sec. Samples 
were centrifuged for 15 min at 12 200 g (4°C). The top aqueous phase was transferred into new 
microcentrifuge tubes and an equal volume of isopropanol was added. Subsequently, the samples 
were incubated at RT for 10 min followed by centrifugation for 10 min at 20 000 g to pellet the RNA 
(4°C). The RNA precipitates were washed twice with 400 µl 70% EtOH and centrifuged for 5 min at 20 
000 g (4°C). The RNA was allowed to air dry for 5 min and resuspended in15 µl DEPC-treated-water. 
The samples were stored at -20°C. 
To confirm the integrity of the isolated RNA denaturing formaldehyde agarose gel electrophoresis was 
performed (Addendum D2 (Sambrook et al., 1989)). Sample loading buffer (15 µl, Addendum C2) was 
added to 0,5 µg of each RNA sample, incubated at 65°C for 10 min to denature secondary structures 
and cooled on ice. The samples were analyzed by gel electrophoresis on and 1% formaldehyde 
agarose gel in RNA electrophoresis buffer (Addendum D2) at 65 V for approximately 1.5 h (Sambrook 
et al., 1989).  
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2.9 cDNA synthesis 
Total RNA was reverse-transcribed using the Transcriptor First Strand cDNA Kit (Roche Applied 
Science, South Africa) according to the manufacturer’s protocol for c-DNA synthesis using anchored 
oligo (dT) priming. Each RNA sample (1 µg) was mixed with 1 µl oligo(dT) pimers (final concentration 
2,5 µM) and DEPC-treated-water added to make up a final volume of 13 µl. The mixture was 
incubated for 10 min at 65°C. Samples were put on ice and allowed to cool down. Subsequently, 4 µl  
Transcriptor Reverse Transcriptase Reaction Buffer, 0,5 µl Protector RNase Inhibitor (20 units), 2 µl 
dNTP mix (final concentration 1 mM of each dNTP) and 0,5 µl Transcriptor Reverse Transcriptase (10 
units) were added to each sample, mixed carefully and incubated at 50°C for 1 h. To stop the 
Transcriptor Reverse Transcriptase samples were incubated for 5 min at 85°C. 
 
2.10 Quantitative real-time PCR 
Quantitative real-time PCR was performed using SensiMixTM dT kit (Quantace, UK) and the Corbett 
real-time PCR machine and reaction tubes according to the manufacture’s protocols (Quantace, UK). 
The following reaction mix was prepared: 25 µl SensiMixdT, 1 µl 50x SYBR®Green I solution, sense 
and anti-sense primers (see table 2.1 for final concentration of primers), 2 µl cDNA and PCR-grade 
H2O to make up a total volume of 50 µl. The PCR protocol was as follows: 95ºC for 10 min followed by 
40 cycles of 95ºC for 10 sec, 58ºC for 10 sec and 72ºC for 10 sec. Melting curve analysis and gel 
electrophoresis were performed to confirm the generated amplicon in each sample. Relative GnRHR 
transcript levels were calculated with the “Fit Points” method described by Pfaffl et al. (Pfaffl, 2001) 
and were normalized to relative GAPDH transcript levels. 
 
 Primer Sequence 
5’ – 3’ 
Stock 
concentration 
of primer 
Final 
concentration 
of primer 
Product 
size  
mGnRHR 
forward 
CCACAGTGGTGGCATCAGGCCTTC 
mGnRHR 
reverse 
TAGCGTTCTCAGCCGAGCTCTTGG 
 
5 µM 
 
0,125 µM 
 
192 bp 
mGAPDH 
forward 
TTCACCACCATGGAGAAGGC 
 
mGAPDH 
reverse 
GGCATGGACTGTGGTCATCA 
 
5 µM 
 
0,25 µM 
 
263 bp 
 
Table 2.1: Sequences and concentrations of primers used for quantitative real-time PCR 
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2.11 Western blot analysis 
LβT2 cells were plated at a density of 9 X 106 cells per well in 6-well plates (Nunc, Denmark) in 2 ml 
DMEM supplemented with 10% fetal calf serum and antibiotics as described above. Twenty four h 
after plating, medium was replaced with serum-free medium and cells were serum-starved overnight. 
The following day cells were incubated with test compounds as indicated in figure legends. Cells were 
washed twice with cold PBS and harvested in 100 µl 1 x SDS sample buffer buffer (5X SDS sample 
buffer: 100 mM Tris-HCL pH 6.8, 5% (w/v) SDS, 20% (v/v) glycerol, 2% ß-mercaptoethanol and 0.1% 
(w/v) bromophenolblue) and incubated at 95ºC for 10 min. Protein samples were separated by SDS-
PAGE at 150 V in 25 mM Tris-HCL, 250 mM glycine and 0,1% SDS, pH 8,4 (Sambrook et al., 1989) 
using a BioRad Mini Protean II electrophoresis cell. Proteins were electroblotted onto Hybond-
ECL (AEC Amersham Biosciences, South Africa) nitrocellulose membrane for 1 h at 180 mA 
(Sambrook et al., 1989) using a BioRad Mini Trans-Blot cell in transfer buffer (25 mM Tris, 200 mM 
glycine, 10% (v/v) methanol). Membranes were blocked in 4% blocking solution (4% (w/v) ECL 
Advance blocking powder, AEC Amersham Biosciences, South Africa) in Tris buffered saline (50 mM 
Tris, 150 mM NaCl) (TBS) containing 0.1% (v/v) Tween (TBS-Tween) for 1 h at RT and subsequently 
incubated with primary antibody (see table 2.2 for specific dilutions) in blocking solution at 4ºC 
overnight. The following day membranes were incubated at RT with an anti-rabbit HRP conjugate 
(1:10000) for 1 h at RT in 5% milkpowder (w/v) in TBS-Tween. After antibody incubation, membranes 
were washed for 15 min and 2 X 5 min in TBS-Tween at RT. For consecutive detection steps, 
membranes were stripped in stripping buffer (100 mM ß-mercaptoethanol, 2% (w/v) SDS, 62.5 mM 
Tris-Cl, pH 6.7, (Sambrook et al., 1989)) for 30 min at 65ºC, washed 2 X 10 min with TBS-Tween and 
blocked for 1 h in 4% blocking solution before repeating antibody incubations as described above. Un
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Antibody Diliution 
GR  1:4000 
PR 1:1000 
MR 1:1000 
AR 1:1000 
ß-actin 1:5000 
phospho JNK 1:1000 
JNK 1:1000 
phospho p38 1:1000 
p38 1:1000 
phospho ERK 1:1000 
ERK 1:1000 
c-Jun 1:3000 
c-Fos 1:3000 
phospho-Ser-234 1:10000 
phospho-Ser-220 1:10000 
 
Table 2.2: Dilutions of primary antibodies used in Western blot analysis 
 
2.12 Autoradiography and quantification 
Autoradiography and ECL visualization were performed with Amersham Hyperfilm MP high 
performance autoradiography film. Autoradiograms were photographed using the Kodak 
Electrophoresis Documentation and Analysis System (EDAS) 290, and bands were quantified with 
Kodak 1D Image Analysis Software. Autoradiograms were quantified using AlphaEaseFCTM Software 
(AlphaInnotech, USA). 
 
2.13 Immunofluorescence 
LßT2 cells were grown on glass cover slips in 6 well plates (Nunc, Denmark) at a density of 2 X 105 
cells per well. Twenty four h after plating, medium was changed to serum-free medium and cells were 
serum-starved overnight. The next day cells were incubated with test compounds for 1 h as indicated 
in figure legends. After stimulation, cells were washed twice with PBS, fixed and permeabilised with 
methanol at -20ºC for 10 min and washed again 3 X with cold PBS. Cells were stained with anti-GR H-
300 antibody (1:100 dilution) in PBS-5% BSA for 1 h, washed 3 x 5 min with PBS and subsequently 
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incubated with a fluorescent labeled secondary antibody (AlexaFluor488 labeled donkey anti-rabbit 
IgG, Molecular Probes, USA) in PBS-5%BSA (1:500) for 1 h. After 3 X 10 min washes with PBS, the 
slides were incubated with Hoechst DNA stain (1:1000) (Sigma-Aldrich, South Africa) in PBS for 10 
min. The slides were washed again and mounted in fluorescent mounting medium (KPL, USA). 
Staining was visualized with an Olympus IX 81 microscope and analyzed with the CellR software 
(Olympus, Gerany). For each treatment approximately 80 individual and randomly chosen cells were 
subjected to intensity analysis whereby the intensity of the fluorescent signal was measured in the 
region of interest (ROI). 
 
2.14 Chromatin immunoprecipitation assay (ChIP assay) 
ChIp assay was perforemed based on (Ma et al., 2003) with some modifications. 
2.14.1 Chromatin preparation 
Cells were grown in 15 cm dishes (Nunc, Denmark) to 80% confluency and treated with compounds 
for 1 h in the absence of serum as indicated in the figure legends. Proteins were cross-linked with 1% 
formaldehyde for 10 min at 37ºC and the reaction stopped with 0,125 M glycine for 5 min at RT. Cells 
were washed twice with cold PBS and scraped in PBS containing 1 x Complete Mini Protease Inhibitor 
Cocktail (1 tablet per 10 ml) (Roche Applied Science, South Africa). Subsequently, the cells were 
pelleted by centrifugation at 5000 g (4ºC) and resuspended in 500 µl nuclear lysis buffer (1% SDS, 50 
mM Tris-HCL, pH 8.0, 10 mM EDTA, 1 tablet 1 x Complete Mini Protease Inhibitor Cocktail per 10 ml). 
Cross-linked samples were fragmented by sonication to obtain DNA fragments between 100 – 400 bp 
using the Misonix Sonicator® 3000 with a microtip at the following conditions: 20 pulses at setting 4 for 
20 sec each with resting phases in between each pulse for 40 sec, on ice. After sonication the 
samples were centrifuged at 15000 g for 10 min (4ºC) and the supernatant was transferred into a new 
microcentrifuge tube. To normalize for equal amounts of DNA per immunoprecipitation, the chromatin 
was quantified by means of optical density readings. Therefore, the sonicated chromatin was diluted 
1:20 in dH2O and the optical density measured at 260 nm. The sonicated chromatin was stored at -
80ºC for short terms or used immediately for immunoprecipitation. To confirm the size of the chromatin 
fragments generated by sonication, the DNA was purified as described below (2.14.3) and analyzed 
on a 1% agarose gel by means of gel electrophoresis.  
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2.14.2 Immunoprecipitation 
An aliquot of 100 µg of chromatin in 100 µl nuclear lysis buffer was diluted with 900 µl IP dilution buffer 
(0.01% SDS, 20 mM Tris-HCL, pH 8.0, 1.1% Triton X-100, 167 mM NaCl, 1.2 mM EDTA, 1 x 
Complete Mini Protease Inhibitor Cocktail, 1 tablet per 10 ml). To reduce non-specific binding, the 
chromatin was pre-cleared for 1 h with 20 µl pre-blocked Protein A/G PLUS beads (sc-2003, Santa 
Cruz Biotechnology, USA) on a rotating wheel at 4ºC. Pre-blocked Protein A/G PLUS beads were 
prepared by incubating 500 µl of pure beads with 2 ml IP dilution buffer, salmon sperm DNA (final 
concentration 0,2 mg/ml) and BSA (final concentration 1 mg/ml) for 1 h on a rotating wheel at 4ºC. 
After centrifugation the beads are resuspended as 50% slurry in IP dilution buffer. After pre-clearing 
the chromatin was centrifuged at 15000 g for 10 min to pellet the beads and the supernatant 
transferred into a new microcentrifuge tube followed by incubation with 5 µg of anti-GR (H-300, sc 
8992), anti-c-Jun (D, Sc-44), anti-c-Fos (K-25, sc-253), or 2 µg anti-p300 (NM11, sc-32244), anti-SRC-
1 (M-341, sc8995, Santa Cruz Biotechnology, USA), anti-GRIP-1 (G8970-10, United States Biological, 
USA) or anti-IgG antibody (sc-2350, Santa Cruz Biotechnology, USA) overnight on a rotating wheel at 
4ºC. The next day 40 µl of pre-blocked Protein A/G PLUS beads were added to the mixture and 
incubated for further 6 h rotating at 4ºC to allow complexes to form. The complexes were collected by 
centrifugation at 5500 g for 1 min (4ºC) and the pellet washed sequentially with 1 ml of each wash 
buffer I (0.1% (w/v) SDS, 1% (v/v) Triton X-100, 2 mM EDTA, 20 mM Tris-HCL pH 8.0 and 150 mM 
NaCl), wash buffer II (0.1% (w/v) SDS, 1% (v/v) Triton X-100, 2 mM EDTA, 20 mM Tris-HCL pH 8.0 
and 500 mM NaCl) and III (1% (v/v) NP-40, 1% (w/v) sodium deoxycholate, 500 mM LiCl, 1 mM EDTA 
and 10 mM Tris pH 8.0) followed by three washes with 1 ml TE (10 mM Tris-HCL pH 8.0 and 0.1 mM 
EDTA). The DNA-protein complexes were eluted from the Protein A/G PLUS beads by incubating the 
beads twice with 150 µl IP elution buffer (1% (w/v) SDS and 100 mM NaHCO3) at RT on a rotating 
wheel. An aliquot of 30 µg sonicated chromatin was set aside as the input, to which 90 µl IP elution 
buffer was added and the volume was adjusted to a total of 120 µl with nuclear lysis buffer. The cross-
links were reversed and input DNA was purified as described below (2.14.3). 
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2.14.3 Reversing formaldehyde crosslinks, DNA purification and analysis of precipitated DNA 
To reverse cross-links NaCL was added to the input or immunoprecipitated samples to a final 
concentration of 300 nM followed by an overnight incubation at 65ºC. The next day EDTA (final 
concentration 15 nM EDTA), Tris-HCL pH 6,5 (final concentration 125 nM) and proteinase K to a final 
concentration of 60 ng/µl (Roche Applied Science, South Africa) were added. The mixture was 
incubated for 1 h at 45°C and immunoprecipitated and input DNA was purified using the QIAquick 
PCR Purification Kit (Qiagen, USA) according to manufacturer’s protocol.  
Conventional PCR and real-time RT-PCR were performed using specific primers spanning the AP-1 
region of the mouse GnRHR-promoter (forward 5’ GTATCTGTCTAGTCACAACAG 3’ and reverse 5’ 
TCCTGAAGGCCAAGTGTAACC 3’ (Sadie, 2006) under the following conditions: 
 
GnRHR Denaturation Annealing        Extension cycling 
Conventional 
PCR 
45 sec 95°C 45 sec 72°C 45 sec 51°C 35 
real-time PCR 8 sec 95°C 8 sec 72°C 10 sec 51°C 
 
40 
 
Primers used for ChIP AP-1 positive control were forward 5’GGTGTGCTGCCATATCAGATTCGG 3’ 
and reverse 5’ GCATCAAGTGCTGCTACTCACCTGTG 3’, spanning the AP-1 site of the mouse 
FSHß-promoter (Coss et al., 2004) under the following conditions:  
 
FSHß Denaturation Annealing        Extension cycling 
real-time PCR 8 sec 95°C 8 sec 72°C 10 sec 56°C 
 
40 
 
Each conventional PCR reaction contained the following: 
 
Input DNA / precipitated DNA   2 µl / 4 µl 
sense primer     final 0,2 µM 
antisense primer    final 0,2 µM 
dNTP Mix     0,05 µM of each dNTP final (0,2 µM dNTP mix final) 
MgCL2      1 mM final 
5xGoTaq® buffer (Promega)   1 x 
GoTaq®Flexi DNA Polymerase  (Promega) 1,25U 
PCR H2O     to make up a final volume of 50 µl 
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Each real-time PCR reaction contained the following: 
 
Input DNA / precipitated DNA  2 µl / 4 µl 
forward primer    final 0,5 µM 
revers primer    final 0,5 µM 
SensiMixdT (Quantace)   12,5 µl 
PCR H2O    to make up a final volume of 25 µl 
 
PCR amplicons were analyzed on a 1,5 % Agarose gel by means of gel electrophoresis.  
Real-time PCR was used to calculate the relative protein recruitment to the gene of interest with the 
“Fit Points” method described by Pfaffl et al. (Pfaffl, 2001) after normalization to the inputs.  
 
2.15 Statistical analysis 
Results were analysed with GraphPad PRISM (version 4) software from GraphPad Software Inc, 
using One-way ANOVA, with either Dunnett's post-test (when comparing all values to a single control) 
or Bonferroni’s post-test (when comparing all values to each other). P values for comparison of 2 
samples were obtained by using the paired t-test. Where statistical significance of difference was 
determined relative to a single control statistical significance is denoted by *, ** or ***, to indicate 
P<0.05, P<0.01 or P<0.001, respectively. Where all values were compared to each other, statistical 
significance of difference is indicated by different lower-case letters, such that all the conditions with 
the same letter are not statistically significantly different from each other (P>0.05), while those having 
different letters are statistically significantly different from each other (P<0.05). 
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CHAPTER 3 
RESULTS 
AN INVESTIGATION INTO HOMOLOGOUS AND GC REGULATION 
OF THE MOUSE GnRHR GENE IN THE LβT2 GONADOTROPE CELL LINE 
 
3.1 BACKGROUND 
At present, the most utilized model systems for investigating expression of gonadotrope-specific 
genes in cell culture are the αT3-1 and LßT2 immortalized mouse gonadotrope cell lines. The αT3-1 
cell line is an immature precursor gonadotrope cell line, which expresses a functional GnRHR, as well 
as the glycoprotein hormone α-subunit, but neither of the glycoprotein hormone-specific β-subunits, 
LHβ and FSHβ (Windle et al., 1990). The LßT2 cell line is a more mature and differentiated 
gonadotrope cell line since these cells express functional GnRHR, as well as the glycoprotein 
hormone α-subunit, LHβ and FSHβ, thus displaying functional characteristics of normal fully 
differentiated gonadotropes (Pernasetti et al., 2001; Turgeon et al., 1996). 
In the past, homologous regulation of the mouse GnRHR gene has been studied predominantly in the 
αT3-1 cell line (Duval et al., 1997b; Norwitz et al., 1999a; White et al., 1999) and very few reports 
have been published on the regulation of the GnRHR gene in LßT2 cells. The synthetic GC dex has 
been shown to upregulate expression of both the endogenous GnRHR gene and a transfected mouse 
GnRHR promoter-reporter construct in somatolactotrope GGH3 cells expressing exogenous GnRHR 
and LβT2 cells (Maya-Nunez and Conn, 2003; McGillivray et al., 2007; Turgeon et al., 1996). The 
transcriptional regulation of the proximal mouse GnRHR gene by GnRH and dex has previously been 
investigated by others in Prof. Hapgood’s laboratory in LßT2 cells (Addendum B figure B1) 
(Fernandes, 2007; Sadie, 2006). It was found that continuous stimulation for 8 h with 100 nM GnRH 
significantly increased the transcriptional activity of the transiently transfected GnRHR promoter-
reporter construct (pLG wild-type, containing 580 bp of the mouse GnRHR gene) by approximately 
2,5-fold compared to the vehicle control (Addendum B figure B2 A and B) (Sadie, 2006). A study by 
Bedecarrats et al. found only weak activation (about 1,5 fold) of a GnRHR-promoter construct by 
GnRH in LßT2 cells (Bedecarrats and Kaiser, 2003). However, in that particular study the cells were 
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stimulated continuously for 10 h with low concentration (10 nM) of GnRH. In addition, it was previously 
found that continuous stimulation of LßT2 cells with 100 nM dex results in a statistically significant 
increase in pLG promoter activity by about 2,5-fold similarly to the response observed with GnRH 
(Addendum B figure B1 C) (Fernandes, 2007). This is in agreement with a recent study showing that a 
1,2 kb mouse GnRHR-promoter construct responds to continuous (24 h) stimulation with 100 nM dex 
by approximately 2-fold (McGillivray et al., 2007). Furthermore, preliminary results from Prof. 
Hapgood’s laboratory show that the endogenous GnRHR gene is transcriptionally regulated by GnRH 
and dex in LßT2 cells (Sadie, 2006; von Boetticher, 2008).  
Previously it has been reported that the activating protein-1 (AP-1) binding site is a critical component 
in regulation of both basal and GnRH-stimulated mouse GnRHR gene expression in αT3-1 cells (Kam 
et al., 2005; Norwitz et al., 1999a; White et al., 1999). The role of the AP-1 site in basal, as well as 
GnRH- and dex-induced expression of the GnRHR has recently been investigated by others in this 
laboratory in LßT2 cells (Addendum B figure B2) (Fernandes, 2007; Sadie, 2006). Basal promoter 
activity of a mutant construct containing a mutation in the AP-1 site within the context of the pLG 
GnRHR promoter-reporter construct (pLGmAP1), was significantly decreased by about 50% to that of 
the wild-type pLG construct (Addendum B figure B2 A) (Fernandes, 2007). This is consistent with 
findings by other groups showing that AP-1 is part of a tripartite basal transcriptional enhancer, since 
the loss of the AP-1 site decreased basal promoter activity in αT3-1 cells (Duval et al., 1997b; White et 
al., 1999). These reports together with previous result presented in Addendum B figure B2 A indicate 
an important role for the AP-1 cis-element in maintaining basal expression in gonadotrope cells. 
Furthermore the loss of the AP-1 site was found to significantly reduce the GnRH-mediated response 
(Addendum B figure B2 B) (Sadie, 2006) which is in agreement with other reports showing the 
involvement of this cis-element in responsiveness to GnRH in transgenic mice (Ellsworth et al., 2003b) 
and in transfected αT3-1 cells (Norwitz et al., 1999a; White et al., 1999). Similarly, mutation of the AP-
1 site has been shown to result in a complete loss of the dex-induced transcriptional activation of the 
promoter (Addendum B figure B2 C) (Fernandes, 2007), as was found by Maya-Nunez and Conn in 
GGH3 cells (Maya-Nunez and Conn, 2003). These data provide evidence that a functional AP-1 site is 
a requirement for the full transcriptional response of the GnRHR gene to GnRH and dex in LßT2 cells. 
While homologous and dex-mediated regulation of endogenous GnRHR levels and a synthetic mouse 
GnRHR promoter occurs in LβT2 cells (Bedecarrats and Kaiser, 2003; Fernandes, 2007; McGillivray 
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et al., 2007; Sadie, 2006; Turgeon et al., 1996; von Boetticher, 2008), more studies are needed to 
unravel the detailed molecular mechanisms of transcriptional regulation of the GnRHR in this more 
differentiated gonadotrope cell line. 
 
3.2 AIMS 
The aim of the present part of the project was to investigate transcriptional regulation of the GnRHR 
gene by GnRH and dex in LβT2 cells and to determine cis-regulatory elements as well as transcription 
factors involved. 
Since both GCs and GnRH have been proposed to regulate GnRHR gene expression in separate 
reports, in the present study each experiment was carried out with dex and GnRH in parallel to directly 
compare the magnitude of the response and the mechanisms involved in LßT2 cells. 
 
The detailed aims of this part of the study were the following: 
- To establish whether the endogenous GnRHR gene is regulated by dex and GnRH in 
LßT2 cells; 
- To investigate the role of the AP-1 site in the GnRHR promoter region in the transcriptional 
response under basal, dex-, and GnRH-stimulated conditions; 
- To examine expression levels of the AP-1 proteins c-Jun and c-Fos as well as binding of 
these transcription factors to the endogenous GnRHR gene in under basal, dex-, or 
GnRH-stimulated conditions in intact LßT2 cells; 
- To investigate expression of functional steroid receptors in LßT2 cells; 
- To investigate recruitment of the GR to the endogenous GnRHR gene in response to 
hormone stimulation in vivo; 
- To establish a requirement for the GR in GnRHR gene expression in LßT2 cells 
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3.3 RESULTS 
3.3.1 Both GnRH and dex increase expression of the endogenous mouse 
GnRHR gene in LßT2 cells  
Previously it has been shown that GnRH and dex increase endogenous GnRHR gene expression in 
LßT2 cells although statistical significance could not be established (Sadie, 2006; von Boetticher, 
2008). Thus in the present study it was thought to confirm these results. Therefore GnRHR mRNA 
levels were measured by means of quantitative real-time PCR. RNA was isolated from cells stimulated 
continuously for 8 h with 100 nM dex or 100 nM GnRH in serum-free medium. It was found that both 
GnRH and dex increased endogenous GnRHR mRNA levels significantly after 8 h of treatment, 
compared to vehicle control in several repeat experiments (figure 3.1). The magnitude of the response 
varied between individual experiments probably due to the high sensitivity of gonadotrope cells to their 
environment and biological variation. However it could be established that both GnRH and dex 
increased GnRHR mRNA levels (figure 3.1) suggesting a direct transcriptional effect on GnRHR 
expression in LßT2 cells. 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Both GnRH and dex increase expression of the endogenous mouse GnRHR gene in 
LßT2 cells 
Total RNA was isolated from cells treated with test compounds for 8 h. RNA was reverse-transcribed, 
and relative levels of GnRHR transcripts were determined by quantitative real-time PCR. Relative 
levels of GnRHR mRNA were normalized to GAPDH mRNA levels transcripts were determined to 
serve as internal control. Fold changes in GnRHR mRNA levels were calculated relative to vehicle-
treated (control) samples. The graph shows combined results of 3 independent experiments. 
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3.3.2 GnRH but not dex induces a minimal AP-1 reporter construct in LßT2 cells 
Since it has previously been found that a functional AP-1 site within the GnRHR promoter is a 
requirement for the full transcriptional dex- and GnRH-mediated response of the GnRHR gene in LßT2 
cells (Addendum B figure B2) (Fernandes, 2007; Sadie, 2006) it was determined in the present study 
whether the AP-1 site within the GnRHR promoter is sufficient for the response to dex and GnRH. 
Therefore LßT2 cells were transfected with a minimal synthetic AP-1-luciferase construct (pAP1-luc) 
and stimulated for 8 h with dex or GnRH. The result presented in figure 3.2 shows a significant 
increase (approximately 50-fold) in the activity of the pAP1-luc construct when cells were treated with 
GnRH, supporting the hypothesis that, in LβT2 cells, GnRH can upregulate transcription from an AP-1 
site without a requirement for other cis-elements. The higher magnitude of the GnRH response of 
pAP1-luc, compared to that of pLG (Addendum B figure B2), may be due to the presence of seven 
AP-1 sites in the pAP-1–luc construct, as opposed to only one in the GnRHR promoter. The result 
together with previous results from Prof. Hapgood’s laboratory, showing that mutation of the AP-1 site 
results in decreased GnRH-mediated transcriptional activity of a transfected GnRHR promoter 
construct, suggest that this cis-element is an essential requirement for GnRH-induced transcriptional 
activation of the GnRHR promoter in LßT2 cells. 
In contrast to the results obtained with GnRH, treatment with dex did not increase the transcriptional 
activity of a pAP1-luc construct, compared to vehicle-treated cells. The result suggests that the AP-1 
site alone is not sufficient to mediate the dex-induced upregulation of the GnRHR promoter activity 
and that other cis-elements present within - 569 to +1 of the GnRHR promoter construct are most 
likely to be involved in the dex-mediated upregulation of this gene. 
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     AP-1 luc:    TGAcTaA 
     mGnRHR:  TGAgTcA 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: GnRH but not dex induces a minimal AP-1 reporter construct in LßT2 cells  
LßT2 cells were transfected with 250 ng of the pAP-1 luc construct and after approximately 24 h cells 
were incubated for 8 h in serum-free medium in the absence or presence of 100 nM GnRH or 100 nM 
dex (A and B). The luciferase activity was normalized to ß-galactosidase activity and the hormone-
stimulated increase in promoter activity was calculated relative to the control. Graphs show combined 
results of at least 3 independent experiments, each performed in triplicate. The sequences of the 
consensus AP-1 site and the AP-1 element in the mouse GnRHR promoter are shown. 
 
 
3.3.3 GnRH but not dex increases AP-1 protein expression levels  
Since it was previously established in this laboratory that the AP-1 site is an essential regulatory 
promoter element for basal as well as dex- and GnRH-stimulated gene expression of the GnRHR in 
LßT2 cells (Addendum B figure B2) (Fernandes, 2007; Sadie, 2006) it was of interest to further 
investigate the role of this cis-element in these cells. Various stimuli increase expression or activity of 
several members of the AP-1 protein family such as Fos and Jun in gonadotrope cell lines (Cesnjaj et 
al., 1994; Coss et al., 2004; Ellsworth et al., 2003b; Kakar et al., 2003; Liu et al., 2002a; Wurmbach et 
al., 2001). In particular GnRH was found to rapidly induce protein expression of c-Jun and c-Fos in 
LßT2 cells (Coss et al., 2004; Liu et al., 2002a; Sadie, 2006) and therefore it is likely that increased 
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expression of c-Jun or c-Fos might present a potential mechanism by which GnRH and/or dex 
regulate GnRHR expression via the AP-1 site. 
In order to investigate the effect of dex and GnRH on AP-1 proteins expression levels, Western blot 
analysis was performed on whole cell extracts of LßT2 cells stimulated with 100 nM dex or 100 nM 
GnRH as indicated in the figure legend (figure 3.3). Immunodetection was performed using specific 
antibodies for c-Jun (figure 3.3 A) and c-Fos (figure 3.3 C). Importantly, since it has been stressed in 
the literature that serum, present in culture medium, results in increased Jun and Fos mRNA levels 
(Chen et al., 1995; Jaffey et al., 1992), in the present study LßT2 cells were serum-starved over night. 
As shown in figure 3.3 A, c-Jun proteins were not detectable in unstimulated or dex-treated samples. 
In contrast GnRH stimulation resulted in a rapid increase in c-Jun protein expression after 30 min, 
reaching its peak at 1 h of treatment (figure 3.3 A and B) which is consistent with reports in the 
literature (Coss et al., 2004; Liu et al., 2002a; Sadie, 2006). Similarly, GnRH strongly induced 
expression of c-Fos proteins in LßT2 cells after 30 min of treatment and was decrease after 4 h while 
c-Fos remained undetectable in untreated as well as dex-stimulated cells at any time point 
investigated (figure 3.3 C and D). Note that in figure 3.3 C the mobility of the bands differs at different 
time points. Since the anti-Fos antibody used in this experiment does detect c-Fos as well as other 
family members, it is likely that these bands represent different Fos proteins.  
Western blotting is a measure of the relative abundance of a protein in whole cell lysates, strongly 
depending on the sensitivity of the specific antibody. Thus, the absence of c-Jun and c-Fos proteins in 
unstimulated or dex-treated samples could be due to very low expression of these proteins in LßT2 
cells. Other reports in the literature show low detectable amounts of c-Jun and c-Fos proteins in 
unstimulated LßT2 cells in the absence of serum (Coss et al., 2004; Liu et al., 2002a). Taken together, 
it appears that both c-Jun and c-Fos proteins are strongly and transiently increased by GnRH while 
dex treatment appeared to have no effect on the expression levels of these proteins.  
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Figure 3.3: Effect of GnRH treatment on AP-1 protein expression in LβT2 cells (legend to follow 
on next page) 
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LßT2 cells were grown and serum-starved overnight before treatment with 100 nM GnRH or 100 nM 
dex for the indicated times. Equal amounts of cell lysates were loaded on an 8% SDS-PAGE gel, 
transferred onto nitrocellulose membrane and probed using specific antibodies for c-Jun (A) or c-Fos 
(C). The graphs in B and D show combined results of at least 2 independent experiments. The relative 
amount of protein was quantified with the value for control (vehicle) set as 1. 
 
 
3.3.4 Both c-Jun and c-Fos proteins are bound under basal as well as dex- and 
GnRH-stimulated conditions to the AP-1 region of the endogenous GnRHR 
promoter in intact cells 
Specific in vitro binding of the AP-1 proteins Jun and Fos to the AP-1 region of the GnRHR gene in 
response to GnRH has been shown in αT3-1 cells (Norwitz et al., 1999a; White et al., 1999) as well as 
in LßT2 cells (Sadie, 2006). Furthermore a study by Jeong et al. demonstrated by ChIP the binding of 
c-Jun to the GnRHR gene in the absence of hormone in LßT2 cells (Jeong et al., 2004). However, 
binding of c-Jun and c-Fos proteins to the endogenous GnRHR promoter in response to dex or GnRH 
in intact cells has not been reported. 
Therefore, the proteins interacting with the AP-1 site on the endogenous GnRHR promoter in 
response to GnRH or dex were investigated in intact LßT2 cells by ChIP. When anti-c-Jun or anti-c-
Fos antibodies were used for immunoprecipitation, PCR products could be detected in samples from 
untreated cells (figure 3.4 A), suggesting that both AP-1 proteins are occupying the AP-1 side under 
basal conditions and are thus likely to be involved in maintaining basal promoter activity. This is in 
agreement with results presented in figure 3.2 A where the pLGmAP-1 construct exhibited decreased 
basal activity, compared to wild type pLG construct. The Western blot results presented in figure 3.3 
did not detect any AP-1 proteins from untreated whole cell lysates which could be due to the low 
affinity of the AP-1 antibodies in conjunction with very low abundance of the AP-1 proteins 
investigated. However, the specificity of the AP-1 antibodies was confirmed using a control IgG 
antibody (figure 3.4 A).  
Stimulation with GnRH or dex did not result in increased binding of either c-Jun or c-Fos proteins, 
suggesting that neither the amounts nor the relative composition of c-Jun or c-Fos proteins at the AP-1 
site were modulated upon hormone stimulation (figure 3.4 A and B). These data further indicate that c-
Jun and c-Fos are bound to the AP-1 site of the GnRHR promoter under basal -, and hormone-
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stimulated conditions, possibly forming a platform for other transcription factors to bind in response to 
hormone. Since the c-Jun antibody used in this experiment detects Jun-B and Jun-D while the c-Fos 
antibody shows cross reactivity with Fos-B, Fra-1 and Fra-2, it is likely that these AP-1 family 
members can be potential occupants on the endogenous GnRHR promoter in the absence and 
presence of hormone. Amplification of the AP-1 region of the FSHß gene promoter from the same 
control and GnRH-treated sample immunoprecipitates revealed that, unlike for the GnRHR AP-1 
region, GnRH stimulation results in an greater than 15-fold recruitment of both c-Jun and c-Fos to this 
promoter (figure 3.4 C and D), as shown previously by others (Coss et al., 2004). This result shows 
that the similar levels of AP-1 proteins observed on the GnRHR promoter in the absence and 
presence of GnRH (figure 3.4 A and B) are not due to a deficiency in the AP-1 ChIP procedure.  
This is in contrast to a report showing that GnRH induces an increase in AP-1 proteins, specifically c-
Jun, binding to the promoter in intact αT3-1 cells (Kam et al., 2005), as well as in vitro results showing 
that c-Jun and not c-Fos proteins are able to bind to the AP-1 element in response to dex in GGH3 
cells (Maya-Nunez and Conn, 2003). The discrepancy in the results obtained is probably due to cell 
specific differences as well as differences in culture conditions.  
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Figure 3.4: (continued on next page) 
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Figure 3.4: Both c-Jun and c-Fos proteins are bound under basal as well as dex- and GnRH-
stimulated conditions to the AP-1 region of the endogenous GnRHR promoter in intact cells  
Chromatin immunoprecipitation (ChIP) assays were performed in LßT2 cells treated with vehicle 
(control), 100 nM GnRH or 100 nM dex for 1 h. ChIP was performed with anti-c-Jun or anti-c-Fos (A, 
B). Precipitated complexes bound to the endogenous GnRHR (A) or FSH-ß promoter (C) were 
detected using PCR primers encompassing the AP-1 region of the promoters. The FSH-ß promoter 
was analyzed using the same samples as a positive control for GnRH-stimulated recruitment of the 
AP-1 proteins (Coss et al., 2004). The co-immunoprecipitated DNA fragments and input DNA were 
analyzed by conventional PCR and by real-time PCR. Pooled and quantified results of three 
independent experiments are shown normalized to input and expressed as fold-response relative to 
control values (B,D). 
 
3.3.5 Steroid receptor expression in LßT2 cells 
There are a few reports in the literature showing expression of mRNA transcripts of the glucocorticoid 
receptor (GR),the progesterone receptor (PR), the estrogen receptor (ER) as well as the androgen 
receptor (AR) in LßT2 cells (Eertmans et al., 2007; Lawson et al., 2001; Schreihofer et al., 2000; 
Thackray et al., 2006). While dex- (Eertmans et al., 2007; Sasson et al., 2008; Turgeon et al., 1996), 
estrogen- (Turgeon et al., 1996) and androgen-mediated induction of gene transcription was shown 
(Eertmans et al., 2007; Lawson et al., 2001), protein expression has only been reported for the PR (An 
et al., 2009) and the ERα (Chen et al., 2009; Schreihofer et al., 2000) in LßT2 cells. However, a study 
by Eertmans et al. reported a lack of ERα protein expression in LßT2 cells and moreover they reported 
that estrogenic responses were absent following co-transfection with an ERα expression vector 
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(Eertmans et al., 2007). In view of these inconsistencies it was of interest to investigate the expression 
of functional GR, ER, PR, MR and AR in the specific LßT2 subclone used in the present study. 
Whole cell lysates from LßT2 cells were analyzed by Western blotting using specific antibodies for the 
GR, PR, MR and AR to determine the expression of these steroid receptors in these cells. As shown 
in figure 3.5 A GR protein expression was detected in the LßT2 cell lysates. The specificity of the band 
was confirmed by using COS-1 cells transfected with a GR expression plasmid as positive control 
(figure 3.5 A). By contrast the PR, MR or AR could not be detected in these cells while specific bands 
with the right molecular weight were detected in COS-1 positive control cell lysates (figure 3.5 A). Note 
that in figure 3.5 A two protein bands can be seen when probing with the MR antibody in COS-1 cells. 
It could be established that the upper band presents a non-specific band while the band with lower 
molecular weight was shown to present the MR since this band was only detectable in COS-1 cells 
expressing exogenous MR and it was absent in untransfected COS-1 cells and LßT2 cells. Due to 
failure of the ER specific antibody, protein expression of this steroid receptor could not be determined 
in LßT2 cells.  
As an alternative strategy towards detecting the presence of a particular receptor in LßT2 cells steroid-
receptor mediated gene transcription was investigated in LßT2 cells using a GRE-luciferase construct 
or an estrogen-responsive-element (ERE) reporter-construct. Treatment of the transfected cells with 
100 nM dex (a potent GR agonist) increased the transcriptional response of the GRE-reporter 
construct by approximately 3-fold which is in agreement with the Western blot result showing protein 
expression of the GR in LßT2 cells. By contrast, treatment with steroid-receptor specific agonists for 
the AR (mibolerone Mib), MR (aldosterone, Ald) or PR (progesterone, Prog and R5020) did not result 
in a significant increase in transcriptional activity of the steroid receptor-driven reporter construct 
(figure 3.5 B). In addition estrogen stimulation failed to activate the ERE-reporter as shown in figure 
3.5 C suggesting that no functional ER is expressed in LßT2 cells. As a positive control assay, COS-1 
cells were cotransfected with a GRE- or a ERE-luciferase construct and expression plasmids coding 
for the full length MR, PR, AR or ER and stimulated with the specific ligands as described above 
(figure 3.5 D and E). The results show that all the specific ligands are functional. Attempts to 
overexpress the steroid receptors in LßT2 cells were unsuccessful possibly due to the low transfection 
efficiancy of the cell line. Taken together the results show that the LßT2 cells used for this study 
express functional endogenous GR but not ER, AR, PR or MR. 
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Figure 3.5: LßT2 cells express functional GR (figure legend to follow on next page) 
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A: LßT2 cells were grown and whole cell lysates prepared. Equal amounts of cell lysates were loaded 
on an 8% SDS-PAGE gel, transferred onto nitrocellulose membrane and probed using specific 
antibodies for GR, MR, AR, PR or ß-actin as a loading control. B-E: LβT2 cells (B and C) or COS-1 
cells (D and E) were transfected with 250 ng TAT-GRE-luciferase construct (B and D) or with 250 ng 
pSG5-ERE-luciferase construct (C and E) in the absence (B and C) or presence of expression 
plasmids for the MR, AR, PR (D) or ER (E). After approximately 24 h cells were incubated for 8 h in 
serum-free medium with vehicle (control), 100 nM dex, 100 nM aldosterone, 100 nM mibolerone, 100 
nM R5020, 100 nM progesterone (B an D) or 100 nM estradiol (E2) (C and E) as indicated below the 
relevant bars. The luciferase activity was normalized to ß-galactosidase and the hormone-stimulated 
increase in promoter activity was calculated relative to the vehicle control. The graphs show the 
promoter activity relative to vehicle (control) of combined results of three (B,C,E) or one (D) 
independent experiment(s), each performed in triplicate, where the luciferase activity was normalized 
to ß-galactosidase. NS: non-specific band 
 
3.3.6 Both dex and GnRH induce recruitment of the GR to the AP-1 region on 
the endogenous GnRHR promoter in intact cells 
As established in section 3.3.4, AP-1 proteins, specifically c-Jun and c-Fos, appear to be bound to the 
GnRHR promoter under basal and stimulated conditions possibly providing a platform for other 
transcription factors to bind. Thus, the same samples (section 3.3.4) were analyzed by ChIP to explore 
whether the GR is recruited to the AP-1 promoter element in response to dex. The results presented in 
figure 3.6 A and B show that treatment with dex promotes a rapid and strong recruitment of the GR to 
the AP-1 region in the GnRHR promoter by approximately 3,5 fold compared to vehicle control treated 
cells (figure 3.6 A and B). Immunoprecipitation with a non-specific IgG antibody confirmed the 
specificity of the GR antibody. This is the first report showing dex-mediated recruitment of the GR to 
the AP-1 region of the GnRHR promoter in intact LßT2 cells. Although it can be concluded that the GR 
is recruited to the endogenous promoter in a hormone dependent fashion, the particular mechanism of 
GR binding to the DNA is unknown. The PCR primers span a region of 168 bp of the proximal GnRHR 
promoter, encompassing the AP-1 site at -336/-330 relative to the translational start site. Thus, the 
possibility of GR binding to proteins on adjacent DNA motifs occupied with other transcription factors 
besides AP-1 cannot be excluded. This hypothesis is in agreement with the result presented in figure 
3.2 showing that dex cannot induce transactivation of a minimal promoter containing only an AP-1 
sites. Attempts to investigate whether GR and AP-1 proteins occur in the same complex by co-
immunoprecipitation and re-ChIP experiments were unsuccessful, possibly due to the low abundance 
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of the endogenous complexes. Interestingly, when chromatin from GnRH-treated samples was 
analyzed, the GR was also found to be significantly recruited to the AP-1 region of the endogenous 
promoter although to a slightly lesser extent than dex (~3,5fold) by approximately 2 fold (figure 3.6 B). 
This result was surprising and unexpected and indicates that GnRH results in activation of the GR in 
the absence of a GR ligand in LßT2 cells.  
 
A     B 
 
 
 
Figure 3.6: Both dex and GnRH induce recruitment of the GR to the AP-1 region on the 
endogenous GnRHR promoter in intact cells 
Chromatin immunoprecipitation assays (ChIP) in LßT2 cells treated with vehicle (control), 100 nM 
GnRH or 100 nM dex for 1 h. ChIP was performed with an anti-GR specific antibody. Precipitated 
complexes bound to the endogenous GnRHR promoter were detected using PCR primers 
encompassing the AP-1 region of the promoter. The co-immunoprecipitated DNA fragments and input 
DNA were analyzed by conventional PCR (A) and by real-time PCR (B), Pooled and quantified results 
of 3 independent experiments are shown normalized to input and expressed as fold-response relative 
to control values (B).  
 
3.3.7 Protein expression levels of the GR remain unchanged in response to dex 
or GnRH 
To investigate whether the dex- and GnRH-mediated increase in GR recruitment to the endogenous 
GnRHR promoter (shown in figure 3.6) was the result of increased GR protein levels, Western blot 
analysis was performed on whole cell lysates of LßT2 cells treated with 100 nM dex or 100 nM GnRH 
for the indicated times. In figure 3.7 it can be seen that GR protein expression levels remained 
unchanged over an 8 h time course in cells treated with dex or GnRH compared to vehicle control 
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suggesting that altered GR protein expression levels are not involved in increased GR recruitment to 
the AP-1 region of the GnRHR in response to dex or GnRH.  
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Figure 3.7: GR expression levels in response to dex or GnRH in LßT2 cells remain unchanged  
LßT2 cells were grown and serum-starved overnight before treatment with 100 nM GnRH or 100 nM 
dex for the indicated times. 1/10 of a whole cell lysate was loaded on an 8% SDS-PAGE gel, 
transferred onto nitrocellulose membrane and probed using specific anti-GR antibody. The graph in B 
shows combined results of at least 4 independent experiments. Relative GR expression levels were 
plotted with the value control (vehicle) for each time-point set as 1. 
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3.3.8 The GR is required for transcriptional regulation of the endogenous 
GnRHR by GnRH and dex 
To investigate the requirement for the GR in transcriptional regulation of the GnRHR gene in response 
to both dex and GnRH, small interfering RNA (siRNA) was used to decrease the GR protein levels in 
LßT2 cells. The cells were transfected with siRNA for the mouse GR or with a scrambled non-silencing 
siRNA, to demonstrate the specificity of the GR oligos. The efficiency of the siRNA was determined by 
Western blotting and in repeated experiments the GR protein levels were decreased by about 50% as 
compared to the non-silencing control (figure 3.8 A and B). Using increased amounts of siRNA oligos 
or transfection reagent as well as longer incubation times or transfecting twice with GR siRNA did not 
further decrease the GR protein levels. In addition, the use of 3 different GR siRNA oligos resulted in 
the same extent of GR knockdown (approximately 50%). 
The siRNA-transfected cells were stimulated with GnRH or dex for 8 h and quantitative real-time PCR 
was performed to determine the effect of reduced GR protein levels on dex- and GnRH-mediated 
GnRHR gene expression (figure 3.8 C). GnRHR mRNA levels were found to be upregulated by dex as 
shown earlier (figure 3.1), and the response was significantly decreased by about 50% in the presence 
of the GR siRNA. The result demonstrates that the GR is required for the dex-mediated upregulation 
of the endogenous GnRHR gene. Moreover, when GR protein levels were diminished by siRNA, the 
GnRH-mediated increase in GnRHR transcripts was also found to be decreased by about 50% relative 
to the non-silencing control. Since the magnitude of the responses varied, significance could not be 
established. However reduced GnRH induction of GnRHR gene expression in the presence of GR 
siRNA was observed in several repeat experiments. These results strongly support the conclusion that 
the GR is required for both dex- and GnRH-mediated transcription of the endogenous GnRHR gene in 
LßT2 cells. 
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Figure 3.8: The GR is required for transcriptional regulation of the endogenous GnRHR by 
GnRH and dex 
A,B: LßT2 cells were transfected either with scrambled siRNA (non silencing control, NSC, black bars) 
or with siRNA for the mouse GR (GR siRNA, white bars). After 96 h, whole cell lysates were analysed 
by Western blotting. The Western blot result of a single experiment is shown in A. The pooled results 
form three independent Western blot experiments are shown in B, where quantification was performed 
using AlphaEaseFCTM Software and the relative GR levels were normalized to ß-actin protein levels. 
C: Cells were transfected as described for A and B. After 96 h cells were stimulated with either 
vehicle, 100 nM GnRH or 100 nM dex and incubated for further 8 h in serum-free medium. Total RNA 
was isolated, reverse-transcribed, and relative levels of GnRHR transcripts were determined by 
quantitative real-time PCR, normalized to GAPDH. The graph shows combined results of at least 3 
experiments where the response is expressed relative to vehicle control with NSC siRNA or GR 
siRNA, respectively. 
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CHAPTER 4 
RESULTS 
 
INVESTIGATION OF LIGAND-INDEPENDENT ACTIVATION OF THE 
GLUCOCORTICOID RECEPTOR BY GnRH AND SIGNALLING PATHWAYS IN 
THE LβT2 GONADOTROPE CELL LINE 
 
4.1 BACKGROUND 
In the classical mechanism of action, the GR resides in the cytoplasm in a multiprotein complex 
containing heat shock proteins and chaperones. Upon ligand binding the GR dissociates from the 
complex and the liganded receptor translocates to the nucleus to regulate expression of specific target 
genes (Griekspoor et al., 2007). In addition to the conventional hormone-dependent activation of 
steroid receptors, there is accumulating evidence for substantial cross talk between signal 
transduction pathways and steroid receptors which is often referred to as non-classical or ligand-
independent activation of steroid receptors. The estrogen receptor (ER) (Bunone et al., 1996; El-
Tanani and Green, 1997), progesterone receptor (PR) (Pierson-Mullany and Lange, 2004) and the 
androgen receptor (AR) (Maudsley et al., 2006) all exhibit ligand-independent activation under 
appropriate conditions. There are a few reports in the literature suggesting that ligand-independent 
activation of the GR occurs in cells other than LßT2 cells. Tanaka et al. found that in hamster ovary 
cells ursodeoxycholic acid (UDCA) promotes nuclear translocation of the GR and transactivation of a 
GRE (Tanaka et al., 1996). Consistent with these findings, ligand-independent activation of the GR 
has been described in primary human lung fibroblasts and vascular smooth muscle cells by beta-
adrenergic receptor agonists salmeterol and salbutamol resulting in rapid nuclear translocation of the 
receptor and activation of a GR-inducible luciferase reporter gene (Eickelberg et al., 1999). However, 
whether the above examples of ligand-independent activation of the GR occur by rapid non-genomic 
mechanisms such as GR phosphorylation, or cross talk with other receptors is not known. 
Several reports have unravelled the downstream kinase pathways in gonadotrope cell lines, showing 
that GnRH can activate extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) 
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and p38 in both αT3-1 (Levi et al., 1998; Reiss et al., 1997; Roberson et al., 1999; Sim et al., 1995) 
and LßT2 cells (Harris et al., 2002; Liu et al., 2002a; Liu et al., 2002b; Yokoi et al., 2000). The role of 
MAPKs pathways in regulation of gonadotropin subunit gene expression is somewhat controversial. 
While some investigators have shown a role for JNK, but not for PKC and ERK, in LHß gene 
expression LßT2 cells, others have shown that PKC, ERK and JNK are involved in GnRH regulation of 
LHß in these cells. In αT3-1 cells it has been suggested that PKC-dependent activation of JNK but not 
ERK plays a critical role in GnRH regulation of the GnRHR (Ellsworth et al., 2003b). In LßT2 cells both 
PKC- and PKA-pathways have been shown to be involved in the transcriptional regulation of a 
transfected GnRHR-promoter construct and the endogenous GnRHR gene (Sadie, 2006). However, a 
possible role for MAPKs in GnRHR gene expression in LßT2 cells has not been reported. 
In rat granulosa cells dex induced rapid activation of ERK and not p38 within 1 min of stimulation 
(Sasson et al., 2003). Other reports show that dex stimulates p38 MAPK phosphorylation in lymphoid 
cells (Miller et al., 2005) and activates p38 and JNK but not ERK in a time-dependent manner in 
human eosinophils (Zhang et al., 2000). By contrast dex appears to prevent proinflammatory stimuli 
induced MAPK activation (Hulley et al., 1998; Lasa et al., 2001; Pelaia et al., 2001). In A549 cells dex 
was shown to attenuate IL-1ß-mediated activation of p38 and JNK (Jang et al., 2007) while another 
group demonstrated that dex significantly inhibited LPS-induced activation of JNK but not p38 or ERK 
in RAW264.7 cells (Swantek et al., 1997). It appears that the opposing results above may be due to 
different cell types, species and culturing condition. To date there are no reports in the literature 
describing signalling pathways induced by GCs in LßT2 cells.  
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4.2 AIMS 
In chapter 3 it was found that GnRH results in recruitment of the GR to the endogenous GnRHR in 
intact LßT2 cells in the absence of a GR ligand. In addition, it could be established that the GR plays 
an essential role in transcriptional regulation of the GnRHR gene in these cells. Thus, it was decided 
in the present part of the study to further investigate the mechanism of ligand-independent activation 
of the GR by GnRH. All experiments were carried out with dex and GnRH to explore both differences 
and similarities in ligand-dependent versus ligand-independent activation of the GR. Furthermore it 
was of great interest to unravel the signalling pathways involved in GnRH- and dex-mediated gene 
expression in LßT2 cells.  
 
The specific aims of this study were as follows: 
- To investigate cellular distribution of the endogenous GR under basal, dex- and GnRH-
stimulated conditions in LßT2 cells; 
- To determine whether the GR can transactivate a minimal GRE reporter-promoter 
construct; 
- To establish a requirement for the GR and GnRHR signalling pathways for GnRH-
mediated transcriptional activation of a GRE in LßT2 cells; 
- To determine whether ligand independent activation of exogenously expressed GR can 
occur in COS-1 cells dependent on the GnRHR; 
- To investigate the phosphorylation status of the GR at two specific serine-residues, Ser-
220 and Ser-234, respectively and examine the role of GnRHR signalling in GnRH-
mediated GR phosphorylation; 
- To determine whether dex or GnRH can activate the MAPKs JNK, p38 and ERK in LßT2 
cells; 
- To investigate the role of JNK, p38 and ERK in dex- and GnRH-mediated GRE and AP-1 
transactivation; 
- To determine the role of MAPK in GnRH- and dex-induced GR phosphorylation at Ser-220 
and Ser-234 in LßT2 cells; 
- To explore whether PKA, PKC and src-tyrosine kinase are involved in dex- and GnRH-
induced transactivation and GR phosphorylation 
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4.3 RESULTS 
4.3.1 GnRH mediates nuclear translocation of the unliganded endogenous GR 
The GR resides in the cytoplasm in an inactive state and classical hormone-dependent activation of 
the GR results in nuclear translocation and its interaction with regulatory regions in primary target 
genes (Griekspoor et al., 2007). Therefore it was explored whether GnRH can cause nuclear 
translocation of the GR in the absence of a GR ligand. LßT2 cells grown on cover slips were serum 
starved over night and stimulated for 1 h with 100 nM dex or 100 nM GnRH followed by fixing and 
staining of the cells with a GR specific antibody. As shown in figure 4.1, the GR was predominantly 
found in the cytoplasm in vehicle-treated control cells. Treatment with dex promoted translocation of 
about 100% of the GR to the nucleus as expected. This is consistent with a study by Webster et al. 
showing that the over expressed mouse GR is predominantly cytoplasmic in the absence of ligand, 
while dex stimulation resulted in rapid nuclear translocation of the receptor (Webster et al., 1997).  
Importantly, treatment with GnRH-induced accumulation of about 50% of the GR in the nucleus in the 
absence of a GR ligand (figure 4.1). The result presented here provides strong evidence for ligand-
independent activation of the GR in the absence of GCs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: (continued on next page) 
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Figure 4.1: Both dex and GnRH mediate nuclear translocation of the endogenous GR 
LßT2 cells were grown on glass cover slips and serum-starved overnight before treatment with 100 
nM GnRH or 100 nM dex for 1 h. Samples were fixed and stained with a GR-specific primary antibody 
and an anti-rabbit secondary fluorescent labelled antibody followed by counterstaining with the DNA 
dye Hoechst. Staining was visualized with an Olympus IX 81 microscope and analyzed with CellR 
software. The graph shows combined results of 3 individual experiments. 
 
4.3.2 Activation of a GRE by GnRH is GR- and GnRHR-dependent in LßT2 cells 
Having established that GnRH induces nuclear import of the GR it was of interest to investigate 
whether the ligand-independent activated GR can activate transcription via glucocorticoid-response-
elements (GREs). Therefore, LßT2 cells were transiently transfected with a GRE-luciferase reporter 
construct (containing 2 copies of the rat GRE) and stimulated with 100 nM dex or 100 nM GnRH for 8 
h in serum-free medium. As shown in figure 4.2 A, dex treatment increased the transcriptional activity 
of a GRE-luciferase construct by approximately 4 fold. Importantly, GnRH treatment resulted in a 
similar increase in promoter activity of the GRE-reporter in the absence of dex. Similarly, both dex and 
GnRH significantly increased the transcriptional activity of a MMTV-luciferase reporter construct 
(containing 4 repeats of the GRE) but to a slightly lesser extent (~2,5 fold) compared to the GRE-
reporter construct (figure 4.2 B). The results indicate that GnRH-mediated transactivation is not 
promoter specific. 
 
Next it was investigated whether the GnRH-induced increase in GRE-promoter activity shown in figure 
4.2 A is mediated via the GR. Therefore, LßT2 cells were transfected with a GRE-reporter construct in 
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the absence and presence of overexpressed GR. Exogenously expressed GR resulted in a significant 
increase in dex-induced GRE-luciferase activity, as compared to in cells expressing only endogenous 
GR (figure 4.2 C). Furthermore exogenously expressed GR significantly increased GnRH-mediated 
transactivation (figure 4.2 C). The result strongly supports the hypothesis that the GnRH-induced 
increase in transcriptional activity of a GRE is mediated via the GR. 
 
Since it cannot be excluded that GnRH directly or indirectly increase endogenous GC concentration by 
increasing the levels or the activity of steroidogenic enzymes in LßT2 cells which in turn could activate 
the GR, it was of interest to determine whether GnRH signalling to GR is GC independent. Thus, cells 
were transfected with a GRE-reporter plasmid and treated with dex and GnRH in the absence or 
presence of the anti-glucocorticoid RU486. As can be seen in figure 4.2 D the dex-induced increase in 
transcription was significantly decreased in the presence of RU486. In contrast the GnRH-induced 
transactivation was unaffected by RU486. The result provides evidence that the GnRH-mediated 
transactivation is independent of ligand binding to the GR in LßT2 cells. 
 
Having established that GnRH mediates transactivation of a GRE by the endogenous unliganded GR 
it was next determined whether the response is dependent on endogenous GnRHR signalling. 
Therefore LßT2 cells were stimulated with dex or GnRH in the absence and presence of the GnRHR 
antagonist Antide. As shown in figure 4.2 E the dex-mediated upregulation of GRE activity was 
unaffected by the GnRHR antagonist. In contrast, GnRH-induced transactivation was completely 
abolished in the presence of Antide.  
Taken together the results provide strong evidence for GnRH-mediated transactivation of a GRE by 
the endogenous unliganded GR and via the GnRHR in LßT2 cells. 
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Figure 4.2: (continued on next page) 
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Figure 4.2: Activation of a GRE by GnRH is GR- and GnRHR-dependent 
LβT2 cells were transfected with 250 ng TAT-GRE-luciferase construct (A,C-E) or with 250 ng MMTV-
luciferase construct (B) in the absence (-GR) or presence (+GR) of cotransfection with 125 ng HA-
human GR expression vector (C). After approximately 24 h cells were incubated for 8 h in serum-free 
medium with vehicle (control) or 100 nM GnRH or 100 nM dex, in the absence or presence of 100 nM 
RU486 (D) or 100 nM Antide (E). The luciferase activity was normalized to ß-galactosidase and the 
hormone-stimulated increase in promoter activity was calculated relative to the vehicle control. The 
graphs show the promoter activity relative to vehicle (control) of combined results of at least 2 
independent experiments, each performed in triplicate.  
 
4.3.3 Ligand-independent activation of a GRE is dependent on both the GR and 
the GnRHR in COS-1 cells 
To investigate whether ligand-independent activation of the GR is cell specific and to further establish 
a requirement for the GR and the GnRHR, the experiments in section 4.3.2 were repeated in COS-1 
cells that do not express detectable levels of both GR and GnRHR (van Biljon, 2006). These cells 
were transfected with the GRE-luciferase construct in the absence and presence of expression 
vectors for the mouse GnRHR and the human GR. Over expression of these constructs was found not 
to affect basal luciferase activity. Significant dex-induced transactivation was only observed when 
COS-1 cells were co-transfected with a human GR expression construct (figure 4.3 A). Importantly, 
GnRH treatment only resulted in a significant increase in promoter activity in the presence of 
exogenous GR and GnRHR, further establishing that GnRH, via the GnRHR, is able to mediate GR-
regulated gene expression (figure 4.3 B). Additionally, since ligand independent activation was found 
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to occur with exogenously expressed human GR and mouse GnRHR in COS-1 cells the result 
suggests that GnRH-mediated GR activation is not cell- or species-specific. Increased transactivation 
by GnRH was not due to changes in GR levels, since GnRH treatment had no effect on the total GR 
levels compared to vehicle control as determined by Western blotting in COS-1 cells (figure 4.3 C and 
D).  
 
A 
co
ntr
ol De
x
co
ntr
ol De
x 
co
ntr
ol De
x
co
ntr
ol
De
x 
0
2
4
6
500
1000
1500
2000
2500
3000
GRE GRE + GR GRE + GnRHR  +GR
GRE-luc
a
GRE + GnRHR
**
**
fo
ld
 
in
du
ct
io
n
 
 
 
 
 
B 
co
ntr
ol
Gn
RH
co
ntr
ol
Gn
RH
co
ntr
ol
Gn
RH
co
ntr
ol
Gn
RH
 
0
5
10
15
20
25
GRE-luc
GRE GRE + GR GRE + GnRHR  +GRGRE + GnRHR
**
fo
ld
 
in
du
ct
io
n
 
 
 
 
Figure 4.3: (continued on next page) 
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C                                                                                  D 
 
 
 
 
 
Figure 4.3 Ligand-independent activation of a GRE is dependent on both the GR and the 
GnRHR in COS-1 cells 
A,B: COS-1 cells were transfected with 250 ng TAT-GRE-luciferase construct (GRE) in the absence 
or presence of cotransfection with 6 ng mouse GnRHR expression vector (GnRHR) and/or 125 ng HA-
human GR expression vector (GR), as indicated below relevant bars. Transfected cells were 
incubated for 8 h in serum-free medium with vehicle (control) or 100 nM dex (A) or 100 nM GnRH (B). 
The luciferase activity was normalized to ß-galactosidase and the hormone-stimulated increase in 
promoter activity was calculated relative to vehicle control. The graphs show the promoter activity 
relative to vehicle (control) of combined results of at least 2 independent experiments, each performed 
in triplicate. C,D: COS-1 cells were transfected with 250 ng TAT-GRE-luciferase construct (GRE) in 
the absence (UT) or presence of cotransfection with 6 ng mouse GnRHR expression vector (GnRHR) 
and/or 125 ng HA-human GR expression vector (GR) and serum-starved overnight before treatment 
with 100 nM GnRH or 100 nM dex for 8 h. Equal amounts of cell lysates were loaded on a 8% SDS-
PAGE gel, transferred onto nitrocellulose membrane and probed using specific anti-GR or anti-ß-actin 
antibodies (C) The graph in D shows combined results of 3 independent experiments. The relative 
amounts of protein was normalized the ß-actin and quantified with the value for control (vehicle) set to 
100%. 
 
4.3.4 The GnRHR mediates site-specific phosphorylation of the unliganded GR 
by GnRH 
 
Both Ser-220 and Ser-234 of the mouse GR (corresponding to Ser-211 and Ser-226, respectively, in 
the human GR) are highly conserved and hyperphosphorylated in response to GR agonist, suggesting 
a link between GR phosphorylation and GR transcriptional activity (Hoeck and Groner, 1990). 
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Furthermore, it has recently been shown that in COS-1 cells, dex-induced phosphorylation of the 
human GR at one or more of residues Ser-203/Ser-211/Ser-226 is required for maximal GR 
transactivation of a GRE and to facilitate GRIP-1 co-activator recruitment (Avenant, 2009). Thus, 
GnRH-induced phosphorylation of the GR in the absence of GCs may be a mechanism whereby 
GnRH activates the GR. To investigate this hypothesis, the phosphorylation status of endogenous GR 
was examined in LßT2 cells, in the absence or presence of either GnRH or dex, using specific anti-P-
Ser-220-GR and anti-P-Ser-234-GR antibodies in Western blotting. The results demonstrate a rapid 
and sustained increase in phosphorylation at Ser-220 and Ser-234 in response to dex (figure 4.4 A 
and B). In contrast, GnRH treatment induced rapid and sustained phosphorylation at Ser-234 but not 
at Ser-220 (figure 4.4 A and B). Phosphorylation at Ser-220 or Ser-234 was not detectable in vehicle-
treated cells, indicating that the observed phosphorylation is strictly hormone-dependent (figure 4.4 A 
and B). These results clearly demonstrate that GnRH selectively modifies the phosphorylation status 
of endogenous GR in LßT2 cells at a specific serine residue in the absence of a GR ligand.  
 
In order to establish the involvement of the GnRHR in the GnRH-induced phosphorylation of the GR at 
Ser-234, cells were treated with the GnRHR antagonist Antide in the presence of both dex and GnRH. 
The results in figure 4.4 C clearly show that the GnRH-induced phosphorylation at Ser-234 was 
abolished in the presence of the GnRHR antagonist, indicating that the GnRHR is required for the 
hyperphosphorylation at that specific serine residue by GnRH. Furthermore, the dex-induced 
phosphorylation remained unchanged in the presence of Antide, demonstrating the specificity of the 
antagonist.  
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Figure 4.4: The GnRHR mediates site-specific phosphorylation of the unliganded GR by GnRH 
LßT2 cells were grown and serum-starved overnight before treatment with 100 nM GnRH or 100 nM 
dex for the indicated times. Equal amounts of cell lysates were loaded on a 8% SDS-PAGE gel, 
transferred onto nitrocellulose membrane and probed using specific antibodies for GR phosphorylated 
at Ser-220 (A) or Ser-234 (B). The blots were stripped and reprobed with an anti-GR antibody as 
control (Total GR). C: LßT2 were treated with hormone for 30 min in the presence or absence of 100 
nM of the GnRHR antagonist Antide. The graphs show combined results of at least 3 independent 
experiments. The relative amounts of phosphorylation at the specific serine residues were quantified 
and expressed as phosphorylated GR content relative to total GR, with the value for control (vehicle) 
set as 1. 
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4.3.5 Activation of MAPKs by GnRH 
4.3.5.1 GnRH but not dex rapidly activates c-Jun-N-terminal kinase (JNK) in LßT2 cells 
In order to determine if JNK is activated by GnRH or dex, LßT2 cells were serum-starved over night 
and stimulated for the indicated times with 100 nM dex or 100 nM GnRH. The activity of the kinase 
was determined by using a phospho-specific JNK antibody detecting endogenous levels of phospho 
JNK1 (p46) and phospho JNK2/3 (p54) dually phosphorylated at threonine 183 and tyrosine 185. 
Western blot analysis revealed that treatment with 100 nM GnRH resulted in a rapid activation of 
endogenous JNK within 10 min, reaching its peak at 30 min and declining after 1 h of treatment (figure 
4.5 A and B). This is in agreement with reports in the literature showing maximal induction of JNK with 
100 nM GnRH at 30 min in LßT2 cells (Bonfil et al., 2004; Liu et al., 2002a). In addition when LßT2 
cells were treated continuously for 8 h with 100 nM GnRH JNK was found to be in its inactive, 
unphosphorylated form as compared to the active, phosphorylated form found at 30 min (Addendum A 
figure A1). In contrast, phosphorylated JNK could not be detected at any time point investigated in 
dex-treated cells (up to 2 h figure 4.5 A and B or 8 h in Addendum A figure A1) indicating that dex 
stimulation does not activate the JNK signalling pathway in LßT2 cells. Furthermore as a control the 
total JNK protein levels were measured by Western blotting using a JNK specific antibody detecting 
JNK1 and JNK2/3. As shown in figure 4.5 C, neither GnRH nor dex treatment modulated the relative 
total JNK protein expression levels in LßT2 cells. This further underscores the specific activation of 
JNK by GnRH since only the phosphorylation status of the kinase and not the total protein levels were 
found to be affected. 
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Figure 4.5: Activation of JNK by GnRH in LßT2 cells  
A: LβT2 cells were treated with 100 nM dex or 100 nM GnRH in serum-free medium for the indicated 
times. Proteins were separated on 8% SDS-PAGE gel, electroblotted onto nitrocellulose membrane 
and probed with anti-phospho JNK antibody. The blots were stripped and reprobed with an anti-total 
JNK antibody as control. B: Pooled and quantified results of 3 independent experiments are presented 
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as relative amounts of phosphorylated kinase over total kinase for phospho JNK 1 (left) and phospho-
JNK 2/3 (right). C: Relative kinase expression levels are shown for JNK 1 (right panel) and JNK 2/3 
(left panel), with vehicle (control) at 10 min set as 1. 
 
 
4.3.5.2 p38 is rapidly induced by GnRH and not dex in LßT2 cells 
Next the activation of another member of the MAPK family, p38 was investigated. The same samples 
as in 5.3.1.1 were analyzed by means of Western blotting, using a phospho specific p38 antibody, 
detecting endogenous p38 proteins phosphorylated at threonine 180 and tyrosine 182. Similarly to the 
results obtained by others (Bonfil et al., 2004; Liu et al., 2002a), phosphorylated p38 was strongly 
induced in cells treated with 100 nM GnRH in LßT2 cells (figure 4.6 A and B). The peak of p38 
activation was observed after 10 min of stimulation and was found to decrease after 1 h. After 2 h of 
GnRH treatment p38 phosphorylation was completely abolished in LßT2 cells. Total p38 protein levels 
remained unaffected in the presence of GnRH compared to unstimulated cells (vehicle control) (figure 
4.6 C). As already observed for JNK (figure 4.5) dex failed to induce activation of p38 at any time point 
investigated (figure 4.6 and Addendum A figure A2). 
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Figure 4.6: (continued on next page) 
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Figure 4.6: GnRH rapidly induces p38 activation in LßT2 cells 
A: LβT2 cells lysates as prepared for figure 4.5 were analyzed by Western blotting using an anti-
phospho p38 antibody The blots were stripped are reprobed with anti p38 as control. B: Pooled and 
quantified results of 3 independent experiments are presented as relative amount of phosphorylated 
p38 over total p38. C: Total p38 expression levels are shown, with vehicle (control) at 10 min set as 1. 
 
4.3.5.3 ERK is activated by short-term GnRH treatment while only long term dex stimulation 
results in ERK activation in LßT2 cells 
ERK1 (p44) and ERK 2 (p42) were found to be strongly and rapidly activated in GnRH treated LßT2 
cells after 10 min (figure 4.7 A and B). In contrast to results obtained with JNK and p38 (figure 4.5 and 
4.6), ERK1/2 activation appears to be more sustained since the kinase is still significantly 
phosphorylated at 8 h of GnRH treatment (Addendum A figure A3). In untreated LßT2 cell lysates 
weak basal phosphorylation of ERK 2 (p42) was observed which reflects autophosphorylation at the 
tyrosine residues of the kinase (Sturgill et al., 1988). The total ERK protein expression levels remained 
unchanged (figure 4.7 C). 
In dex-treated samples no ERK phosphorylation could be detected up until 2 h of continuous treatment 
(figure 4.7 A and B). However continuous stimulation of LßT2 cells with 100 nM dex for 8 h resulted in 
increased ERK1/2 phosphorylation while the total kinase levels remained unchanged (Addendum A 
figure A3). Activation of MAPKs including ERK occurs rapidly (Johnson and Lapadat, 2002) and since 
8 h presents a rather long time point it is likely that phosphorylation of ERK1/2 is not a direct result of 
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dex stimulation. It is feasible that dex increases the levels or activity of upstream kinases such as MKK 
or other signalling molecules and pathways eventually leading to activation of ERK.  
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Figure 4.7: Activation of ERK1/2 by GnRH (legend to follow on next page) 
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A: LβT2 cells were treated as described for figure 4.5 and Western blotting performed using an anti-
phospho-ERK1/2 antibody. The blots were stripped are reprobed with anti-ERK1/2 antibody as control. 
B: Pooled and quantified results of 3 independent experiments are presented as relative amount of 
phosphorylated kinase over total kinase on separate graphs for phospho-ERK 1 (left panel) and 
phospho-ERK 2 (right panel) C: Relative kinase expression levels are shown for ERK 1 (left panel) 
and ERK 2 (right panel), with vehicle (control) at 10 min set as 1. 
 
4.3.6 Role of kinases in dex- and GnRH-mediated transactivation and GR 
phosphorylation 
4.3.6.1 MAPKs are involved in GnRH- and dex-mediated transactivation of the GR in LßT2 cells 
Having established that the MAPK JNK, p38 and ERK are expressed and activated by GnRH in LßT2 
cells, their possible involvement in the dex- or GnRH-mediated GR activation was next investigated. 
LßT2 cells transfected with the GRE-luciferase construct were stimulated with 100 nM GnRH or 100 
nM dex, in the absence or presence of selective kinase inhibitors (figure 4.8). Dex-induced 
transactivation of the reporter gene was significantly increased by approximately 3,5 fold in the 
presence of the JNK inhibitor while inhibition of p38 appeared to slightly decrease the response, 
although statistical significance was not established (figure 4.8 A). The results are difficult to interpret 
since ERK but not p38 or JNK appeared be activated directly or indirectly at 8 h in response to dex 
(Addendum A figures A1-3). Thus, it is likely that p38 and JNK are activated by dex at a time point that 
has not been investigated in the present study. The GnRH-mediated transcriptional activity of the 
luciferase construct was significantly decreased in the presence of ERK pathway inhibitor (~50%) and 
p38 inhibitor (~30%) which is in agreement with findings presented in figure 4.6 and 4.7 showing 
strong induction of these kinases by GnRH. By contrast, GnRH-mediated transactivation was 
significantly increased by approximately 2 fold when cells were co-treated with JNK inhibitor (figure 4.8 
B).  
 
The increase in transcription in the presence of the JNK inhibitor in response to both dex and GnRH 
was unexpected and suggests that activated JNK displays an inhibitory effect on GR-mediated 
transactivation. To further investigate this hypothesis, a dose-response experiment was performed 
with increasing concentration of JNK inhibitor varying from 1 µM to 10 µM (figure 4.8 C and D). As 
shown in figure 4.8 C in the presence of 1 µM JNK inhibitor dex-mediated transactivation was 
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significantly increased compared to dex alone. Increasing amounts of JNK inhibitor resulted in a 
further increase in GRE-reporter activity. Similarly, the presence of 5 µM JNK inhibitor significantly 
increased GnRH-mediated transactivation (figure 4.8 C). Importantly, the JNK inhibitor did not 
significantly increase basal transcriptional activity of the reporter construct (figure 4.8 C and D), 
indicating that the increased responses are not due to a general activation of the basal transcription 
machinery. The results strongly support the hypothesis that the active form of JNK exhibits an 
inhibitory effect on transactivation in this system. By Western blotting it was shown that the JNK 
inhibitor is efficient and specific since GnRH-induced JNK phosphorylation was completely abolished 
in the presence of 10 µM JNK inhibitor, while it had no effect on GnRH-mediated activation of ERK or 
p38 (Addendum A figure A4D, A5D and A6D). 
Take together these data highlight both similarities and differences in the kinase pathways involved in 
GR-mediated transactivation of a GRE-reporter construct via dex and GnRH. JNK inhibits while p38 
seems to stimulate both dex- and GnRH-mediated transactivation. Interestingly ERK appears to be 
involved in GnRH-mediated transactivation but has no effect on the dex response. 
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Figure 4.8: (continued on next page) 
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Figure 4.8: MAPKs are involved in GnRH- and dex-mediated transactivation of the GR in LßT2 
cells 
A,B: LßT2 cells were transfected with 250 ng TAT-GRE-luciferase construct and 24 h later stimulated 
with 100 nM dex (left panel) or 100 nM GnRH (right panel) for 8 h in serum-free medium in the 
absence or presence of the following inhibitors (A and B): 10 µM p38 inhibitor (SB203580), 10 µM JNK 
inhibitor (SP600125) or 50 µM ERK pathway inhibitor (PD98059). The graph shows pooled results of 3 
independent experiments carried out in triplicates, where the promoter activity is expressed as 
percentage of induction relative to dex (A) or GnRH (B) which were set to 100%. C,D: LßT2 cells were 
transfected as described above and stimulated with 100 nM Dex or 100 nM GnRH in the absence or 
presence of increasing concentrations of JNK inhibitor as indicated below the relevant bars. The 
hormone-stimulated increase in GRE-promoter activity was calculated relative to vehicle control. The 
graphs show combined results of at least 3 independent experiments, each performed in triplicate. 
 
 
4.3.6.2 MAPK are involved in GnRH-mediated AP-1 transactivation 
It was next thought to investigate the possible involvement of the MAPKs JNK, p38 and ERK in GnRH-
mediated AP-1 transactivation shown in figure 3.2. Therefore, similar experiments as in section 4.3.6.1 
were carried out in LßT2 cells to determine the requirement of several MAPKs in activation on an AP-1 
promoter construct. The GnRH-mediated transcriptional activity of the luciferase construct was 
significantly decreased in the presence of ERK pathway inhibitor to approximately 20% and in the 
presence of the p38 inhibitor to about 50% (figure 4.9). In addition, a significant increase in AP-1 
promoter activity by approximately 2 fold was observed when cells were co-treated with JNK inhibitor 
(figure 4.9). The result is similar to the increased reporter activity seen for the GRE-promoter construct 
in the presence of GnRH and JNK inhibitor (compare with figure 4.8 B) and suggests an inhibitory role 
for JNK in GRE and AP-1 transactivation. This was an unexpected finding. Since the AP-1 binding 
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protein c-Jun is a known substrate for JNK (Smeal et al., 1991) and GnRH has been shown to 
increase JNK activity in LßT2 cells (figure 4.5) it was anticipated that the JNK inhibitor would have an 
inhibitory effect on GnRH-mediated AP-1 transactivation. However, the present data suggest that JNK 
has a negative effect on activation of an AP-1 reporter construct and that a novel mechanism might be 
involved in AP-1 transactivation in LßT2 cells.  
Given that the endogenous GnRHR promoter contains an AP-1 site and that this promoter element 
has been shown to be important in GnRH-induced gene expression (figure 3.2, Addendum B figure B2 
B and figure 3.4) it can be speculated that the MAPKs p38, ERK and JNK are important pathways 
involved in a positive and a negative fashion in transcriptional regulation of the GnRHR in LßT2 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: MAPKs are involved in GnRH-induced transactivation of a pAP-1 construct in LßT2 
cells  
LβT2 cells were transfected with 250 ng pAP-1-luc construct and 24 h later stimulated with 100 nM 
GnRH in serum-free medium in the presence of MAPK inhibitors as described in figure 4.8. The 
luciferase activity was normalized to ß-galactosidase activity. The graph shows pooled results of 3 
independent experiments carried out in triplicates, where the promoter activity is expressed as 
percentage of induction relative to GnRH which was set as 100%. Please note that the GnRH-
mmediated AP-1 transactivation is shown in figure 3.2.  
 
4.3.6.3 GnRH-stimulated phosphorylation of the unliganded GR at Ser-234 is mediated by a 
combination of JNK, p38 and ERK  
Having shown in figure 4.4 A and B that both dex and GnRH induce site-specific GR phosphorylation it 
was next investigated which MAPKs are required for GnRH-stimulated phosphorylation of the 
endogenous GR. Several individual MAPK inhibitors failed to completely abolish dex- or GnRH-
p3
8 
JN
K 
ER
K 
0
25
50
75
100
125
200
300
AP-1 luc
  GnRH
a
a
b
ap
er
ce
n
ta
ge
 
in
du
ct
io
n
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 84 
stimulated transactivation of a GRE (figure 4.8 A), indicating that more than one kinase may be 
required to act in parallel to mediate these effects. In order to further investigate this, the effect of 
different MAPK kinase inhibitors was determined, individually or in combination, on dex induced Ser-
220 as well as on GnRH- and dex-induced Ser-234 phosphorylation of endogenous GR in LβT2 cells. 
The result showed a significant decrease in Ser-220 phosphorylation in response to dex in the 
presence of a ERK pathway inhibitor while p38, JNK or combinations of the inhibitors did not effect 
phosphorylation at that specific site (figure 4.10 A and B). As found previously (figure 4.4 A) GnRH 
treatment did not result in increased phosphorylation at Ser-220 (figure 4.10 A and C). The total GR 
protein levels remained unaffected by any MAPK inhibitor (figure 4.10 D and H). Furthermore, the 
results presented in figures 4.10 E and F show that inhibition of the individual kinases ERK, p38 or 
JNK had no influence on the dex-stimulated phosphorylation of Ser-234. However, treatment with dex 
in the presence of both p38 and JNK inhibitors, or with both JNK and ERK pathway inhibitors, lead to 
a small but statistically significant decrease in GR phosphorylation at that specific site (figure 4.10 E 
and F). GnRH-stimulated phosphorylation at Ser-234 was similarly not influenced by inhibition of p38 
or JNK alone (figure 4.10 E and G). However, inhibition of ERK alone did cause a significant decrease 
in phosphorylation of the GR, consistent with the results for GnRH-induced transactivation (figure 4.10 
E and G). These results strongly support a role for ERK in GnRH-mediated phosphorylation of the 
unliganded GR. Interestingly; combinations of any two MAPK inhibitors did result in about 30 - 45% 
inhibition of Ser-234 phosphorylation in response to GnRH. This suggests that in addition to ERK, both 
JNK and p38 kinases cooperate in a complex interplay to mediate GnRH-induced phosphorylation of 
the unliganded GR in LßT2 cells. Taken together, these results suggest that dex- and GnRH- induced 
GR phosphorylation at Ser-234 involves a combination of the MAPKs JNK, p38 and ERK most likely 
involving a complex interplay of kinase events. 
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Figure 4.10: (continued on next page) 
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Figure 4.10: Several MAPKs are involved in site specific phosphorylation of the liganded and 
unliganded GR at Ser-234 in LßT2 cells (legend to follow on next page) 
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LβT2 were stimulated for 30 min with 100 nM GnRH or 100 nM dex in the absence or presence of the 
following inhibitors: 10 µM JNK inhibitor (SP600125), 10 µM p38 inhibitor (SB203580), 50 µM ERK 
pathway inhibitor (PD98059) or a combination thereof as indicated. Western blotting was performed 
using an anti-GR phospho Ser-220 (A) or an anti-GR phospho Ser-234 antibody (E). The blots were 
stripped and reprobed with anti-GR antibody as control (A and E). The combined results from three 
independent experiments for dex (B and F) and GnRH (C and G) are presented on separate graphs, 
where phospho GR levels were normalized to total GR, with the value for control (vehicle) set as 1. 
The total GR protein levels are shown on separate graphs with vehicle (control) set as 1 (D and H). 
 
4.3.6.4 PKC and c-src are involved in GnRH-mediated transactivation 
Several groups in the field have studied kinase pathways in gonadotrope cells including LßT2 cells as 
described in chapter 1 (section 1.14). Since PKC, PKA (Bonfil et al., 2004; Liu et al., 2002a; Liu et al., 
2003; Mulvaney et al., 1999; Roberson et al., 1999; Sundaresan et al., 1996) and c-src (Benard et al., 
2001; Levi et al., 1998) have been implicated in GnRH-mediated activation of MAPKs it was 
interesting to examine next whether PKA, PKC or c-src participate in dex- and GnRH-mediated 
transcriptional activation in LßT2 cells. Please note that the specificity of the PKC-, PKA -, or c-src 
inhibitor was not determined in the present study. 
The stimulatory effect of GnRH on GRE-transactivation was reduced (~40%) by the specific PKC 
inhibitor BIM (figure 4.11 B) and the tyrosine kinase inhibitor PP2 (figure 4.11 D) while no statistically 
significant effect was seen for dex-mediated transcriptional activation of the reporter in the presence of 
these inhibitors (figure 4.11 A and C). Inhibition of PKA did not significantly affect transactivation 
induced by dex or by GnRH (figure 4.11 A and B). Due to the lack of a positive control for the tyrosine 
kinase inhibitor PP2, the PKA inhibitor (H89) or the PKC inhibitor (BIM) the eficiancy of these inhibitors 
was not determined. However, together with results in figure 4.8 B and reports in the literature (Benard 
et al., 2001; Sundaresan et al., 1996) the results would be consistent with a mechanism that possibly 
involves PKC-and c-src-dependent activation of ERK by GnRH in LßT2 cells. 
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Figure 4.11: PKC and c-src are involved in GnRH-mediated transactivation 
A-D: LßT2 cells were transfected with 250 ng TAT-GRE-luciferase construct and 24 h later stimulated 
with 100 nM dex (left panel) or 100 nM GnRH (right panel) for 8 h in serum-free medium in the 
absence or presence of the following inhibitors (A and B): 1 µM PKA inhibitor (H89), 100 nM PKC 
inhibitor (BIM), or 100 µM c-src inhibitor (PP2) (C and D). The graphs show combined results of at 
least 2 independent experiments carried out in triplicate, where the luciferase activity was normalized 
to ß-galactosidase and is expressed as percentage of induction relative to dex (A and C) or GnRH (B 
and D), set at 100%. 
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4.3.6.5 PKC and c-src are involved in AP-1 transactivation by GnRH 
To examine the effect of PKC, PKA and c-src on AP-1 reporter gene activity, similar experiments as 
presented in section 4.3.6.4 were carried out in LßT2 cells transfected with an AP-1 reporter construct. 
As shown in figure 4.12 the GnRH-induced activity of the reporter gene was significantly reduced in 
the presence of the PKC- or c-src inhibitor while inhibition of PKA appeared to have no effect (figure 
4.12). These results further support the hypothesis that PKC and c-src play an important role in 
GnRH-mediated signalling in LßT2 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: PKC and c-src are involved in AP-1 transactivation by GnRH  
LβT2 cells transfected with 250 ng pAP-1 luc construct were stimulated with 100 nM GnRH in serum-
free medium in the presence of 1 µM PKA inhibitor (H89), 100 nM PKC inhibitor (BIM), or 100 µM c-
src inhibitor (PP2). The luciferase activity was normalized to ß-galactosidase activity. The graph 
shows pooled results of 3 independent experiments carried out in triplicates, where the promoter 
activity is expressed as percentage of induction relative to GnRH set at 100%. Please note that the 
GnRH-mmediated AP-1 transactivation is shown in figure 3.2.  
 
4.3.6.6 PKC is involved in GnRH-mediated GR phosphorylation of Ser-234 
In the next set of experiments the role of PKC, PKA and c-src in GnRH-induced GR phosphorylation 
was investigated in LßT2 cells. Therefore LßT2 cells were stimulated with 100 nM dex or 100 nM 
GnRH in the presence or absence of PKC, PKA or c-src inhibitors and the phosphorylation status of 
the GR was analyzed by Western blotting. For these experiments only phosphorylation at Ser-234 of 
the GR was investigated since GnRH failed to induce phosphorylation at Ser-220 (figure 4.4 A). 
The results presented in figure 4.13 A and B suggest that PKA is not required for dex- or GnRH- 
induced Ser-234 phosphorylation since a PKA inhibitor did not effect the extent of phosphorylation at 
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that site. By contrast, inhibition of PKC resulted in a significant decrease for GnRH-, but not dex-
induced phosphorylation at Ser-234 (figure 4.13 A and B). These results are consistent with the results 
obtained for GnRH-induced transactivation of the GRE-reporter construct (figure 4.13 B) where PKC 
but not PKA was found to inhibit GnRH-mediated transactivation. Inhibition of c-src had no effect on 
both dex- or GnRH-induced phosphorylation at Ser-234 (figure 4.13 D and E), although it was found 
that c-src inhibitor decreased GnRH-mediated GRE activation (figure 4.11 D). Total GR protein 
expression levels were found to be unaffected by PKA, PKC or c-src inhibitors (figure 4.13 C and F). 
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Figure 4.13: (continued on next page) 
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Figure 4.13: PKC is involved in GnRH-mediated GR phosphorylation of Ser-234  
A-F: LβT2 were stimulated for 30 minutes with vehicle (control), 100 nM GnRH or 100 nM dex in the 
absence or presence of 1 µM PKA inhibitor (H89), 100 nM PKC inhibitor (BIM) (A-C) or 100 µM c-src 
inhibitor (PP2) (D-E) as indicated. Proteins were separated on an 8% SDS-PAGE gel, electroblotted 
onto a nitrocellulose membrane and probed with a phospho GR Ser-234 antibody. The blots were 
stripped and reprobed with anti-GR antibody as a control. Representative Western blot are shown in A 
and D. The graphs in B and E show combined results of 3 independent experiments where levels of 
GR phosphorylated at Ser-234 were normalized to total GR levels with the value for control (vehicle) 
set to 1. The total GR expression levels are presented on separate graphs with vehicle (control) set as 
1 (C and F). 
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CHAPTER 5 
RESULTS 
 
AN INVESTIGATION INTO THE SYNERGISTIC EFFECT OF DEX AND GnRH IN 
LßT2 CELLS 
 
5.1 BACKGROUND 
In the literature it has been reported that GnRH acts synergistically with activin, estradiol and DHT 
(Kowase et al., 2007; Norwitz et al., 2002a; Norwitz et al., 2002b; Yasin et al., 1995). Activin A was 
shown to augment GnRH-mediated transcriptional activation of the mouse GnRHR gene in αT3-1 cells 
(Norwitz et al., 2002a; Norwitz et al., 2002b) as well as the rat (Gregory et al., 2005) and human 
(Wang et al., 2008) FSHß gene in LßT2 cells. It was further suggested that the synergism between 
Activin A and GnRH is mediated via AP-1 (Jun/Fos) and SMAD proteins acting at the conserved AP-1 
element of the FSHß promoter in LßT2 cells (Gregory et al., 2005; Wang et al., 2008). Furthermore, 
GnRH and estradiol were shown to synergistically upregulate LHβ and α-subunit promoters and 
endogenous mRNA levels in LβT2 cells (Kowase et al., 2007). Kowase et al. postulated that the 
mechanism of the synergistic effect of estradiol in part involves transcriptional regulation of both 
activators and suppressors of transcription (Kowase et al., 2007).  
GCs have also been found to result in synergistic effects in combination with other hormones in rat 
pituitary cells and other cell lines (D'Agostino et al., 1990; Leal et al., 2003; McGillivray et al., 2007; 
Rosen et al., 1991). GCs were found to synergistically augment the activin-induced increase in FSHβ 
gene expression in both primary rodent pituitary cells (Leal et al., 2003) and in LβT2 cells (McGillivray 
et al., 2007). In contrast, the presence of both activin and dex reduced the dex-induced transactivation 
of a transfected human glycoprotein hormone α-subunit (αGSU) luciferase reporter plasmid in LßT2 
cells (Sasson et al., 2008). Sasson et al. further report that co-treatment with dex and GnRH resulted 
in a synergistic increase in αGSU promoter activity. Whether these synergistic effects occur on 
endogenous genes and the precise mechanisms thereof remain to be determined. 
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5.2 AIMS 
In the present study it was found that both dex and GnRH increase GnRHR gene expression in LßT2 
cells to a similar extent (figure 3.1). In addition, it could be established that both dex and GnRH require 
an intact AP-1 promoter element bound by c-Jun and c-Fos (figure 3.2 and figure 3.4 A and B), induce 
recruitment of the GR to the AP-1 region on the endogenous GnRHR promoter in intact cells (figure 
3.6) and that the GR appears to be an essential requirement in both dex- and GnRH-mediated 
transcriptional regulation of the GnRHR (figure 3.8 C). These results demonstrate that both hormones 
utilize a similar mechanism to induce transcription of the GnRHR and thus, it was important to 
determine the effect on gene transcription when cells were co-stimulated both with dex and GnRH. 
 
The detailed aims of this study were the following: 
- To determine whether stimulation with dex plus GnRH results in a synergistic increase in 
expression of the endogenous GnRHR gene and a transfected GRE-promoter construct in 
LßT2 cells and COS-1 cells; 
- To establish a requirement for the GR and the GnRHR for synergism with dex plus GnRH 
in both cell lines; 
- To investigate the dex plus GnRH-mediated phosphorylation status of the endogenous GR 
and examine the role of MAPKs, PKA, PKC and c-src kinase pathways involved in GR 
phosphorylation in LßT2 cells in response to dex plus GnRH; 
- To determine which proteins are recruited to the AP-1 region of the endogenous GnRHR 
promoter in intact cells in response to dex plus GnRH as compared to these hormones 
alone in LßT2 cells 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 94 
5.3 RESULTS 
5.3.1 GnRH and dex synergistically increase gene expression  
5.3.1.1 GnRH and dex synergistically increase expression of the endogenous mouse GnRHR 
gene and a transfected GRE in a GR- and GnRHR-dependent fashion 
In order to investigate the effects of co-incubation with both dex and GnRH on gene expression, LßT2 
cells were stimulated with 100 nM dex, 100 nM GnRH or both dex plus GnRH for 8 h in serum-free 
medium. Total RNA was isolated, reverse transcribed and relative levels of GnRHR transcripts were 
determined by quantitative real-time PCR. As shown in figure 5.1 A, co-incubation with GnRH plus dex 
resulted in a dramatic synergistic increase in expression of the endogenous GnRHR gene compared 
to dex or GnRH alone. As already mentioned above, the GR was shown in chapter 3 to play an 
important role in dex- and GnRH-induced transcription of the GnRHR. Thus, using specific mouse GR 
siRNA, it was established that the synergistic effect on GnRHR gene expression was also dependent 
on the presence of the GR since GnRHR expression levels were significantly reduced by 
approximately 50% in the presence of GR siRNA (figure 5.1 B). 
Similarly, co-incubation with GnRH plus dex also resulted in a synergistic increase in transcriptional 
activity of a transfected GRE-reporter construct in LßT2 cells after 8 h of treatment (figure 5.1 C). To 
further investigate the role of the GR in the synergistic effect on GRE-transactivation, LßT2 cells were 
co-transfected with a GR expression construct and stimulated with dex plus GnRH. As shown in figure 
5.1 D, overexpression of exogenous GR led to a significant increase in transactivation when cells were 
treated with both dex and GnRH compared to cells only expressing endogenous GR (figure 5.1 D first 
bar compared to third bar). As a control, LßT2 cells co-transfected with a GRE-reporter and an 
expression plasmid for GR were stimulated with only dex to determine that co-treatment of both 
hormones and not overexpression of GR yields enhanced transcriptional activity (figure 5.1 D second 
bar). Moreover, the synergistic increase in transcription with dex plus GnRH was found to be 
decreased in the presence of the GnRHR antagonist Antide (figure 5.1 D fourth bar). Since the 
response was not completely abolished it can be speculated that Antide specifically antagonized the 
GnRH- but not the dex-mediated transactivation. Similarly, dex plus GnRH-induced GRE-
transactivation was decreased but not abolished in the presence of a GC-antagonist RU486, possibly 
because the dex- and not the GnRH-mediated response was blocked by the antagonist (figure 5.1 D 
last bar).  
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To exclude the possibility that the synergistic effect is a result of increased GR protein levels in 
response to dex plus GnRH, Western blotting was performed on samples treated for 8 h with dex, 
GnRH or a combination thereof. Figure 5.1 E and F show that dex or GnRH alone did not have an 
effect on endogenous GR protein levels, while co-treatment with both hormones resulted in reduced 
GR protein levels clearly demonstration that synergism is not due to increased GR protein levels 
(figure 5.1 E and F). Taken together the results suggest that dex plus GnRH induces a synergistic 
increase in GnRHR mRNA levels as well as in GRE-transactivation which is dependent upon the 
presence of both the GR and the GnRHR.  
 
A      B 
 
 
 
 
 
 
 
 
 
 
 
 
 
C      D 
 
 
 
 
 
 
 
 
 
 
 
Figure: 5.1: (continued on next page) 
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Figure: 5.1: GnRH and dex synergistically increase expression of the endogenous mGnRHR 
gene and a transfected GRE-reporter in a GR- and GnRH-dependent fashion 
A,B: LßT2 cells were treated with vehicle (control) or 100 nM dex, 100 nM GnRH or combinations of 
both for 8 h in the presence of non silencing control siRNA (B, first four bars) or presence of specific 
mouse GR siRNA as indicated (B, last bar). Total RNA was isolated, reverse-transcribed and relative 
levels of GnRHR transcripts were determined by quantitative real-time PCR. Fold changes in GnRHR 
mRNA levels were normalized to GAPDH transcripts and were calculated relative to vehicle-treated 
(control) samples. C,D: LβT2 cells were transfected with 250 ng TAT-GRE-luciferase construct and 24 
h later stimulated with vehicle (control) or 100 nM dex, 100 nM GnRH or combinations of both for 8 h 
in serum-free medium in the absence (C) or presence of cotransfection with 125 ng HA-GR (+GR), 
100 nM Antide or 100 nM Ru486 as indicated (D). E,F: LßT2 cells serum-starved overnight before 
treatment with 100 nM GnRH or 100 nM dex or a combination of both for 8 h. Equal amounts of cell 
lysates were loaded on a 8% SDS-PAGE gel, transferred onto nitrocellulose membrane and probed 
using specific anti-GR or anti-ß-actin antibodies (E). The graph in F shows combined results of at least 
4 independent experiments. The relative amounts of protein was normalized the ß-actin and quantified 
with the value for control (vehicle) set as 1. 
 
5.3.1.2 The GR and GnRHR are essential for the the GnRH- and dex-induced synergistical 
increase in GRE-transactivation in COS-1 cells 
The results presented in figure 5.1 demonstrate a synergistic effect on GnRHR-, and GRE-
transcription mediated by GnRH plus dex in a GR- and GnRHR-dependent fashion in LßT2 cells. In 
order to explore whether the synergistic effect is cell-specific, COS-1 cells, lacking endogenously 
expressed GnRHR or GR (van Biljon 2003), were cotransfected with a synthetic GRE-reporter and 
expression plasmids for the GR and the GnRHR. As shown in figure 5.2 A, promoter activity in cells 
overexpressing GR and the GnRHR was increased with dex or GnRH stimulation as previously shown 
in figure 4.3. Importantly, co-incubation with dex plus GnRH significantly increased GRE-
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transactivation compared to dex or GnRH alone, similar to results obtained in LßT2 cells (figure 5.1 
C), suggesting that synergism is not cell or tissue specific (figure 5.2 A). As expected, GRE-
transactivation was only significantly increased in cells overexpressing the GR as shown in figure 5.2 
B. Importantly, reporter activity was further increased when cells were cotransfected with both GR and 
GnRHR expression plasmids suggesting a requirement for both the GR and the GnRHR for the 
synergistic response (figure 5.2 B). 
To ensure that the synergism was not due to increased GR levels in response to dex plus GnRH in 
COS-1 cells, the expression levels were monitored by Western blotting. As shown in figure 5.2 C 
untransfected COS-1 cells did not display any detectable GR expression levels while transfected cells 
were found to strongly express exogenous GR. Furthermore, since an increase in the total GR levels 
for any incubation condition as compared to vehicle control was not observed upon Western blotting it 
can be concluded that the synergy was not due to changes in GR levels (figure 5.2 C and D). 
Interestingly, in dex-treated samples GR levels were found to be significantly decreased compared to 
vehicle control (figure 5.2 C and D). This is in agreement with findings by others showing dex-
dependent protein degradation of overexpressed GR in COS-1 cells (Webster et al., 1997). In contrast 
GnRH treatment did not decrease GR protein levels at 8 h of continuous stimulation as observed for 
dex and moreover co-stimulation with both dex and GnRH prevented dex-induced down-regulation of 
the GR (figure 5.2 C and D). 
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Figure 5.2: (continued on next page) 
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Figure 5.2: The GR and GnRHR are essential for GnRH- and dex-induced synergistically 
increase in GRE-transactivation in COS-1 cells 
A,B: COS-1 cells were transfected with 250 ng TAT-GRE-luciferase construct (GRE) in the absence 
or presence of cotransfection with 6 ng mouse GnRHR expression vector (GnRHR) and/or 125 ng HA-
human GR expression vector (GR), as indicated below relevant bars. Transfected cells were 
incubated for 8 h in serum-free medium with vehicle (control), 100 nM dex, 100 nM GnRH or co-
stimulated with both dex plus GnRH. The luciferase activity was normalized to ß-galactosidase and 
the hormone-stimulated increase in promoter activity was calculated relative to the vehicle control. The 
graph in A shows promoter activity in the presence of both the GnRHR and the GR. The graph in B 
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shows dex plus GnRH-induced promoter activity with the individual control transfections as indicated. 
The results present the promoter activity relative to vehicle (control) of combined results of at least 2 
independent experiments, each performed in triplicate. C,D: COS-1 cells were transfected with 250 ng 
TAT-GRE-luciferase construct (GRE) in the absence (UT) or presence of cotransfection with 6 ng 
mouse GnRHR expression vector (GnRHR) and/or 125 ng HA-human GR expression vector (GR) and 
serum-starved overnight before treatment with 100 nM GnRH or 100 nM dex for 8 h. Equal amounts of 
cell lysates were loaded on a 8% SDS-PAGE gel, transferred onto nitrocellulose membrane and 
probed using specific anti-GR or anti-ß-actin antibodies (C) The graph in D shows combined results of 
3 independent experiments. The relative amounts of protein was normalized the ß-actin and quantified 
with the value for control (vehicle) set as 1. 
 
 
5.3.2 Co-stimulation with dex plus GnRH does not change the GR 
phosphorylation levels relative to dex alone at Ser-220 or Ser-234 in LßT2 cells 
As established previously, dex induces strong GR phosphorylation at both Ser-234 and Ser-220, while 
GnRH only increased phosphorylation at Ser-234 and not Ser-220 (figure 4.4 A and B). Towards 
understanding the mechanism of synergism, the phosphorylation status of the endogenous GR was 
investigated in response to co-treatment with dex plus GnRH. The results presented in figure 5.3 show 
that co-incubation with dex plus GnRH induced phosphorylation at both Ser-220 and Ser-234 at levels 
comparable to the phosphorylation levels observed for dex alone (figure 5.3 A and B). The results 
suggest that differential phosphorylation at these specific GR residues appears not to be responsible 
for the synergistic transcriptional effect with dex plus GnRH. However, since GR phosphorylation has 
been reported to modulate maximal transcriptional activity (Avenant, 2009; Chen et al., 2008; Hoeck 
and Groner, 1990; Kino et al., 2007) it cannot be excluded that other GR phosphorylation sites, not 
investigated in this study, play a role in synergism.  Un
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Figure 5.3: Co-stimulation with dex plus GnRH does not change the GR phosphorylation levels 
at Ser-220 or Ser-234 as compared to dex alone in LßT2 cells 
LßT2 cells were grown and serum-starved overnight before treatment with 100 nM GnRH, 100 nM dex 
or combination of both for 8 h. Equal amounts of cell lysates were loaded on a 8% SDS-PAGE gel, 
transferred onto nitrocellulose membrane and probed using specific antibodies for GR phosphorylated 
at Ser-220 (A) or Ser-234 (B). The blots were stripped and reprobed with an anti-GR antibody as 
control (Total GR). The graphs show combined results of at least 3 independent experiments. The 
relative amounts of phosphorylation at the specific serine residues were quantified and expressed as 
phosphorylated GR content relative to total GR, with the value for control (vehicle) set as 1. 
 
5.3.3 GnRH plus dex-stimulated phosphorylation of the GR is mediated by a 
combination of JNK, p38 and ERK 
Having shown that co-stimulation with dex plus GnRH induces GR phosphorylation levels at Ser-220 
and Ser-234 similar to dex alone in LßT2 cells it was next investigated which MAPKs are required for 
the phosphorylation event in response to co-treatment. 
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The results presented in figure 5.4 A show that phosphorylation at Ser-220 is significantly decreased 
only in the presence of both JNK and ERK MAPK inhibitors. This is in contrast to results shown in 
figure 4.10 A and B where ERK appears to be involved in dex-induced Ser-220 phosphorylation. 
Inhibition of PKA, PKC or c-src had no effect on the dex plus GnRH-induced Ser-220 phosphorylation 
(figure 5.4 A and B). 
Similarly, phosphorylation at Ser-234 was unaffected by PKA, PKC or c-src inhibitors (figure 5.4 B), 
while it was previously found that PKC is involved in GnRH- but not dex-mediated phosphorylation at 
that specific serine residue (figure 4.13 A and B). Inhibition of the individual JNK and p38 kinases 
appeared to have no effect on Ser-234 phosphorylation whereas inhibition of ERK led to a statistically 
significant small decrease in GR phosphorylation at Ser-234 (figure 5.4 B). Furthermore, inhibition of 
any two MAPK led to a significant decrease in dex plus GnRH-mediated phosphorylation consistent 
with the results for GnRH alone at Ser-234 (figure 4.10 C and D).  
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Figure 5.4: (continued on next page) 
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Figure 5.4: GnRH plus dex-stimulated phosphorylation of the GR is mediated by a combination 
of JNK, p38 and ERK 
LβT2 were stimulated for 30 min with either vehicle or 100 nM GnRH plus 100 nM dex in the absence 
or presence of the following inhibitors: 1 µM PKA inhibitor (H89) or 100 nM PKC inhibitor (BIM), 100 
µM c-src inhibitor (PP2), 10 µM JNK inhibitor (SP600125), 10 µM p38 inhibitor (SB203580), 50 µM a 
ERK pathway inhibitor (PD98059) or combinations thereof as indicated. Western blotting was 
performed using anti-GR phospho Ser-220 antibody (A) or anti-GR phospho Ser-234 antibody (B). 
The blots were stripped and reprobed with anti-GR antibody as a control. Results shown in the graphs 
are combined results from 2 independent experiments, where phospho-GR levels were normalized to 
total GR, with the value for control (vehicle) set as 1. 
 
5.3.4 Transcription factors involved in synergism 
5.3.4.1 AP-1 protein levels bound to the AP-1 region of the GnRHR-promoter remain unchanged 
in response to dex plus GnRH in intact LßT2 cells 
As already shown in figure 3.4 A and B both c-Jun and c-Fos were found to occupy the AP-1 site 
under basal as well as dex- and GnRH-stimulated conditions. To further study the mechanism 
underlying the synergistic effect with dex plus GnRH, the promoter occupancy with AP-1 proteins was 
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examined using ChIP assays. The results presented in figure 5.5 confirm previous results by showing 
that both c-Jun and c-Fos are bound to the AP-1 region of the endogenous GnRHR promoter under 
basal as well as dex- and GnRH-stimulated conditions. Co-stimulation with dex plus GnRH did not 
result in increased or decreased binding of either c-Jun (figure 5.5 A and B) or c-Fos (figure 5.5 A and 
C) to the promoter suggesting that the composition of the AP-1 heterodimer is not changed when cells 
are subjected to both hormones. 
Interestingly, it was found that co-stimulation with dex plus GnRH had a differential effect on c-Jun but 
not c-Fos protein expression compared to GnRH on its own (Addendum A figure A7 and A8). As 
shown in Addendum A in figure A7 GnRH-induced c-Jun expression declines after 2 h while co-
treatment with dex plus GnRH resulted in a further increase in c-Jun protein expression after 2 h of 
incubation. This could possibly indicate a mechanism whereby dex plus GnRH have a differential 
effect on gene transcription compared to the hormones on their own. However, the results presented 
in figure 5.5 show that co-treatment did not result in altered recruitment of c-Jun or c-Fos to the 
GnRHR gene suggesting that different levels of these AP-1 proteins are not involved in the synergistic 
effect in LßT2 cells. 
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Figure 5.5: (continued on following page) 
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Figure 5.5: Effect of dex plus GnRH treatment on AP-1 protein recruitment to the endogenous 
GnRHR promoter LβT2 cells 
ChIP in LßT2 cells treated with vehicle (control), 100 nM GnRH, 100 nM dex or a combination of both 
for 1 h. ChIP was performed with anti-c-Jun (A and B) or anti-c-Fos (A and C) specific antibodies. The 
co-immunoprecipitated DNA fragments and input DNA were analyzed by conventional PCR (A) and by 
real-time PCR (B and C) using primer spanning the AP-1 region of the mouse GnRHR promoter. 
Pooled and quantified results of 2 independent experiments are shown normalized to input and 
expressed as fold-recruitment relative to control values (B and C). 
 
 
5.3.4.2 GR recruitment to the endogenous GnRHR promoter in response to dex plus GnRH is 
similar to that observed for dex alone in intact LßT2 cells 
Having shown that there is no change in levels of bound AP-1 proteins to endogenous GnRHR 
promoter it was next investigated whether the GR is differentially recruited when cells are stimulated 
with both dex and GnRH. It was found by ChIPs that the extent of GR recruitment to the AP-1 region 
of the endogenous GnRHR promoter was similar to that observed for dex alone suggesting that 
differential levels of recruitment of the GR is also not responsible for the synergism (figure 5.6).  
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A                                                                            B 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: GR recruitment on the endogenous GnRHR promoter does not change in response 
to dex plus GnRH 
C,D ChIP was performed in LßT2 cells treated with vehicle (control) 100 nM GnRH, 100 nM dex or 
combination of both for 1 h using a specific anti-GR antibody. ChIP was analyzed by conventional 
PCR (A) or real-time PCR (B). Pooled and quantified results of at least 3 independent experiments are 
shown normalized to input and expressed as fold-response relative to control values. 
 
5.3.4.3 Synergism between dex and GnRH involves recruitment of SRC-1 to the GnRHR 
promoter in LßT2 cells  
The activated GR can interact with many components of the transcriptional machinery, as well as co-
activators (Kumar and Thompson, 2005). A recent study demonstrated a direct correlation between 
the transcriptional response mediated by the GR and GR binding of co-activators, in particular GRIP-1 
(Ronacher et al., 2009).  
Therefore the possibility of differential GR-mediated assembly of cofactors to the endogenous GnRHR 
promoter was explored by ChIP using specific antibodies for known GR cofactors. The results 
presented in figure 5.7 A and B show that dex stimulation strongly induced GRIP-1 recruitment to the 
promoter while GnRH stimulation did not lead to GRIP-1 binding in intact LßT2 cells. Importantly, co-
stimulation with dex plus GnRH resulted in GRIP-1 binding to levels similar to that observed for dex 
alone (figure 5.7 A and B). In addition, it was found that p300 appears to occupy the AP-1 promoter 
region in the absence of hormone (control) while stimulation with dex, GnRH or combination thereof 
resulted in reduced binding of p300 (figure 5.7 A and C). Although the responses varied between 
experiments and statistical significance could not be established, it was repeatedly found that p300 is 
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bound under basal conditions while treatment with dex, GnRH or a combination of both decreased 
p300 occupancy on the GnRHR promoter. Interestingly, it was found that unlike for dex or GnRH 
alone, GnRH plus dex resulted in SRC-1 recruitment to the AP-1 region of the GnRHR promoter 
(figure 5.7 A and D). The result suggests that SRC-1 is involved in the synergistic effect of dex plus 
GnRH on the GnRHR gene, as only co-stimulation induces recruitment of that cofactor. 
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Figure 5.7: Synergism involves recruitment of SRC-1 to the AP-1 region of the GnRHR 
promoter in LßT2 cells 
ChIP was performed in LßT2 cells treated with vehicle (control) 100 nM GnRH, 100 nM dex or 
combination of both for 1 h using anti-GRIP-1 (B), anti-p300 (C) or anti-SRC-1 (D) specific antibodies. 
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Conventional PCR was performed, using primers as describes before on input chromatin and 
precipitated chromatin and products were resolved on agarose gels (A). Pooled and quantified results 
analyzed by real-time PCR of at least 2 independent experiments normalized to input and expressed 
as fold-response relative to control values are shown in B-D. 
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CHAPTER 6 
DISCUSSION AND CONCLUSION 
 
6.1 Both GnRH and dex upregulate the GnRHR gene via the GR by a genomic 
cross talk mechanism converging on the AP-1 site on the mouse GnRHR 
promoter in LßT2 cells 
The mechanisms underlying transcriptional regulation of the GnRHR gene have been a focus of 
numerous research groups in the field. Several hormones including GnRH were found to have a 
significant effect on GnRHR levels in vivo (Kaiser et al., 1993; Wu et al., 1994; Yasin et al., 1995). 
Whether transcriptional regulation of GnRHR expression occurs by GnRH in gonadotrope cells has 
also been the focus of several groups in recent years. Studies in αT3-1 cells describe homologous 
regulation of GnRHR transcription (Norwitz et al., 1999a; Sadie et al., 2003; White et al., 1999) while 
only some reports have been published showing homologous regulation of GnRHR gene expression 
in LβT2 cells. Bedecarrats et al. reported that continuous stimulation for 10 h with 10 nM GnRH has a 
small effect (approximately 1,5 fold) on the activity of the transfected GnRHR promoter-reporter 
construct and resulted in decreased GnRHR numbers (Bedecarrats and Kaiser, 2003). Previous data 
from Prof. Hapgood’s laboratory showed that continuous stimulation with 100 nM GnRH increased the 
expression of a synthetic transfected mouse GnRHR promoter-reporter construct (pLG) by about 2,5 
fold (Addendum B figure B1 B) (Sadie, 2006). It was further established that 8 h of continuous 
stimulation with 100 nM GnRH resulted in maximal transcriptional response while longer incubation 
times were found to decrease the promoter activity (Fernandes, 2007; Sadie, 2006). In addition, 
preliminary results from Prof. Hapgood’s laboratory showed that endogenous GnRHR mRNA levels 
are upregulated after 8 h of continuous stimulation with GnRH in LßT2 cells supporting the earlier 
findings obtained with the transfected promoter-construct (Addendum B figure B1 B) (Sadie, 2006). 
This observation was confirmed in the present study since it was found that GnRH treatment results in 
a significant increase in GnRHR transcripts (figure 3.1). In support of these findings White et al. 
reported that continuous stimulation with 100 nM GnRH for 4 h resulted in maximal increase in 
transcriptional activity of a mouse GnRHR construct and endogenous mRNA levels in αT3-1 cells 
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(White et al., 1999) and similarly Norwitz et al. reported that continuous stimulation with 100 nM GnRH 
(4 h) increased the transcriptional activity of a transfected mouse GnRHR construct in the same cells 
(Norwitz et al., 1999a). Bedecarrats et al. found that pulsatile GnRH stimulation (1 pulse every 30 min) 
for 10 h resulted in a 2-fold increase in GnRHR promoter activity as well as a 2-fold increase in 
GnRHR numbers on the cell surface which is similar to results obtained from our laboratory when cells 
were treated continuously for 8 h with 100 nM GnRH (Bedecarrats and Kaiser, 2003). Taken together 
the results above suggest that the GnRHR is transcriptionally activated under both pulsatile and 
continuous treatment in LßT2 cells. 
In addition to GnRH, GCs have also been found to play an important role in modulating GnRHR levels 
in vivo (Breen and Karsch, 2004; Daley et al., 1999; Rosen et al., 1991; Tilbrook et al., 2000). 
Previously, it was established that GCs exert a direct effect on GnRHR transcription in gonadotrope 
cells of the pituitary. In the somatolactotrope GGH3 cell line dex was found to significantly upregulate a 
transfected mouse GnRHR promoter construct (Maya-Nunez and Conn, 2003). However, GGH3 cells 
are rat somatolactotrope cells that artificially express the GnRHR receptor. Evidence for a direct 
transcriptional effect of GCs on GnRHR gene expression comes from previous reports showing that 
dex upregulates expression of both a transfected promoter-reporter construct (McGillivray et al., 2007) 
and the endogenous GnRHR gene in LβT2 cells (McGillivray et al., 2007; von Boetticher, 2008). In the 
present study the stimulatory effect of dex treatment on endogenous GnRHR gene expression could 
be confirmed (figure 3.1). Interestingly, when comparing the responses of dex versus GnRH on the 
synthetic reporter-gene (Addendum B figure B1) and on the endogenous GnRHR gene (figure 3.1) it 
was found that the magnitude is comparable suggesting that both hormones exhibit a similar 
transcriptional potential. However, the magnitude of the responses observed for the endogenous gene 
was much greater than the response of the transfected promoter for both dex and GnRH (Addendum 
B figure B1 and figure 3.1) (Fernandes, 2007; Sadie, 2006; von Boetticher, 2008). Since the pLG 
promoter-construct contains only 580 bp of the mouse GnRHR promoter relative to the translational 
start site it is likely that upstream promoter elements are involved in maximal transcriptional activity. 
Also, transiently transfected promoters lack natural promoter architecture and chromatin structure 
which could explain the different extent in fold induction compared to the endogenous gene. 
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In the literature there are several reports demonstrating that GnRH responsiveness of the mouse 
GnRHR promoter in αT3-1 cells is mediated via two regions namely SURG-1, containing binding sites 
for nuclear factor Y (NF-Y) and Oct-1 (Kam et al., 2005), and SURG-2 which contains the AP-1 
binding site (Duval et al., 1997b; Norwitz et al., 1999a). In LßT2 cells it was shown that mutation of the 
AP-1 site decreased the basal activity of the promoter by about 50% (Addendum B figure B2 A) 
(Fernandes, 2007). In addition the GnRH responsiveness of the promoter-reporter construct 
containing the AP-1 mutation was significantly decreased compared to the wild type promoter clearly 
demonstrating that an intact AP-1 element is essential to confer transcriptional activity by GnRH in 
LßT2 cells (Addendum B figure B2 B) (Sadie, 2006). This result is consistent with findings by other 
groups in αT3-1 cells where the AP-1 site was shown to play an important role in transcriptional 
regulation of both basal and GnRH-stimulated mouse GnRHR gene expression (Duval et al., 1997b; 
Kam et al., 2005; Norwitz et al., 1999a). Interestingly, two AP-1 sites are found in the human GnRHR 
promoter, one of which has been shown to regulate GnRH responsiveness, showing the importance of 
this site for homologous regulation in both mouse and human (Hapgood et al., 2005). Furthermore, the 
loss of the AP-1 site was found to significantly decrease the dex-mediated transactivation of the 
transfected mouse GnRHR promoter-construct (Addendum B figure B2 C) (Fernandes, 2007). The 
critical role for the AP-1 element in the activation of the mouse promoter by GCs has been reported by 
Maya-Nunez et al. (Maya-Nunez and Conn, 2003), however that particular study was carried out in 
GGH3 cells and therefore the result obtained previously in Prof. Hapgood’s laboratory is more 
significant since it demonstrates the requirement of the AP-1 promoter element for GC-mediated 
transcription in a gonadotrope cell line. In addition the results obtained in the present study presented 
in figure 3.2 show that GnRH was able to trigger transactivation of an AP-1 promoter (pAP-1-luc) 
giving further insight into the mechanism of GnRH-mediated transcriptional activation. Indeed several 
investigators have shown that GnRH treatment increases the mRNA levels (Kakar et al., 2003; 
Wurmbach et al., 2001) and protein expression levels (figure 3.3) (Coss et al., 2004; Sadie, 2006) of 
several Jun and Fos proteins in LβT2 cells providing a mechanism whereby the transcriptional effects 
of GnRH can be mediated via AP-1. By contrast, dex did not activate the AP-1 promoter- reporter 
construct (figure 3.2) suggesting that the AP-1 site in the GnRHR promoter is not the sole requirement 
for dex-induced gene expression. 
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The present finding that c-Jun proteins are associated with the AP-1 region of the endogenous 
GnRHR promoter in the absence of both GnRH and dex (figure 3.4 A and B) is consistent with results 
from another study by Jeong et al. also showing the presence of c-Jun proteins on the endogenous 
promoter under basal conditions in LßT2 cells (Jeong et al., 2004). In addition, the findings are 
consistent with previous results (Addendum B figure B2 A) (Fernandes, 2007) showing that the AP-1 
site is required for maximal basal expression of the GnRHR gene in LßT2 cells. By ChIP analysis it 
was established that GnRH- or dex-treatment did not change the levels or relative composition of c-
Jun or c-Fos proteins associated with the AP-1 region of the promoter (figure 3.4 A and B). This is in 
contrast to a report in αT3-1 cells where GnRH was found to induce an increase in AP-1 proteins, 
specifically c-Jun, binding to the promoter in intact cells (Kam et al., 2005), as well as in vitro results 
showing that c-Jun and not c-Fos proteins are able to bind to the AP-1 element in response to dex in 
GGH3 cells (Maya-Nunez and Conn, 2003). However, this inconsistency could be due to cell-specific 
differences or differences in cell culturing conditions. Although c-Jun and c-Fos are only present at low 
levels in the absence of GnRH (Coss et al., 2004; Liu et al., 2002a), the results of the present study 
suggest that these levels are sufficient to occupy the GnRHR promoter under basal conditions. It has 
previously been shown that the transcriptional activity of AP-1 proteins can be induced via post-
translational mechanisms, such as the phosphorylation of c-Jun by JNK (Ellsworth et al., 2003b; Yokoi 
et al., 2000). Several transcription factors including c-Jun and c-Fos are constitutively expressed at 
low levels and associated with genes in the nucleus without activating these. The transcriptional 
activity of transcription factors can be increased via post-translational modifications such as the 
phosphorylation and thereby inducing gene transcription (Brivanlou and Darnell, 2002; Ellsworth et al., 
2003b; Treisman, 1995; Yokoi et al., 2000). These proteins may have a structural role in maintaining 
the chromatin in a certain state to ensure rapid transcriptional activation or they might be involved in 
conferring basal gene expression. Thus it can be speculated that GnRH-induced signalling pathways 
could change the phosphorylation status of the AP-1 proteins bound to the DNA and thereby in part 
enhance GnRHR gene expression.  
The above mentioned results suggest that c-Jun and c-Fos are the key components in regulating 
basal- and hormone-induced expression of the mouse GnRHR gene Thus, it is likely that the AP-1 
proteins form a platform for other transcription factors to bind in response to hormone. Consistent with 
this hypothesis the GR was found to be recruited to the AP-1 region of the GnRHR promoter (figure 
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3.6). It is tempting to speculate that the GR does not bind directly to the promoter but rather via a 
tethering mechanism to AP-1 proteins since no glucocorticoid response element (GRE) has been 
reported to be present in the mouse GnRHR promoter (Albarracin et al., 1994; Norwitz et al., 1999b). 
Direct or indirect interaction between the GR and members of the AP-1 protein family members has 
been well described in the literature (Herrlich, 2001; Kassel and Herrlich, 2007). This interaction does 
not require direct DNA binding of the GR (Touray et al., 1991) and mostly results in transrepression of 
AP-1-controlled genes, under conditions where AP-1 consists of c-Jun/c-Fos heterodimers 
(Yamamoto et al., 1998). By contrast, GR tethering to c-Jun homodimers has been shown to activate 
AP-1-regulated promoters (Teurich and Angel, 1995; Yamamoto et al., 1998). Results shown in the 
present study indicate a novel mechanism of GR transactivation via an AP-1 element, since both c-
Jun and c-Fos appear to occupy the promoter. In addition, it was shown that the GR is recruited to the 
AP-1 region of the GnRHR promoter in response to GnRH in the absence of its ligand (figure 3.6). 
That exciting finding was unexpected as there are no reports in the literature showing that this or any 
other peptide hormone can activate the GR in the absence of a GR ligand. Results in figure 3.8 
established the requirement for the GR in GnRHR gene expression for both dex and GnRH since 
decreasing of GR protein levels by specific mouse GR siRNA reduced the hormone-mediated GnRHR 
gene expression. These novel results illustrate that the liganded and the unliganded GR play a critical 
role in GnRHR gene expression via an intact AP-1 response element bound by c-Jun and c-Fos. 
 
Attempts to investigate whether GR and AP-1 proteins occur in the same complex by co-
immunoprecipitation from cell lysates and re-ChIP experiments with endogenous proteins were 
unsuccessful, possibly due to the low abundance of the endogenous complexes. Although the present 
results do not provide direct evidence for GR-AP-1 interaction on the GnRHR promoter, it can be 
speculated that the dex- and GnRH-induced upregulation of the mouse GnRHR gene involves a 
tethering mechanism via direct or indirect binding of the GR to c-Jun/c-Fos heterodimers. Consistent 
with results reported in this study, the estrogen receptor (ER) has been shown to increase the 
transcriptional activity of bound c-Jun/c-Fos heterodimers (Kushner et al., 2000). Kushner et al. 
proposed that the ER does not directly interact with c-Jun/c-Fos proteins but rather binds to a complex 
of co-activators recruited to AP-1, including CBP/p300 and p160s. Similarly, it has been reported that 
nTRIP6, a member of the zyxin family of LIM domain-containing proteins acts as a transcriptional co-
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activator for AP-1 target genes, such as collagenase I occupied by c-Jun/c-Fos heterodimers, while 
nTRIP6 is also required for GR-mediated transrepression of AP-1 regulated genes (Kassel et al., 
2004). Therefore, it is likely the dex-activated GR requires the presence of another cis-element plus 
associated transcription factor which enables GnRHR promoter activation in response to dex in LßT2 
cells.  
The result presented in figure 3.2 is striking since dex treatment failed to induce transcription of an AP-
1 promoter-construct, suggesting that other cis-regulatory elements besides the AP-1 site in the 
GnRHR promoter are involved in mediating the response. The mouse GnRHR promoter harbours 
functional elements for Oct-1, NF-Y, SF-1 and CREB adjacent to the AP-1 site (Hapgood et al., 2005). 
Since the GR is known to cross talk with other transcription factors (Kassel and Herrlich, 2007) it is 
plausible that the receptor might interact with another transcription factors bound to the promoter and 
forming a multiprotein complex including AP-1 proteins. A study by Kam et al. showed binding of Oct-1 
to the GnRHR gene in vitro in αT3-1 cells (Kam et al., 2005) making Oct-1 a possible candidate to 
facilitate GR binding to the promoter. Unpublished data from Prof. Hapgood’s laboratory suggest that 
the AP-1 site and the CRE site of the mouse GnRHR promoter are required for GnRH responsiveness 
(Sadie, 2006) while the AP-1 site and a novel NRS adjacent to the AP-1 region, binding SF-1 proteins 
in vitro, were found to be essential for dex responsiveness of the GnRHR promoter in LßT2 cells 
(Fernandes, 2007). Thus it is tempting to speculate that SF-1 and/or CREB are involved in GR binding 
to the GnRHR promoter in LßT2 cells. 
 
6.2 GnRH activates the unliganded GR by a rapid non-genomic cross talk 
mechanism involving GnRHR-dependent GR phosphorylation at Ser-234  
Several lines of evidence support the finding that the GnRHR signals via rapid non-genomic cross talk 
to the unliganded GR. Using siRNA technology, it was demonstrated that the GR is required for 
transcriptional upregulation of the endogenous mouse GnRHR in LßT2 cells in response to GnRH 
(figure 3.8). Immunofluorescence experiments revealed that GnRH induces nuclear translocation of 
the unliganded endogenous GR in LßT2 cells (figure 4.1). This is in agreement with findings presented 
in figure 3.6 showing GnRH-mediated recruitment of the GR to the endogenous GnRHR promoter 
after 1 h of hormone treatment. It has previously been reported that GnRH causes nuclear 
translocation of the PR in αT3-1 cells after 1 h of stimulation (An et al., 2006). In primary human lung 
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fibroblasts ß2-agonists were shown to induce nuclear translocation of the GR after 4 h of stimulation 
(Eickelberg et al., 1999). The authors further showed by nuclear fractionation that dex stimulation 
induced a more rapid depletion of the GR from the cytosol compared to ß2-agonist. Similarly Tanaka 
et al. demonstrated that stimulation with the bile acid ursodeoxycholic acid (UDCA) results in nuclear 
import of the GR after 2 h of treatment but to a lesser extent than observed with dex in Chinese 
hamster ovary cells (Tanaka et al., 1996). However, this is the first study demonstrating that GnRH 
treatment results in altered cellular distribution of the GR in LßT2 cells compared to unstimulated cells.  
Furthermore it was shown that GnRH can activate the unliganded GR resulting in transactivation of a 
synthetic GRE-reporter in both LßT2 and in COS-1 cells, in a GnRHR-dependent fashion (figure 4.2 
and 4.3). These results suggest that the ability of the GnRHR to activate the unliganded GR is not 
gonadotrope-specific, and that the unliganded GR can regulate the GnRHR gene via recruitment to 
the AP-1 region of the GnRHR promoter. Additionally, it can be speculated that the GR can regulate 
other genes via direct binding to GREs in the absence of its ligand providing a potential novel 
mechanism of action for the nuclear receptor. Since the GnRHR is expressed in many extra-pituitary 
tissues (Hapgood et al., 2005), cross talk between the GnRHR and the GR could occur in many cell 
types endogenously expressing both receptors to fine tune the biological effects of each other.  
 
Since the GnRHR antagonist Antide abolished the GnRH-induced transcriptional response of a GRE-
reporter construct (figure 4.2 E) it was further investigated whether the GnRH-mediated activation of 
the unliganded GR requires the activity of specific kinase pathways activated by the GnRHR. The 
study provides direct experimental evidence that GR phosphorylation is required for the GnRHR-
mediated GnRH response of the GRE-reporter construct. Figure 4.8 and 4.11 show that MAPKs and 
PKC are involved in GnRH-mediated transactivation of the GRE by the GR in LßT2 cells. By probing 
the phosphorylation status of the GR using specific antibodies, it was found that GnRH mediates site-
specific phosphorylation of the GR at Ser-234 in the absence of dex in intact LßT2 cells in a GnRHR-
dependent fashion, since this phosphorylation can be inhibited with a GnRHR antagonist (figure 4.4). 
In addition, it was found that this GnRH-stimulated phosphorylation of the unliganded GR is mediated 
by a combination of the MAPKs JNK, p38 and ERK in LßT2 cells, since combinations of specific 
inhibitors thereof resulted in decreaded GR phosphorylation in intact cells. Furthermore a PKC 
inhibitor was found to inhibit GnRH-induced GR phosphorylation in these cells. In addition several 
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reports (Bonfil et al., 2004; Harris et al., 2002; Liu et al., 2002a) have shown by Western blotting and 
probing for phosphorylated MAPKs that GnRH treatment rapidly (within ten minutes) induces JNK, p38 
and ERK activation in intact LßT2 cells (figures 4.5 – 4.7). These data support a direct role for GnRHR 
in phosphorylation of the unliganded GR via JNK, p38 and ERK. The findings are consistent with 
previous studies in LßT2 cells showing that GnRH induces phosphorylation of JNK and ERK, 
mediated predominantly by PKC and c-src, to activate several promoters such as LH-ß, FSH-ß or 
COX-1 (Bonfil et al., 2004; Harris et al., 2002; Liu et al., 2002a; Naor et al., 2007). Thus, it can be 
speculated that GnRH activation of MAPK signal transduction pathways via the GnRHR also leads to 
the activation and nuclear translocation of the endogenous GR protein. Moreover, inhibition of PKC 
(figure 4.13 A and B) or ERK alone (figure 4.10 E and G) decreased GnRH-mediated GR Ser-234 
phosphorylation, which suggests that PKC may induce ERK, which in turn might be directly upstream 
of the GR phosphorylation event.  
 
Protein kinases involved in GC-mediated GR phosphorylation have been studied intensively in cells 
other than LßT2 cells (Ismaili and Garabedian, 2004; Krstic et al., 1997; Rogatsky et al., 1998; Wang 
et al., 2007). The results suggest that GC-mediated GR phosphorylation is dependent on multiple 
kinases in a cell-, promoter- and GC-dose-dependent manner (Chen et al., 2008; Ismaili and 
Garabedian, 2004; Kino et al., 2007; Webster et al., 1997). However, to the present author’s 
knowledge, agonist-mediated GR-phosphorylation at Ser-220 and Ser-234 and transactivation have 
not to date been directly linked to a particular kinase in intact cells, possibly due to a complex interplay 
of kinases involving multiple sites. MAPK pathways, in particular JNK and ERK, have been shown to 
be involved in phosphorylation of the rat GR at Ser-246 or human GR at Ser-211 (equivalent to mouse 
GR Ser-234) and to be involved in dex-mediated transcription supporting a role for JNK and ERK in 
GR phosphorylation and transcription (Krstic et al., 1997; Miller et al., 2007; Rogatsky et al., 1998; 
Tsutsumi et al., 1995). Miller et al. provided evidence for a positive role for p38 and a negative role for 
JNK in phosphorylation of the human GR at Ser-211 (equivalent to mouse GR Ser-234) in CEM-C7-14 
cells (Miller et al., 2005). The authors did not investigate the effect of the kinase inhibitor on total GR 
levels, thus making it difficult to interpret the data (Miller et al., 2005). Chen et al. recently showed that 
turmeric, the yellow colouring agent in curry powder, inhibited human GR phosphorylation at Ser-211 
and Ser-226 as well as transactivation via a GRE. However the kinase(s) targeted by the turmeric was 
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not established and specific inhibition of a wide range of MAPKs had no effect on GR phosphorylation 
in U2OS-hGR cells (Chen et al., 2008). In the present study it was shown that combinations of JNK, 
ERK and p38 MAPK inhibitors decreased dex-induced phosphorylation of the endogenous mouse GR 
at Ser-234 after 30 min of ligand stimulation while the inhibitors on their own had no effect (figure 4.10 
E and F). The data are difficult to interpret since short-term dex stimulation (up to 2 h) did not induce 
ERK, p38 and JNK phosphorylation while long-term (8 h) stimulation was found to only induce ERK 
activation in LßT2 cells. In the literature it is well established that GCs can cross talk with signalling 
pathways such as MAPK signalling (Hulley et al., 1998; Kassel and Herrlich, 2007; Lasa et al., 2001; 
Miller et al., 2005; Pelaia et al., 2001; Sasson et al., 2003; Swantek et al., 1997; Zhang et al., 2000). In 
contrast to results presented in this study GCs have been shown to rapidly induce ERK and JNK 
phosphorylation within 30 min in rat ovarian follicular cells and human eosinophils (Sasson et al., 
2003; Zhang et al., 2000) while Miller et al. reported dex-induced p38 phosphorylation after 20 h of 
continuous stimulation in human lymphoid cells (Miller et al., 2005). It is possible that the 
discrepancies between these reports and results from the present study may be due to cell-specific 
effects and culturing conditions. Furthermore, GCs have been reported to interfere negatively with 
MAPK signalling (Engelbrecht et al., 2003; Pelaia et al., 2001). The underlying mechanism was shown 
to involve GC-mediated expression of the MAPK inhibitor, MAPK phosphatase (MKP) which 
dephosphorylates and inactivates p38 and ERK rapidly within 2 h (Imasato et al., 2002; Kassel et al., 
2001; Lasa et al., 2001). However, since ERK phosphorylation was observed at 8 h of dex stimulation 
it is rather unlikely that MKP-1 activity can explain the failure to detect MAPKs phosphorylation in 
LßT2 cells after short-term GCs treatment. Inhibition of JNK was reported to occur within less than a 
minute via direct interaction of JNK and the liganded GR in HeLa and COS-7 cells (Bruna et al., 2003; 
Caelles et al., 1997). In the above examples dex was proposed to attenuate activation of MAPK 
pathway induced by proinflammatory stimuli as an anti-inflammatory mechanism mediated by GCs 
binding to the GR. It is however possible that dex activates the MAPKs p38 and JNK in LßT2 cells at a 
time point not investigated in this study. Furthermore, the decrease in dex-mediated GR 
phosphorylation in the presence of combinations of JNK, ERK and p38 MAPK inhibitors could not be 
directly link with an effect of the kinase inhibitors on GR-mediated transactivation, since the p38 
inhibitor slightly decreased transactivation of the GRE construct while the ERK pathway inhibitor alone 
had no effect on dex-mediated transactivation. Additionally, it was found that JNK inhibition increased 
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transactivation about 2-fold (figure 4.8 A). This result would suggest that the active form of JNK has an 
inhibitory effect on GRE-transactivation or that the JNK inhibitor inhibits other signalling molecules in 
LßT2 cells. Evidence for the latter hypothesis comes from reports in the literature showing that high 
concentration of a specific p38 inhibitor enhanced NF-κB-driven promoter activity via activation of the 
ERK pathway (Birkenkamp et al., 2000). Similarly, another study showed that the p38 inhibitor induced 
the activation of c-Raf which is an upstream activator of ERK, in vivo (Hall-Jackson et al., 1999). 
Although in the present study the JNK inhibitor was shown to have no effect on ERK or p38 activation 
it cannot be excluded that other pathways or proteins such as RNA-polymerase II or phosphatases 
might be affected by the JNK inhibitor resulting in increased transactivation. Interestingly, it was found 
that inhibition of p38 resulted in a significant increase in JNK phosphorylation (Addendum A figure A4) 
and decreased GRE-transactivation. This is in agreement with the hypothesis that the active form of 
JNK exerts an inhibitory effect on transactivation. Taken together the results from the present study 
suggest that a complex interplay between MAPKs and possibly other kinases and phosphatases 
occurs in response to dex treatment to modulate mouse GR phosphorylation and transcription in LßT2 
cells. However, further experiments are required to validate the results obtained with the 
pharmacological kinase inhibitors.  
 
Interestingly, GnRH stimulation induced hyperphosphorylation of the GR at Ser-234 while dex 
stimulation induced hyperphosphorylation of the GR at both Ser-234 and Ser-220 in LßT2 cells (figure 
4.4). Strikingly, the GnRH-induced phosphorylation was as rapid (within ten minutes) and similar in 
magnitude to the phosphorylation induced by dex at Ser-234, suggesting that non-genomic signalling 
cascades activated by GnRH are responsible for the unliganded GR phosphorylation. The finding that 
GnRH-induced GR phosphorylation was completely abolished in the presence of the GnRHR 
antagonist supports the idea that signalling pathways downstream of the GnRHR are mediating the 
response. To the present author’s knowledge, this is the first report showing hyperphosphorylation of 
the GR with a non-GC ligand, resulting in a differential phosphorylation pattern as compared to dex. 
The significance of the differential pattern of GR phosphorylation obtained with GnRH versus dex is 
unclear, but suggests that the GR activated by GnRH may exert differential biological effects as 
compared to the GR activated by dex. Unpublished data from the laboratory of the present author as 
well as others has shown that phosphorylation of the human GR at Ser-211, equivalent to Ser-220 in 
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the mouse GR, has a positive effect on transactivation via a GRE while phosphorylation at Ser-226 of 
the human GR, equivalent to Ser-234 in the mouse GR, has a negative effect on transactivation via a 
GRE (Avenant, 2009; Ismaili and Garabedian, 2004). Furthermore, Blind et al. suggested that different 
GR phosho-isoforms selectively occupy different GR target genes (Blind and Garabedian, 2008). 
Consistent with the idea that GnRH-activated GR exhibits differential biological effects as compared to 
dex-activated GR, results presented in the present study show by ChIP assays in LßT2 cells that 
GnRH-induced recruitment of the GR to the endogenous GnRHR promoter is about 50% less than 
dex-mediated recruitment of the GR (figure 3.6), and that about 50% less GR is translocated to the 
nucleus upon GnRH versus dex stimulation (figure 4.1). The above results would be consistent with a 
mechanism involving a less efficient release of cytosolic GR inhibitory proteins and/or nuclear 
translocation of the GR induced by GnRH as opposed to dex in LßT2 cells. Additionally, the efficacy of 
dex-induced GR-mediated transactivation of a synthetic GRE in COS-1 cells overexpressing 
exogenous GR and GnRHR was considerably greater than the GnRH-mediated effect (figure 4.3 A 
and B). COS-1 cells express very low levels of GR and do not express detectable endogenous 
GnRHR protein (van Biljon, 2006). Therefore it is possible that some of the components downstream 
of the GnRHR that are required for maximal GnRHR-mediated activation of the unliganded GR are 
present in lower amounts in COS-1 cells than in LßT2 cells, resulting in weaker transcriptional 
activation of the unliganded GR by GnRH compared to activation of the GR by dex in COS-1 cells. 
These results further suggest that the extent of GnRHR-mediated activation of the unliganded GR may 
vary in different cell types depending on expression levels of both the GR and GnRHR. 
 
6.3 Synergism occurs between the dex and GnRH response 
The finding that dex synergistically enhances the GnRH-induced increase in endogenous GnRHR 
gene expression in the LßT2 gonadotrope cell line is consistent with other reports of synergistic action 
of these hormones in the pituitary. GnRH has been found to act synergistically with the steroid 
hormones estradiol and progesterone, as well as with activin (An et al., 2006; Kowase et al., 2007; 
Yasin et al., 1995). GnRH and estradiol synergistically upregulate pituitary GnRHR mRNA production 
in female rats (Yasin et al., 1995). Furthermore, co-stimulation with GnRH and estradiol was found to 
synergistically increase LHβ and α-subunit promoters (Kowase et al., 2007) but not an ERE-reporter 
construct (Chen et al., 2009) in LβT2 cells. An et al. reported that GnRH-induced PRE-promoter 
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activity was synergistically augmented in the presence of progesterone in αT3-1 cells (An et al., 2006). 
However, the precise mechanisms thereof remain to be determined. GCs have been shown to 
synergistically enhance the GnRH-induced increase in endogenous GnRHR pituitary mRNA in rats 
(Rosen et al., 1991), as well as FSH secretion in rat pituitary fragments (D'Agostino et al., 1990). An 
important synergistic physiological role for GCs and the GR in stimulating reproductive function in rat 
pituitary gonadotropes is further supported by the finding that GCs synergistically enhance the activin-
induced increase in FSHβ gene expression in both primary rodent pituitary cells (Leal et al., 2003) and 
in LβT2 cells (McGillivray et al., 2007). In contrast, the presence of both activin and dex did not have a 
synergistic effect on transactivation of a GnRHR promoter-reporter construct (McGillivray et al., 2007) 
while others found that activin reduced the dex-induced transactivation of a transfected human 
glycoprotein hormone α-subunit (αGSU) luciferase reporter plasmid in LßT2 cells (Sasson et al., 2008) 
suggesting that synergism between activin and the GR is promoter-specific. In the same study it was 
shown that co-treatment with dex and GnRH resulted in a synergistic increase in αGSU promoter 
activity. Interestingly, results in figure 5.1 show that GnRH and dex act synergistically on both a 
synthetic GRE-reporter in COS-1 and LβT2 cells, as well as on the endogenous GnRHR gene in LβT2 
cells, suggesting that the mechanism of synergism between the GR and the GnRH receptor is not 
gonadotrope- or promoter-specific.  
 
The finding that dex plus GnRH results in a similar pattern of GR phosphorylation at Ser-220 and Ser-
234 compared to that obtained with dex alone (figure 5.3) suggests that differential phosphorylation at 
these GR residues does not play a role in the synergism. Since in the present study only two specific 
serine residues were investigated, Ser-220 and Ser-234 respectively, it cannot be excluded that other 
GR phosphorylation sites may be involved.  
In LßT2 cells it was further shown that synergism is not due to increased GR protein levels since co-
treatment with dex and GnRH was found to significantly decrease GR protein levels relative to vehicle 
control (figure 5.1 E and F). In fact it is possible that the dex plus GnRH-mediated synergistic increase 
in transactivation results in faster GR turnover compared to the hormones on their own in LßT2 cells. 
Unpublished data from our laboratory demonstrate a correlation between ligand-induced maximal 
transcriptional activity and GR turnover (Avenant, 2009) with strong GR ligands inducing maximal 
transactivation and rapid GR turnover. In the present study it was also found that in COS-1 cells dex 
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treatment decreased GR protein levels relative to control which is in agreement with reports in the 
literature (Webster et al., 1997), while co-stimulation with both dex and GnRH prevented dex-induced 
down-regulation of the GR (figure 5.2 C and D). The results indicate that a different mechanism is 
involved for the liganded versus the unliganded GR in these cells. It is interesting to point out that GR 
levels were affected differentially in LßT2 cells (figure 5.1 E and F) and COS-1 cells (figure 5.2 C and 
D) in response to dex, GnRH or a combination of both hormones which could be explained by 
differential GR activation and turnover occurring in a cell - and/or species-specific fashion. 
Furthermore it was shown by ChIPs that synergism does not involve differential recruitment of GR 
(figure 5.6), AP-1 proteins (figure 5.5), GRIP-1 or p300 (figure 5.7), as compared to dex or GnRH 
alone (illustrated in figure 6.1 D). By contrast the results suggest a role for SRC-1 since dex plus 
GnRH resulted in increased recruitment of this co-activator to the AP-1 region of the GnRHR promoter 
(figure 5.7). This finding might in part explain the synergistic effect of dex plus GnRH on transcriptional 
expression of the GnRHR gene. It is tempting to speculate that SRC-1 is recruited to the promoter to 
further enhance the transcriptional effect of other cofactors already bound to the promoter, such as 
GRIP-1 (figure 6.1 D). A study by Smith et al. supports this hypothesis showing that simultaneous 
expression of exogenous SRC-1 and CBP synergistically enhances ER and PR transcriptional activity 
of a reporter gene in HeLa cells (Smith et al., 1996). However, the precise mechanisms involved in the 
synergistic transcriptional effect of dex plus GnRH requires further investigation. Collectively the 
results suggest that cross talk between steroid receptor and peptide hormone receptor signaling 
pathways may be a common strategy, involving different mechanisms, for fine-tuning the reproductive 
response of the pituitary gonadotropes to changes in the hormonal milieu.  
 
6.4 Ligand-independent activation of the GR and other steroid receptors: 
physiological implications 
A few reports in the literature suggest that ligand-independent activation of the GR occurs in cells 
other than LßT2 cells. Tanaka et al. found that in hamster ovary cells UDCA promotes nuclear 
translocation of the GR mediated by the ligand-binding domain of the GR (Tanaka et al., 1996). In 
primary human lung fibroblasts and vascular smooth muscle cells the GR was rapidly depleted from 
the cytosol, translocated into the nucleus, and activated a GR-inducible luciferase reporter gene in 
response to ß2-agonists (Eickelberg et al., 1999). The authors suggested a possible role for 
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cAMP/PKA pathways in the ligand-independent activation of the GR in these cells (Eickelberg et al., 
1999). However, whether these examples of ligand-independent activation of the GR occur by rapid 
non-genomic mechanisms such as GR phosphorylation, or cross talk with others receptors is not 
known. 
 
Several reports have been published describing ligand-independent activation of steroid receptors 
other than the GR. The estrogen receptor (ER) has been shown to be activated in a ligand-
independent fashion by EGF via mechanisms involving PKA and MAPKs and phosphorylation of the 
ER at Ser-118 (Bunone et al., 1996; El-Tanani and Green, 1997). Phosphorylation of the human PR at 
Ser-400 has been shown to be mediated by cyclin-dependent protein kinase 2 (CDK2) in response to 
EGF in breast epithelial cells (Pierson-Mullany and Lange, 2004). By contrast, An et al. reported that 
GnRH-induced rapid ligand-independent phosphorylation of the mouse PR at Ser-294 and not at Ser-
400 in αT3-1 cells (An et al., 2006). They also reported nuclear translocation of the unliganded mouse 
PR and a requirement for SRC-3 in PR transactivation in response to GnRH in a GnRHR-dependent 
manner (An et al., 2006). Similarly, a later study by the same authors demonstrated GnRH-induced 
increase in FSHß mRNA levels in a PR-, and SRC-3-dependent fashion in LßT2 cells (An et al., 
2009). The results from the latter study further suggest that GnRH-induced phosphorylation of the PR 
at Ser-243 is required for increased PRE-promoter activity and FSHß mRNA levels in these cells. 
Moreover, a recent study by Chen et al. demonstrates that GnRH-induced rapid phosphorylation of the 
ER and transactivation of an ERE-reporter via the GnRHR in LßT2 cells (Chen et al., 2009). The 
authors further show a requirement for the ER and pCAF for the GnRH-mediated gene expression of 
fosB in these cells (Chen et al., 2009). Taken together with findings from the present study, these 
results suggest that the GnRHR can cross talk to both the GR and the PR via a mechanism involving 
steroid receptor phosphorylation. Thus it appears that ligand-independent activation of steroid 
receptors by phosphorylation may be a common mechanism of receptor activation in several different 
cells, via several different pathways. 
The present study provides the first evidence that GnRH acting via a GPCR, the GnRHR, can cross 
talk with the GR. Furthermore the results suggests that this occurs via a novel non-genomic 
mechanism resulting in rapid site-specific GR phosphorylation at Ser-234 involving PKC and MAPK’s, 
leading to nuclear translocation and transactivation of a GRE in LßT2 cells. Since GnRH regulates 
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several genes in pituitary gonadotropes, this non-genomic cross talk represents a mechanism 
whereby the GnRHR and unliganded GR may modulate expression of several GnRH and GR target 
genes. Thus cross talk may have important physiological implications since GR expression is 
widespread and the GnRHR is expressed in pituitary gonadotropes as well as many extra-pituitary 
tissues (Hapgood et al., 2005). This could be a mechanism for fine-tuning interplay between 
reproductive, stress and immune responses. Several lines of evidence show that the neuroendocrine, 
immune, inflammatory and stress-response systems are functionally integrated and bidirectionally 
regulated (An et al., 2006; Chrousos and Gold, 1992; Da Silva et al., 1993; Elenkov and Chrousos, 
1999). For example, stress or chronic activation of the HPA-axis suppresses reproduction via elevated 
GC levels that exert their effects at all levels of the HPG-axis (Rivier and Rivest, 1991). In the present 
study a direct transcriptional effect of GCs on GnRHR gene expression via the GR in a pituitary 
gonadotrope cell line was shown, representing another mechanism whereby the HPA axis could 
modulate the HPG axis.  
 
6.5 Proposed model for genomic and non-genomic cross talk of GnRHR and 
GR signalling pathways in LßT2 cells 
The results from the present study are summarized as proposed models shown in figure 6.1 and 6.2. 
In the absence of hormone the endogenous GnRHR promoter appears to be occupied by c-Jun and c-
Fos heterodimers which was discussed under section 6.1. In addition, by ChIP it was shown that p300 
occupies the proximal promoter as indicated in panel A of figure 6.1. Current models suggest that 
binding of p300 assists in positioning histone acetyltransferases (HATs) in target gene promoter 
regions and it has been proposed that p300 can interact with components of the general 
transcriptional machinery such as RNA-polymerase II or transcription factor (TF) IID or TFIIB (Sterner 
and Berger, 2000; Vo and Goodman, 2001). Conversely, p300 is also known to play a negative role in 
transcription (Santoso and Kadonaga, 2006). Although the role of p300 in GnRHR gene expression 
was not established in the present study, the results suggest that p300 has a negative effect on 
GnRHR gene expression. Unpublished data from our laboratory suggest that SF-1 occupies the 
nuclear receptor sites (NRSs) of the GnRHR promoter located at positions –244/-236 and –15/-7 
relative to the translational start site, under unstimulated conditions in vitro, possibly recruiting a 
corepressor (Sadie, 2006). Furthermore it was found that GnRH stimulation results in decreased SF-1 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 123 
binding to these NRSs in vitro (Sadie, 2006). Since p300 has been proposed to bind to SF-1 (Monte et 
al., 1998; Vo and Goodman, 2001) it can be speculated that p300 and SF-1 might interact under basal 
conditions on the endogenous GnRHR promoter in LßT2 cells resulting in transcriptional inhibition. 
This would be in agreement with the ChIP data presented in figure 5.7 showing that p300 binding is 
decreased under stimulated conditions although significance could not be established due to variation 
in the response and more repeats are needed to establish significance. Alternatively, the AP-1 
proteins c-Jun and c-Fos that associate with the GnRHR promoter could recruit p300 and thus 
maintain basal transcriptional activity (indicated by an arrow in figure 6.1 A). The role of p300 in 
GnRHR gene regulation as well as the specific binding site, however, remain to be determined in 
future experiments. 
Besides the possibility that p300 is removed from the promoter in response to hormone it is also 
possible that p300 mediates the assembly of transcription factors which reduces the accessibility of 
the epitope recognized by the p300 antibody. In a recent report by Stossi et al. p300 was proposed to 
act as a bridging factor between the ERα and coregulator complexes (Stossi et al., 2009). It is 
tempting to speculate that p300 bound to c-Jun/c-Fos enables recruitment of the GR and GRIP-1 in 
response to dex. Interestingly, Rogtsky et al. demonstrated recruitment of GRIP-1 to a complex 
containing GR directly bound to AP-1 proteins in intact U2OS cells at a collagenase3 response 
element regardless of the composition of AP-1. However, this interaction resulted in transcriptional 
repression of the gene dependent on the liganded GR (Rogatsky et al., 2001). To the present author’s 
knowledge this is the first report showing GRIP-1 recruitment to a positively GR regulated gene 
without a DNA-binding site for the GR. Although a direct interaction between GR and GRIP-1 was not 
established the data from the present study indicate that both GR and GRIP-1 are recruited to the AP-
1 region of the GnRHR promoter without direct binding of the GR to the DNA thus presenting a novel 
mechanism of GR dependent transcriptional activation mediated via cross talk with AP-1 (figure 6.1 
B). 
 
Results from the present study indicate that a complex interplay between MAPKs and possibly other 
kinases and phosphatases occurs in response to dex treatment to modulate mouse GR 
phosphorylation and transcription in LßT2 cells. However, within the scope of this study the detailed 
kinase cascade involved in dex-mediated transcriptional regulation of the GnRHR was not fully 
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established. Interestingly, progestin binding to PR-B has been shown to mediate non-classical gene 
transcription through rapid extra-nuclear activation of the epidermal growth factor receptor (EGFR), c-
src, and ERK MAPK cascade to stimulate phosphorylation of PR-B at Ser-345. PR phosphorylated at 
Ser-345 was found to tether to Sp1 to regulate EGFR and p21 gene transcription (Faivre et al., 2008). 
A similar non-classical mechanism could be utilized by the GR, possibly involving cross talk with 
membrane receptors such as the EGFR or the GnRHR. A study by Asadi et al. supports this 
hypothesis demonstrating that the FMS-like tyrosine kinase 3 directly interacts with the GR thereby 
affecting GR signalling in rat hepatoma cells (Asadi et al., 2008).  
 
The finding that the GR is recruited to the GnRHR promoter by GnRH strongly suggests another novel 
mechanism of action of the receptor in the absence of ligand possibly mediated via receptor cross talk 
(figure 6.1 C). Sex steroid hormone receptor functions have been shown to be affected by 7 
transmembrane receptors (TMR) (An et al., 2006; Bunone et al., 1996; Maudsley et al., 2006; Turgeon 
and Waring, 1994). GnRH was found to induce nuclear translocation of the PR in rat anterior pituitary 
cells (Turgeon and Waring, 1994) and αT3-1 cells (An et al., 2006) in a steroid-independent fashion. 
However, the mechanism involved including signalling pathways or target domains of these steroid 
receptors were not investigated by these authors. In the present study the data suggest that PKC as 
well as MAPKs might be mediators of GnRH signalling leading to activation of the GR. It is intriguing 
whether cross talk occurs via direct interaction of the GR and the GnRHR, G-proteins or kinases. 
Recent reports demonstrate that steroid receptors are associated with the plasma membrane. Jain et 
al. provide the first evidence for a functional contribution of membrane-raft associated GR in Hep3B 
cells (Jain et al., 2005) while another group found that the ER is associated with the plasma 
membrane via caveolae in endothelial cells (Razandi et al., 2002; Razandi et al., 1999). In addition the 
GnRHR has been proposed to co-localize with membrane rafts in association with Gαq/11 and raf (Bliss 
et al., 2007). Thus it is tempting to speculate that binding of GnRH to the GnRHR in LßT2 cells 
triggers the assembly of a multiprotein complex including components of signalling pathways and the 
GR in association with specialized membrane rafts at the plasma membrane to exhibit the activation of 
the steroid receptor. 
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The finding that GnRH fails to induce GRIP-1 recruitment to the GnRHR promoter suggests that 
GRIP-1 acts as a selective co-activator for the dex-activated GR and not for the unliganded GR. 
Recent studies demonstrate that differences in the phosphorylation status of the GR influence the 
interaction of the GR with other proteins (Chen et al., 2008; Galliher-Beckley et al., 2008; Ismaili et al., 
2005; Kino et al., 2007). Studies on the ER show that the phosphorylation status of one specific serine 
residue of the ER determines the recruitment of co-activator versus co-repressor (Endoh et al., 1999; 
Gburcik et al., 2005; Likhite et al., 2006; Weigel and Moore, 2007). Results from the present study 
demonstrate differential GR phosphorylation for dex and GnRH at Ser-220 and Ser-234. Thus, in 
LßT2 cells GRIP-1 recruitment to the GnRHR promoter could be determined by the phosphorylation 
status of specific serine residues of the GR, i.e. Ser-220 which is rapidly and transiently 
hyperphosphorylated by dex and not GnRH. This is in agreement with a recent study showing that 
phosphorylation of the human GR at one or more of residues Ser-226, Ser-211 and Ser-203 
(equivalent to mouse Ser-220, Ser-234 and Ser 212) is required for maximal transactivation efficacy 
and importantly for GRIP-1 recruitment to the MMTV promoter in intact COS-1 cells (Avenant, 2009). 
Interestingly, An et al. found that GnRH promotes PR interaction with SRC-3 and co-recruitment of 
both PR and SRC-3 to a PRE in the gonadotropin α-subunit gene (An et al., 2006). Although the 
recruitment of SRC-3 to the GnRHR promoter was not investigated in the present study it is possible 
that SRC-3 or another cofactor not investigated in this study is recruited to the AP-1 region to regulate 
the activity of the unliganded GR in response to GnRH (illustrated as “Y” in figure 6.1 C). 
 
The commonly held hypothesis is that GR dimerization is essential for binding of the receptor to a 
GRE and induction of gene expression but dispensable for repression of genes under the control of 
AP-1 or NF-κB (De Bosscher et al., 1997; Heck et al., 1994; Reichardt et al., 1998; Reichardt et al., 
2001; Tuckermann et al., 1999). Although the stoichiometric composition of the GR has not been 
investigated in the present study it can be hypothesized that the liganded-GR binds to the AP-1 region 
in the GnRHR promoter as a dimer (figure 6.1 B), although this theory needs to be tested with 
additional experiments. Support for the involvement of a GR dimer rather than a GR monomer in dex-
mediated GnRHR transactivation on the GnRHR promoter (figure 6.1 B) comes from results in the 
present study showing that the AP-1 site is not the sole cis-regulatory element in conferring the 
response, thus making it likely that a GR dimer is required for GR binding to both AP-1 and factor “X” 
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as illustrated in figure 6.1 B. Furthermore, since GnRH treatment appears to recruit GR to a lesser 
extent than dex to the GnRHR promoter (figure 3.6) it is tempting to speculate that the unliganded-GR 
might act as a monomer on the GnRHR promoter to regulate gene expression (figure 6.1 C). It is 
possible that GnRH induces a differential GR conformation compared to dex in favour of the formation 
of active GR monomers. This is in agreement with results from the present study showing that dex but 
not GnRH induces GRIP-1 binding where a different binding surface of the GR, as presented by a 
monomer versus a dimer, could in part explain the differential co-factor recruitment (figure 5.7). In 
addition, since co-stimulation with dex plus GnRH induces GR recruitment to the AP-1 region of the 
GnRHR promoter with levels similar to that observed with dex alone it is tempting to speculate that the 
presence of both hormones induces formation of a GR dimer possibly consisting of a ligand-
dependent and ligand-independent activated GR monomer (figure 6.1 D). Furthermore, the formation 
of this novel dimer might thereby enable interaction with differential co-factors such as SRC-1 through 
a novel binding site formed by this GR dimer. However, it is clear that more experiments are needed 
to establish the role of GR dimerization in GnRHR regulation. 
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Figure 6.1: Model for genomic and non-genomic cross talk of the gonadotropin-releasing 
hormone receptor and glucocorticoid receptor signalling pathways converging at the GnRHR 
gene in LβT2 cells  
A proposed model for GR-mediated regulation of the GnRHR promoter in LβT2 cells in the absence 
(A), or presence of dex (B) or GnRH (C) or both dex and GnRH (D) is shown. The c-Jun and c-Fos 
proteins are shown bound to the AP-1 site in the GnRHR promoter under basal and hormone-
stimulated conditions. The cofactor p300 is shown associated with the AP-1 region only under basal 
condition (A). The GR is depicted in two different conformations, one activated by dex with the GR 
phosphorylated at Ser-220 and Ser-234 (indicated by two “Ps”), and another activated by GnRH which 
binds the GnRHR to activate Gq (Liu et al., 2002b), resulting in activation of PKC and MAPKs, in 
particular ERK, to mediate GR site-specific phosphorylation at Ser-234 (indicated by one “P”) via a 
rapid non-genomic mechanism. It can be speculated that a transcription factor X bound at an as yet 
unidentified response element (RE) is required for the dex response in B, since dex did was not found 
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to increase the transcriptional response on a simple AP-1 promoter-reporter. The co-activator GRIP-1 
is shown associated with the dex-activated GR in B and D, consistent with the results. It can be 
speculated that another as yet unidentified co-activator Y is associated with the GnRH-activated GR in 
C. Consistent with the data, recruitment of SRC-1 co-activator is only shown in D. The model would be 
consistent with the data, although it should be noted that this study does not provide proof for the 
monomer versus dimer status of the GR, or for a direct interaction between the GR and AP-1 proteins 
or factor X, or for a lack of involvement of other cofactors, kinases or phosphatases not investigated. 
 
Result from the present study suggest that non-genomic cross talk between the GR and the GnRHR 
signalling pathways do not only converge at the GnRHR promoter but also at GRE-containing genes 
since GnRH induced a minimal GRE in both LßT2 cells and COS-1 cells (figure 4.2 and 4.3). Although 
it was established that both the GR and the GnRHR are required for this response, the present study 
did not investigate whether the effect occurs on endogenous genes or the precise mechanism thereof. 
However, it can be assumed that the dex-activated GR binds to the GRE-promoter as a dimer to 
induce transactivation (illustrated in figure 6.2 B) as reported in the literature (Chalepakis et al., 1990; 
Griekspoor et al., 2007; Reichardt et al., 1998). In addition it is tempting to hypothesize that the dex-
activated GR recruits a co-activator, most likely GRIP-1 to the minimal reporter thereby inducing 
transactivation (figure 6.1 B). Evidence for this hypothesis comes from recent reports showing dex-
dependent GRIP-1 binding to GRE-bound GR in vitro and to the MMTV-promoter in COS-1 and COS-
7 cells, respectively (Avenant, 2009; Ronacher et al., 2009). Furthermore, since it has been reported 
in the literature that GR dimerization is a requirement for GR-mediated transactivation of simple GRE’s 
it can be speculated that GnRH-induced increase in transcriptional activity of a GRE-reporter construct 
is mediated by GR dimers as illustrated in figure 6.2 C (Reichardt et al., 1998; Reichardt et al., 2001). 
Interestingly, it has been shown that GnRH-activated PR and ER recruit co-factors to simple hormone-
response elements in mouse pituitary cell lines (An et al., 2006; Chen et al., 2009). While An et al. 
showed recruitment of the PR and SRC-3 to the PRE on a reporter plasmid and the endogenous 
gonadotropin α-subunit gene promoter in αT3-1 cells, a recent study by Chen et al. demonstrated that 
GnRH-activated ER directly interacts with the p300/CBP-associated factor (pCAF) and furthermore the 
authors showed that the ER and pCAF are recruited to an ERE-reporter construct as well as the 
endogenous fosB gene containing a known ERE (An et al., 2006; Chen et al., 2009). Thus, it can be 
speculated that GnRH-mediated GRE-transactivation found in the present study involves co-factor 
recruitment to mediate the response in LßT2 cells (figure 6.2 C). Interestingly, it was found that co-
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stimulation with dex plus GnRH results in a synergistic effect on GRE-transactivation as observed for 
the endogenous GnRHR gene which lacks a GRE. Thus, it is tempting to speculate that co-treatment 
with both hormones induces the formation and binding of a novel dimer composed of a ligand-
dependent and ligand independent activated GR as described for the GnRHR gene above (figure 6.1 
D). This novel dimer might enable the recruitment of similar co-factors such as GRIP-1 and SRC-1 
thereby resulting in synergism (illustrated in figure 6.2 D). However, it is clear that further 
investigations are needed to establish the mechanism involved in transcriptional activation of a GRE 
by GnRH in these cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Proposed model for transcriptional regulation of a GRE in response to dex, GnRH 
and a combination thereof in LβT2 cells (legend to follow on following page) 
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A proposed model for GRE-transactivation in the absence (A), or presence of dex (B) or GnRH (C) or 
both dex and GnRH (D) is shown. The GR is depicted in two different conformations, one activated by 
dex with the GR phosphorylated at Ser-220 and Ser-234 (indicated by two “Ps”), and another 
activated by GnRH resulting in GR site-specific phosphorylation at Ser-234 (indicated by one “P”) via a 
rapid non-genomic mechanism. Although the present study does not provide proof for the involvement 
of a GR dimer or the recruitment of co-activators to the GRE promoter it can be speculated that the 
dex-activated GR is associated with GRIP-1 (B and D) while an unknown co-activator Y is associated 
with the GnRH-activated GR in C. It can further be hypothesized that the synergistic effect of co-
treatment with dex and GnRH on GRE-transactivation might be due to the recruitment of yet another 
cofactor such as SRC-1 (as observed for the GnRHR gene).  
 
The data presented in this study strongly suggest that simultaneous activation of the GR by GCs and 
the GnRHR by GnRH induces simultaneous interaction of several transcription factors including AP-1, 
the GR, GRIP-1 and SRC-1 which could contribute to transcriptional synergy. It can be speculated that 
cross talk between the GR and the GnRHR may occur at several levels including modulation of each 
others signalling pathways whereby GnRHR signalling pathways modify ligand-dependent as well as 
ligand-independent GR transactivation and in turn the activated GR modulate GnRHR signalling 
pathways. There is support for this hypothesis in the literature. Kino et al. demonstrated that the 
liganded GR directly interacts with G-protein-β and comigrates to the plasma membrane in human 
colon carcinoma cells HCT116 (Kino et al., 2005). Thus, it is likely that the GR associated with G-
proteins modulates the activity of the GnRHR at the plasma membrane via direct protein - protein 
interactions with GnRHR-coupled G-proteins (Kino et al., 2005). Further evidence for an effect of the 
liganded GR on other receptor pathways is supported by findings from another group demonstrating 
that GCs inhibit insulin signalling through a GR-dependent and transcription-independent mechanism 
in adipocytes and T lymphocytes (Lowenberg et al., 2006a). Un
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6.6 Conclusions 
In summary the present study demonstrates for the first time that rapid non-genomic as well as 
genomic cross talk occurs between the GnRHR and GR signalling pathways in LßT2 cells. It was 
established that GnRH and dex increase expression of the endogenous GnRHR in a GR-dependent 
fashion converging on the same AP-1 site on the mouse GnRHR promoter in LßT2 cells. Additionally 
this study provides strong evidence for ligand-independent activation of the GR by GnRH. This novel 
mechanism was found to be mediated by the GnRHR, resulting in GR phosphorylation, nuclear 
translocation and GR-mediated transcriptional regulation in both LßT2 cells and COS-1 cells. The 
results suggests that the ability of the GnRHR to activate the unliganded GR is not gonadotrope-
specific, and that the unliganded GR can regulate the GnRHR gene via recruitment to the AP-1 region 
of the GnRHR promoter as well as regulate other genes via direct binding to GREs. Furthermore it 
was established that GnRH and dex together act synergistically to upregulate the mouse GnRHR 
promoter in a GR- and GnRHR-dependent fashion, most likely involving increased recruitment of 
SRC-1. 
Taken together the results reported in the present study underscore the importance of cross talk 
between membrane-associated receptors and intracellular receptors and the functional consequences 
of cross talk. Furthermore the results suggest a novel mechanism whereby the HPG axis could 
modulate the HPA axis and immune function where GR-dependent stress, immune or inflammatory 
response could be modulated by GnRH via GnRHR-dependent activation of the unliganded GR.  
 
6.7 Future perspectives 
The results from the present study show that the GR and GnRHR pathways cross talk to each other 
by rapid non-genomic as well as genomic mechanisms. Yet, many questions remain unanswered. For 
example, what is the function of c-Jun, c-Fos or p300 on the GnRHR promoter under basal 
conditions? Whether c-Jun, c-Fos, or p300 have a structural role or a direct positive activation role in 
transcription of the GnRHR can be investigated by knock down experiments or by utilizing dominant-
negative proteins that cannot bind DNA or that have no transcriptional capacity. In addition, it would be 
of interest to investigate the phosphorylation status of c-Jun and c-Fos under basal as well as dex- 
and GnRH-mediated conditions and further determine by ChIP whether the phosphorylated forms of c-
Jun and c-Fos occupy the AP-1 region of GnRHR promoter under hormone stimulated conditions. 
Since the AP-1 site in the GnRHR promoter was found not to be the sole regulatory region in 
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mediating the dex-response, 5’-deletion mutants of the GnRHR promoter or constructs carrying 
mutations in one or more cis-regulatory element(s) transfected into LßT2 cells could be analysed to 
identify other regulatory cis-elements (indicated as “RE” in figure 6.1 B) in the GnRHR promoter 
required for the response. The results obtained with such promoter-constructs could be further 
investigated by ChIPs or knock down experiments establishing a requirement as well as occupancy of 
this regulatory element (illustrated as “X” in figure 6.1 B). In addition co-immunoprecipitation assays 
may reveal a direct interaction of the GR with the transcription factors identified in experiments 
described above. Additionally, it would be important to identify by ChIPs which cofactor is recruited by 
the unliganded GR to induce GnRHR transcription (indicated as “Y” in figure 6.1 C). By Western 
blotting the protein expression levels of already identified cofactors such as GRIP-1, SRC-1 and p300 
as well as cofactors and transcription factors identified in experiments as described above could be 
investigated in respose to dex, GnRH or a combination thereof.  
An intriguing question is how GnRH activates the GR and whether the receptor activated in the 
absence of GCs has different biological activity compared to the dex-activated GR. As shown in figure 
4.2 GnRH stimulation resulted in a differential phosphorylation pattern to that obtained with dex. It 
would be useful to analyze several other phospho-specific serine residues of the mouse GR since 
phosphorylation of the receptor has been proposed to play an important role in regulating transcription 
(Avenant, 2009; Bodwell et al., 1991; Chen et al., 2008; Hoeck and Groner, 1990; Kino et al., 2007; 
Mason and Housley, 1993; Webster et al., 1997). Moreover, other post translational modifications 
could be investigated, such as the acteylation status of the GR, to gain further insight into the 
mechanism whereby GnRH activates the receptor. Additionally, it would be interesting to study the 
receptor domains of the GR that are essential for GnRH-induced activation, possible structural 
changes in GR conformation as well as the implications thereof for GR function. In order to do so the 
effect of several GR constructs containing mutations in the structural domains such as AF-1, AF-
2/LBD the DBD and the hinge region as well as the effect of isolated receptor domains on 
transactivation in response to ligand can be investigated. 
When considering the result presented in figure 4.2 and 4.3 demonstrating transactivation of a minimal 
GRE in both LßT2 cells and COS-1 cells it appears that GnRH regulates GRE-containing genes via 
cross talk with the GR. To confirm that GnRH induces gene expression in a GRE-dependent fashion, 
a mutant of a GRE-promoter construct carrying mutations in the GRE sites or GRE deletion mutants 
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could be transfected into LßT2 cells. The results obtained with such mutant promoter constructs could 
establish a requirement of a GRE for GnRH-induced transcription. Similarly, the observation that dex 
plus GnRH induce a synergistic increase in GRE-transactivation suggests that GRE-containing genes 
are regulated by both dex and GnRH via a non-classical GR mechanism. Thus, it would be particularly 
interesting to identify endogenous GRE-containing GR target genes which are regulated by dex and 
GnRH synergistically and unravel the molecular mechanism thereof. In addition it would be important 
to establish the recruitment of the GR as well as co-factors to the GRE in response to dex, GnRH or a 
combination thereof in LßT2 cells. 
In order to explore whether GR dimerization is a requirement for the dex- and GnRH-mediated 
transcriptional activation of the GnRHR gene and a GRE-reporter, GR mutants unable to dimerize 
could be utilized in overexpression studies in both LßT2 and COS-1 cells. Furthermore, it would be of 
interest to investigate other genes that have been shown to be regulated by GnRH such as LHß 
(Kowase et al., 2007), FSHß (Gregory et al., 2005; Wang et al., 2008) as well as genes recently 
identified by microarray analysis involved in transcriptional regulation, cell growth or metabolism 
(Kakar et al., 2003) and determine whether transcriptional regulation of these genes involves ligand 
activated or unliganded GR as found for the GnRHR gene in the present study. 
 
Another fascinating question is whether cross talk of the GnRHR and the GR involves direct 
interaction of the GR with components involved in GnRHR signalling such as G-proteins or kinases 
and whether these interactions might be associated within microdomains at the plasma membrane. 
Since it has been shown that the GR is rapidly phosphorylated in response the GnRH (within 10 min, 
figure 4.4) and that this phosphorylation event could be blocked with the GnRHR antagonist, it 
appears that signalling pathways downstream of the GnRHR are involved. Thus, it would be sensible 
to investigate the presence of microdomains, such as caveolae or membrane rafts, in LßT2 cells and 
to determine whether the GR, the GnRHR, G-proteins, kinases such as PKC or MAPKs are 
associated in a multiprotein complex in the absence or presence of hormone. Ligand-independent 
activation of the GR by the GnRHR could occur in these specialized membrane domains by 
assembling a distinct protein complex at the plasma membrane. This hypothesis would be particularly 
interesting to follow up since reports in the literature indicate that steroid receptor and GPCRs can 
interact at the plasma membrane (Asadi et al., 2008; Bliss et al., 2007; Dobkin-Bekman et al., 2009; 
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Navratil et al., 2003; Razandi et al., 2002; Roberson et al., 2005). Additionally it would be of great 
interest to establish whether posttranslational modifications such as phosphorylation of the GR occur 
within these microdomains. Similarly, it would be important to investigate the possible role of proteins 
associated with the GR such as heat shock proteins (Griekspoor et al., 2007) or phosphatases (Wang 
et al., 2007) in cross talk with the GnRHR. The results might yield valuable information on the 
mechanism of non-classical and non-genomic modulation of GR activity via a GPCR.  
GPCR and GR signalling pathways could bidirectional modulate each other’s activity: Activation of the 
GR by GCs could potentially modulate a GPCR signalling pathway. Thus, it would also be exciting to 
investigate whether ligand-activated GR can modulate GnRHR signalling. It could be explored whether 
the GR associates with the GnRHR in the above mentioned membrane domains in the presence of 
GCs and thereby directly activating or inhibiting GPCR signalling by modulating coupling to G-
proteins, and activating or inhibiting downstream kinase or transcription factors of the GPCR pathway. 
Furthermore, it would be interesting to examine whether GCs directly interfere with GPCR function by 
modulating post-translational modifications of the membrane receptor such as phosphorylation, 
glycosylation or palmitoylation. 
 
Multiple ligands act simultaneously on pituitary gonadotropes. In addition to GnRH, gonadal steroids, 
peptide hormones, neurotransmitters and pituitary hormones have been demonstrated to act as 
regulators (Evans, 1999). Thus, stimulation of cells with a single ligand in vitro does not reflect the 
effects of several ligands acting collectively in vivo and raises the question of how relevant the results 
obtained in immortalized cell lines like LßT2 cells are. In addition, the anterior pituitary contains a 
heterogenic cell population and the effect of GnRH and dex might be more complex and exhibit 
differential effects in a mixed cell population compared to an isolated cell type due to paracrine effects. 
Hence, the results obtained in immortalized cell lines should be confirmed in primary pituitary cell 
cultures. The effect of the endogenous GC corticosterone on GnRHR gene expression should be 
investigated to further establish that data obtained with the synthetic GC dex are relevant in vivo. 
Furthermore, it would be interesting to study the role of the GR in gonadotrope function in vivo by 
analyzing gene expression in knock-out mice deficient in GR exclusively in the gonadotropes. Gene 
expression profiles of primary pituitary cells stimulated with dex, GnRH or a combination thereof could 
be obtained by performing microarray analysis. This would allow the identification of various novel 
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responsive genes and potentially differential regulation mediated by these hormones. In the future it 
might also be relevant to investigate the effects of dex, GnRH and dex plus GnRH in primary cells 
from GR knock out mice to further establish the role of the GR in gene regulation. 
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ADDENDUM A 
SUPPLEMENTARY DATA 
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Figure A1: Activation of JNK kinases by GnRH in LßT2 cells (figure legend to follow on next page) 
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A: LβT2 cells were treated with 100 nM dex, 100 nM GnRH or a combination thereof in serum free 
medium for the indicated times. Proteins were separated on 8% SDS-PAGE gel, electroblotted onto 
nitrocellulose membrane and probed with anti-phospho JNK antibody. The blots were stripped and 
reprobed with an anti-total JNK antibody as a control. B: Pooled and quantified results of 3 
independent experiments are presented as relative amounts of phosphorylated kinase over total 
kinase for phospho JNK 1 (left) and phospho-JNK 2/3 (right). C: Relative kinase expression levels are 
shown for JNK 1 (right) and JNK 2/3 (left), with vehicle (control) at 30 min set as 1. 
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Figure A2: GnRH rapidly induces p38 activation in LßT2 cells 
A: LβT2 cells lysates as prepared for figure A1 were analyzed by Western blotting using an anti-
phospho-p38 antibody The blots were stripped are reprobed with anti JNK1/2 as control. B: Pooled 
and quantified results of 3 independent experiments are presented as relative amount of 
phosphorylated p38 over total p38. C: Total p38 expression levels are shown, with vehicle (control) at 
30 min set as 1. 
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Figure A3: Activation of ERK kinase by GnRH and dex 
A: LβT2 cells were treated as described for figure A1 and Western blotting performed using an anti-
phospho-ERK1/2 antibody. The blots were stripped are reprobed with anti-ERK1/2 antibody as control. 
B: Pooled and quantified results of 3 independent experiments are presented as relative amount of 
phosphorylated kinase over total kinase on separate graphs for phospho-ERK 1 (left panel) and 
phospho-ERK 2 (right panel) C: Relative kinase expression levels are shown for ERK 1 (left panel) 
and ERK 2 (right panel), with vehicle (control) at 30 min set as 1. 
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The JNK inhibitor SP600125 used in the study has been characterized by Bennett et al. in 2001 as an 
anthrapyrazolone inhibitor of JNK (Bennett et al., 2001) These authors found that in the presence of 
the JNK inhibitor SP600125 stimuli-induced phosphorylation of JNK was reduced to a similar extent as 
phosphorylation of the downstream JNK substrate c-Jun. They further suggest that this effect may be 
due to MKK4 inhibitory activity which is upstream of JNK. Therefore the effect of the JNK inhibitor 
SP600125 on JNK phosphorylation was investigated to determine the efficiency of the inhibitor (figure 
A4)  
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Figure A4: (continued on next page) 
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Figure A4: Effects of MAPK inhibitors PD98059, S203580 and SP600125 on GnRH-mediated 
activation of JNK 
LβT2 were stimulated for 30 minutes with 100 nM GnRH in the absence or presence of the following 
inhibitors: 10 µM JNK inhibitor (SP600125), 10 µM p38 inhibitor (SB203580), 50 µM ERK pathway 
inhibitor. Proteins were separated on an 8% SDS-PAGE gel, electroblotted onto a nitrocellulose 
membrane and probed with phospho JNK antibody (A). The blots were stripped and reprobed with 
antibodies for total JNK (A). The combined results from three independent are presented in B, where 
phospho JNK levels were normalized to total JNK with the value for control (vehicle) set to 1. The total 
JNK protein levels are shown on separate graphs with vehicle (control) at as 1 (C). D: Results are 
presented as phospho JNK over total JNK relative to GnRH induced phosphorylation which was set to 
100%. 
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Figure A5: (continued on next page) 
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Figure A5: Specificity of MAPK inhibitors on ERK induction 
A-C: LβT2 were stimulated were as described in figure A4. Proteins were separated on an 8% SDS-
PAGE gel, electroblotted onto a nitrocellulose membrane and probed with phospho ERK antibody. 
The blots were stripped and reprobed with antibodies for total ERK as a control. The combined results 
from three independent are presented in B, where phospho JNK levels were normalized to total JNK 
with the value for control (vehicle) set to 1. The total ERK protein levels are shown on separate graphs 
with vehicle (control) at as 1 (C). D: Results are presented as phospho ERK over total ERK relative to 
GnRH induced phosphorylation which was set to 100%. 
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Figure A6: (continued on next page) 
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Figure A6: Specificity of MAPK inhibitors PD98059, S203580 and SP600125 
A-C: LβT2 were stimulated were stimulated as described in figure A4 Proteins were separated on an 
8% SDS-PAGE gel, electroblotted onto a nitrocellulose membrane and probed with phospho p38 
antibody (A). The blots were stripped and reprobed with antibodies for total p38 (A). The combined 
results from three independent are presented in B, where phospho JNK levels were normalized to total 
JNK with the value for control (vehicle) set to 1. The total p38 protein levels are shown on separate 
graphs with vehicle (control) at as 1 (C). D: Results are presented as phospho p38 over total p38 
relative to GnRH induced phosphorylation which was set to 100%. 
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Figure A7: (continued on next page) 
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Figure A7: Protein expression of c-Jun is rapidly induced by GnRH and not dex in LßT2 cells 
LßT2 cells were grown and serum-starved overnight before treatment with vehicle, 100 nM GnRH, 100 
nM dex or a combination thereof for the different times as indicated. Equal amounts of cell lysates 
were loaded on an 8% SDS-PAGE gel, transferred onto nitrocellulose membrane and probed using 
specific antibodies for c-Jun (A). The graphs in B shows combined results of at least 2 independent 
experiments. The graphs in C, D and E show relative c-Jun protein expression levels in response to 
dex (C), GnRH (D) or dex plus GnRH (E). 
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Figure A8: (continued on following page) 
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Figure A8: GnRH but not dex increases c-Fos protein expression in LßT2 cells 
LßT2 cells were grown and serum-starved overnight before treatment with vehicle, 100 nM GnRH, 100 
nM dex or a combination thereof for the indicated times as indicated. Equal amounts of cell lysates 
were loaded on an 8% SDS-PAGE gel, transferred onto nitrocellulose membrane and probed using 
specific antibodies for c-Fos (A). The graphs in B shows combined results of at least 2 independent 
experiments and the graphs in C, D and E show relative c-Fos protein expression levels in response 
to dex (C), GnRH (D) or dex plus GnRH (E). 
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ADDENDUM B 
RESULTS RELEVANT TO THE PRESENT STUDY 
OBTAINED BY OTHER’S IN PROF. HAPGOOD’S LABORATORY  
 
The results presented in figure B1 (B) and B2 (B) were obtained by Dr. Hanél Sadie-Van Gijsen 
(Sadie, 2006) and the figures presented in figure B1 (C) and B2 (A) and B2 (B) were obtained 
from Sandra Fernandes (Fernandes, 2007). (previous students in Prof. Hapgood’s research 
group).  
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Figure B1: Both GnRH and dex increase expression of the transfected GnRHR promoter-
reporter in LßT2 cells 
A: Schematic of the mouse GnRHR promoter-luciferase construct (pLG). Transcription factor binding 
sites are indicated as boxes, with positions relative to translation start site indicated at the top. NRS: 
nuclear receptor binding site; AP-1 activator protein-1; CRE: cAMP response element. B,C: LβT2 cells 
were transfected with 100ng of pLG and 24 h later stimulated with vehicle (control), 100 nM GnRH (B) 
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or 100 nM dex (C) for 8 h in the absence of serum. The luciferase activity was normalized to ß-
galactosidase activity and the hormone-stimulated increase in wild-type GnRHR promoter activity was 
calculated relative to the control. Graphs show combined results of at least 3 independent 
experiments, each performed in triplicate. 
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Figure B2: Basal activity plus GnRH- and dex-induced stimulation of the synthetic mouse 
GnRHR promoter require an intact an AP-1 site  
LßT2 cells were transfected with 100 ng of pLG or pLGmAP1 and after approximately 24 h cells were 
incubated for 8 h in serum-free medium in the absence (A) or presence of 100 nM GnRH (B) or 100 
nM dex (B). The luciferase activity was normalized to ß-galactosidase activity and the hormone-
stimulated increase in promoter activity was calculated relative to the control. The graphs show the 
combined results of at least 3 independent experiments, each performed in triplicate.  
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ADDENDUM C 
Primer Sequences 
 
C1: Primers used for quantitative real-time PCR 
 
mouse GnRHR gene ( product size: 192 bp) (Sadie, 2006) 
 forward 5’CCACAGTGGTGGCATCAGGCCTTC 3’ 
 reverse 5’TAGCGTTCTCAGCCGAGCTCTTGG 3’ 
 
 
mouse GAPDH gene (product size: 263 bp) (Overbergh et al., 1999) 
 forward 5’ TTCACCACCATGGAGAAGGC 3’ 
 reverse 5’ GGCATGGACTGTGGTCATCA 3’ 
 
C2: Primers used in ChIP assays 
 
mouse GnRHR promoter* (product size: 168 bp) (Kam et al., 2005) 
 forward 5’ GTATCTGTCTAGTCACAACAG 3’ 
 reverse 5’ TCCTGAAGGCCAAGTGTAACC 3’ 
 
mouse FSHß promoter* (product size: 280 bp) (Coss et al., 2004)  
 forward 5’GGTGTGCTGCCATATCAGATTCGG 3’ 
 reverse 5’ GCATCAAGTGCTGCTACTCACCTGTG 3’ 
 
 
 
 
 
 
 
* spanning the AP-1 site of the mouse promoter 
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ADDENDUM D 
BUFFERS AND SOLUTIONS 
 
 
D1. Growth medium 
SOC medium  
2% (w/v) tryptone  
0.5% (w/v) yeast extract 
0.05% (w/v) NaCl 
2.5 mM KCl 
10 mM MgCl2 
20 mM glucose 
 
LB medium  
1% (w/v) tryptone 
0.5% yeast extract 
1% NaCl 
containing 50 µg/mL ampicillin 
for LB-agar plates add 1,5% agar 
 
D2: RNA isolation 
DEPC-treated H2O 
1 ml diethyl pyrocarbonate (DEPC) in 1 L dH2O (1:1000 dilution) 
Incubate 2 h at 37ºC, autoclave twice to inactivate DEPC 
 
10X Morpholinopropanesulfonic acid (MOPS) buffer 
0.2 M MOPS  
0,05 M sodium acetate 
0,01M EDTA, pH 8.0, adjust pH to 7.0 with 10 M NaOH 
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Denaturing formaldehyde gel mix (1% 100 ml) 
Dissolve 1 g agarose in 70 ml DEPC-treated H2O and bring to boil. Add 10 ml 10X MOPS buffer and 
20 ml formaldehyde in fume hood. Mix well and pour.  
 
RNA sample loading buffer  
1,8 ml DEPC H2O 
0,8 ml Bromophenol blue solution (saturated) 
1 ml glycerol 
1.5 ml 10x MOPS 
2,6 ml 12.3 M formaldehyde 
7,3 ml formamide 
Add 2,5 µl 10 mg/ml ethidium bromide per 1 ml RNA sample loading buffer just before use. 
 
RNA electrophoresis buffer (500 ml) 
50 ml 1x MOPS 
14 ml formaldehyde 
436 ml DEPC-treated water 
 
D3: Western blot analysis 
5X SDS sample buffer 
100 mM Tris-HCL, pH 6.8 
5% (w/v) SDS 
20% (v/v) glycerol 
2% (v/v) ß-mercaptoethanol 
0.1% (w/v) bromophenol blue 
 
Running buffer  
25 mM Tris-HCL 
250 mM glycine 
0,1% SDS (w/v), pH 8,4 
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Transfer buffer  
25 mM Tris 
200 mM glycine 
10% (v/v) methanol 
 
Tris buffered saline (TBS) 
50 mM Tris 
150 mM NaCl 
 
TBS-Tween (TBS-T) 
50 mM Tris 
150 mM NaCl 
0.1% (v/v) Tween 
 
Stripping buffer  
100 mM ß-mercaptoethanol 
2% (w/v) SDS 
62.5 mM Tris-Cl, pH 6.7 
 
D4: Chromatin immunoprecipitation (ChIP) buffers (Ma et al., 2003) 
nuclear lysis buffer 
1% SDS 
50 mM Tris-HCL, pH 8.0 
10 mM EDTA, 
1 x Complete Mini Protease Inhibitor Cocktail per 10 ml buffer 
 
IP dilution buffer 
0.01 % (w/v) SDS 
20 mM Tris-HCL, pH 8.0 
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1.1% Triton X-100 
167 mM NaCl 
1.2 mM EDTA 
1 x Complete Mini Protease Inhibitor Cocktail per 10 ml buffer 
 
Wash buffer I 
0.1% (w/v) SDS 
1% (v/v) Triton X-100 
2 mM EDTA 
20 mM Tris-HCL pH 8.0 
150 mM NaCl 
 
Wash buffer II 
0.1% (w/v) SDS 
1% (v/v) Triton X-100 
2 mM EDTA 
20 mM Tris-HCL pH 8.0 
500 mM NaCl 
 
Wash buffer III 
1% (v/v) NP-40 
1% (w/v) sodium deoxycholate 
500 mM LiCl 
1 mM EDTA 
10 mM Tris-HCL pH 8.0 
 
TE 
10 mM Tris-HCL pH 8.0 
0.1 mM EDTA 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 156 
 
BIBLIOGRAPHY 
 
AbdAlla S, Lother H, Quitterer U. 2000. AT1-receptor heterodimers show enhanced G-protein 
activation and altered receptor sequestration. Nature 407(6800):94-98. 
Adams TE, Sakurai H, Adams BM. 1999. Effect of stress-like concentrations of cortisol on estradiol-
dependent expression of gonadotropin-releasing hormone receptor in orchidectomized sheep. 
Biol Reprod 60(1):164-168. 
Ahn S, Shenoy SK, Wei H, Lefkowitz RJ. 2004a. Differential kinetic and spatial patterns of beta-
arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem 
279(34):35518-35525. 
Ahn S, Wei H, Garrison TR, Lefkowitz RJ. 2004b. Reciprocal regulation of angiotensin receptor-
activated extracellular signal-regulated kinases by beta-arrestins 1 and 2. J Biol Chem 
279(9):7807-7811. 
Albarracin CT, Kaiser UB, Chin WW. 1994. Isolation and characterization of the 5'-flanking region of 
the mouse gonadotropin-releasing hormone receptor gene. Endocrinology 135(6):2300-2306. 
An BS, Poon SL, So WK, Hammond GL, Leung PC. 2009. Rapid Effect of GNRH1 on Follicle-
Stimulating Hormone Beta Gene Expression in LbetaT2 Mouse Pituitary Cells Requires the 
Progesterone Receptor. Biol Reprod 81(2):243-249. 
An BS, Selva DM, Hammond GL, Rivero-Muller A, Rahman N, Leung PC. 2006. Steroid receptor 
coactivator-3 is required for progesterone receptor trans-activation of target genes in response 
to gonadotropin-releasing hormone treatment of pituitary cells. J Biol Chem 281(30):20817-
20824. 
Angel P, Karin M. 1991. The role of Jun, Fos and the AP-1 complex in cell-proliferation and 
transformation. Biochim Biophys Acta 1072(2-3):129-157. 
Asadi A, Hedman E, Widen C, Zilliacus J, Gustafsson JA, Wikstrom AC. 2008. FMS-like tyrosine 
kinase 3 interacts with the glucocorticoid receptor complex and affects glucocorticoid 
dependent signaling. Biochem Biophys Res Commun 368(3):569-574. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 157 
Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. 1995. Immunosuppression by 
glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. 
Science 270(5234):286-290. 
Avenant C. 2009. Molecular mechanism of action of the glucocorticoid receptor: role of ligand-
dependent receptor phosphorylation and half-life in determination of ligand-specific 
transcriptional activity. PhD thesis University of Cape, Town, Cape Town, South Africa. 
Baldi E, Luconi M, Bonaccorsi L, Forti G. 1998. Nongenomic effects of progesterone on spermatozoa: 
mechanisms of signal transduction and clinical implications. Front Biosci 3:D1051-1059. 
Baldwin DM, Roser JF, Muyan M, Lasley B, Dybdal N. 1991. Direct effects of free and conjugated 
steroids on GnRH stimulated LH release in cultured equine anterior pituitary cells. J Reprod 
Fertil Suppl 44:327-332. 
Barnes PJ. 2006. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J 
Pharmacol 148(3):245-254. 
Bartholome B, Spies CM, Gaber T, Schuchmann S, Berki T, Kunkel D, Bienert M, Radbruch A, 
Burmester GR, Lauster R, Scheffold A, Buttgereit F. 2004. Membrane glucocorticoid receptors 
(mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated 
after in vitro stimulation and in patients with rheumatoid arthritis. Faseb J 18(1):70-80. 
Bartis D, Boldizsar F, Kvell K, Szabo M, Palinkas L, Nemeth P, Monostori E, Berki T. 2007. 
Intermolecular relations between the glucocorticoid receptor, ZAP-70 kinase, and Hsp-90. 
Biochem Biophys Res Commun 354(1):253-258. 
Bartis D, Boldizsar F, Szabo M, Palinkas L, Nemeth P, Berki T. 2006. Dexamethasone induces rapid 
tyrosine-phosphorylation of ZAP-70 in Jurkat cells. J Steroid Biochem Mol Biol 98(2-3):147-
154. 
Beato M. 1989. Gene regulation by steroid hormones. Cell 56(3):335-344. 
Bedecarrats GY, Kaiser UB. 2003. Differential regulation of gonadotropin subunit gene promoter 
activity by pulsatile gonadotropin-releasing hormone (GnRH) in perifused L beta T2 cells: role 
of GnRH receptor concentration. Endocrinology 144(5):1802-1811. 
Beebe SJ. 1994. The cAMP-dependent protein kinases and cAMP signal transduction. Semin Cancer 
Biol 5(4):285-294. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 158 
Benard O, Naor Z, Seger R. 2001. Role of dynamin, Src, and Ras in the protein kinase C-mediated 
activation of ERK by gonadotropin-releasing hormone. J Biol Chem 276(7):4554-4563. 
Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, 
Satoh Y, Bhagwat SS, Manning AM, Anderson DW. 2001. SP600125, an anthrapyrazolone 
inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 98(24):13681-13686. 
Bhat GJ, Thekkumkara TJ, Thomas WG, Conrad KM, Baker KM. 1994. Angiotensin II stimulates sis-
inducing factor-like DNA binding activity. Evidence that the AT1A receptor activates 
transcription factor-Stat91 and/or a related protein. J Biol Chem 269(50):31443-31449. 
Biola A, Lefebvre P, Perrin-Wolff M, Sturm M, Bertoglio J, Pallardy M. 2001. Interleukin-2 inhibits 
glucocorticoid receptor transcriptional activity through a mechanism involving STAT5 (signal 
transducer and activator of transcription 5) but not AP-1. Mol Endocrinol 15(7):1062-1076. 
Birkenkamp KU, Tuyt LM, Lummen C, Wierenga AT, Kruijer W, Vellenga E. 2000. The p38 MAP 
kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-
specific effect upon the ERK pathway. Br J Pharmacol 131(1):99-107. 
Birnbaumer L. 1992. Receptor-to-effector signaling through G proteins: roles for beta gamma dimers 
as well as alpha subunits. Cell 71(7):1069-1072. 
Blackmore PF. 1998. News and views of non-genomic progesterone receptors on spermatozoa. 
Andrologia 30(4-5):255-261. 
Bledsoe RK, Stewart EL, Pearce KH. 2004. Structure and function of the glucocorticoid receptor ligand 
binding domain. Vitam Horm 68:49-91. 
Blind RD, Garabedian MJ. 2008. Differential recruitment of glucocorticoid receptor phospho-isoforms 
to glucocorticoid-induced genes. J Steroid Biochem Mol Biol 109(1-2):150-157. 
Bliss SP, Navratil AM, Breed M, Skinner DC, Clay CM, Roberson MS. 2007. Signaling complexes 
associated with the type I gonadotropin-releasing hormone (GnRH) receptor: colocalization of 
extracellularly regulated kinase 2 and GnRH receptor within membrane rafts. Mol Endocrinol 
21(2):538-549. 
Bloom FE, Battenberg EL, Rivier J, Vale W. 1982. Corticotropin releasing factor (CRF): 
immunoreactive neurones and fibers in rat hypothalamus. Regul Pept 4(1):43-48. 
Bockaert J, Pin JP. 1999. Molecular tinkering of G protein-coupled receptors: an evolutionary success. 
Embo J 18(7):1723-1729. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 159 
Bodwell JE, Orti E, Coull JM, Pappin DJ, Smith LI, Swift F. 1991. Identification of phosphorylated sites 
in the mouse glucocorticoid receptor. J Biol Chem 266(12):7549-7555. 
Bonfil D, Chuderland D, Kraus S, Shahbazian D, Friedberg I, Seger R, Naor Z. 2004. Extracellular 
signal-regulated kinase, Jun N-terminal kinase, p38, and c-Src are involved in gonadotropin-
releasing hormone-stimulated activity of the glycoprotein hormone follicle-stimulating hormone 
beta-subunit promoter. Endocrinology 145(5):2228-2244. 
Borgeat P, Chavancy G, Dupont A, Labrie F, Arimura A, Schally AV. 1972. Stimulation of adenosine 
3':5'-cyclic monophosphate accumulation in anterior pituitary gland in vitro by synthetic 
luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A 69(9):2677-2681. 
Bouvier M. 2001. Oligomerization of G-protein-coupled transmitter receptors. Nat Rev Neurosci 
2(4):274-286. 
Brann DW, Mahesh VB. 1991. Role of corticosteroids in female reproduction. Faseb J 5(12):2691-
2698. 
Breen KM, Davis TL, Doro LC, Nett TM, Oakley AE, Padmanabhan V, Rispoli LA, Wagenmaker ER, 
Karsch FJ. 2008. Insight into the neuroendocrine site and cellular mechanism by which 
cortisol suppresses pituitary responsiveness to gonadotropin-releasing hormone. 
Endocrinology 149(2):767-773. 
Breen KM, Karsch FJ. 2004. Does cortisol inhibit pulsatile luteinizing hormone secretion at the 
hypothalamic or pituitary level? Endocrinology 145(2):692-698. 
Breuner CW, Orchinik M. 2002. Plasma binding proteins as mediators of corticosteroid action in 
vertebrates. J Endocrinol 175(1):99-112. 
Brivanlou AH, Darnell JE, Jr. 2002. Signal transduction and the control of gene expression. Science 
295(5556):813-818. 
Brooks J, Taylor PL, Saunders PT, Eidne KA, Struthers WJ, McNeilly AS. 1993. Cloning and 
sequencing of the sheep pituitary gonadotropin-releasing hormone receptor and changes in 
expression of its mRNA during the estrous cycle. Mol Cell Endocrinol 94(2):R23-27. 
Bruggemeier U, Kalff M, Franke S, Scheidereit C, Beato M. 1991. Ubiquitous transcription factor OTF-
1 mediates induction of the MMTV promoter through synergistic interaction with hormone 
receptors. Cell 64(3):565-572. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 160 
Bruna A, Nicolas M, Munoz A, Kyriakis JM, Caelles C. 2003. Glucocorticoid receptor-JNK interaction 
mediates inhibition of the JNK pathway by glucocorticoids. Embo J 22(22):6035-6044. 
Bunone G, Briand PA, Miksicek RJ, Picard D. 1996. Activation of the unliganded estrogen receptor by 
EGF involves the MAP kinase pathway and direct phosphorylation. Embo J 15(9):2174-2183. 
Caelles C, Gonzalez-Sancho JM, Munoz A. 1997. Nuclear hormone receptor antagonism with AP-1 by 
inhibition of the JNK pathway. Genes Dev 11(24):3351-3364. 
Campion CE, Turzillo AM, Clay CM. 1996. The gene encoding the ovine gonadotropin-releasing 
hormone (GnRH) receptor: cloning and initial characterization. Gene 170(2):277-280. 
Carman CV, Som T, Kim CM, Benovic JL. 1998. Binding and phosphorylation of tubulin by G protein-
coupled receptor kinases. J Biol Chem 273(32):20308-20316. 
Cesnjaj M, Catt KJ, Stojilkovic SS. 1994. Coordinate actions of calcium and protein kinase-C in the 
expression of primary response genes in pituitary gonadotrophs. Endocrinology 135(2):692-
701. 
Chalepakis G, Schauer M, Cao XA, Beato M. 1990. Efficient binding of glucocorticoid receptor to its 
responsive element requires a dimer and DNA flanking sequences. DNA Cell Biol 9(5):355-
368. 
Chen A, Ganor Y, Rahimipour S, Ben-Aroya N, Koch Y, Levite M. 2002. The neuropeptides GnRH-II 
and GnRH-I are produced by human T cells and trigger laminin receptor gene expression, 
adhesion, chemotaxis and homing to specific organs. Nat Med 8(12):1421-1426. 
Chen D, Ma H, Hong H, Koh SS, Huang SM, Schurter BT, Aswad DW, Stallcup MR. 1999a. 
Regulation of transcription by a protein methyltransferase. Science 284(5423):2174-2177. 
Chen F, Watson CS, Gametchu B. 1999b. Association of the glucocorticoid receptor alternatively-
spliced transcript 1A with the presence of the high molecular weight membrane glucocorticoid 
receptor in mouse lymphoma cells. J Cell Biochem 74(3):430-446. 
Chen F, Watson CS, Gametchu B. 1999c. Multiple glucocorticoid receptor transcripts in membrane 
glucocorticoid receptor-enriched S-49 mouse lymphoma cells. J Cell Biochem 74(3):418-429. 
Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM. 
1997. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a 
multimeric activation complex with P/CAF and CBP/p300. Cell 90(3):569-580. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 161 
Chen J, An BS, Cheng L, Hammond GL, Leung PC. 2009. Gonadotropin releasing hormone-mediated 
phosphorylation of estrogen receptor {alpha} contributes to fosB expression in mouse 
gonadotrophs. Endocrinology. 
Chen SL, Tsao YP, Yang CM, Lin YK, Huang CH, Kuo SW. 1995. Differential induction and regulation 
of c-jun, junB, junD and c-fos by human papillomavirus type 11 E5a oncoprotein. J Gen Virol 
76 ( Pt 11):2653-2659. 
Chen W, Dang T, Blind RD, Wang Z, Cavasotto CN, Hittelman AB, Rogatsky I, Logan SK, Garabedian 
MJ. 2008. Glucocorticoid receptor phosphorylation differentially affects target gene 
expression. Mol Endocrinol 22(8):1754-1766. 
Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. 1999d. Estrogen 
receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by 
estrogen. J Clin Invest 103(3):401-406. 
Cheng CK, Leung PC. 2005. Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-
II, and their receptors in humans. Endocr Rev 26(2):283-306. 
Cheng KW, Cheng CK, Leung PC. 2001. Differential role of PR-A and -B isoforms in transcription 
regulation of human GnRH receptor gene. Mol Endocrinol 15(12):2078-2092. 
Cheng KW, Leung PC. 2001. Human gonadotropin-releasing hormone receptor gene transcription: up-
regulation by 3',5'-cyclic adenosine monophosphate/protein kinase A pathway. Mol Cell 
Endocrinol 181(1-2):15-26. 
Cherrington BD, Farmerie TA, Lents CA, Cantlon JD, Roberson MS, Clay CM. 2005. Activin 
responsiveness of the murine gonadotropin-releasing hormone receptor gene is mediated by 
a composite enhancer containing spatially distinct regulatory elements. Mol Endocrinol 
19(4):898-912. 
Cheung J, Smith DF. 2000. Molecular chaperone interactions with steroid receptors: an update. Mol 
Endocrinol 14(7):939-946. 
Cheung LW, Wong AS. 2008. Gonadotropin-releasing hormone: GnRH receptor signaling in 
extrapituitary tissues. Febs J 275(22):5479-5495. 
Cheung TC, Hearn JP. 2003. Developmental expression and subcellular localization of wallaby 
gonadotropin-releasing hormone receptor and its splice variants. Gen Comp Endocrinol 
133(1):88-99. 
U
ive
rsi
ty 
of 
Ca
pe
 To
wn
 162 
Chi L, Zhou W, Prikhozhan A, Flanagan C, Davidson JS, Golembo M, Illing N, Millar RP, Sealfon SC. 
1993. Cloning and characterization of the human GnRH receptor. Mol Cell Endocrinol 91(1-
2):R1-6. 
Chinenov Y, Rogatsky I. 2007. Glucocorticoids and the innate immune system: crosstalk with the toll-
like receptor signaling network. Mol Cell Endocrinol 275(1-2):30-42. 
Chrousos GP. 1995. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N 
Engl J Med 332(20):1351-1362. 
Chrousos GP, Gold PW. 1992. The concepts of stress and stress system disorders. Overview of 
physical and behavioral homeostasis. Jama 267(9):1244-1252. 
Clay CM, Nelson SE, DiGregorio GB, Campion CE, Wiedemann AL, Nett RJ. 1995. Cell-specific 
expression of the mouse gonadotropin-releasing hormone (GnRH) receptor gene is conferred 
by elements residing within 500 bp of proximal 5' flanking region. Endocrine 3:615-622. 
Cohen DR, Ferreira PC, Gentz R, Franza BR, Jr., Curran T. 1989. The product of a fos-related gene, 
fra-1, binds cooperatively to the AP-1 site with Jun: transcription factor AP-1 is comprised of 
multiple protein complexes. Genes Dev 3(2):173-184. 
Conn PM, Crowley WF, Jr. 1994. Gonadotropin-releasing hormone and its analogs. Annu Rev Med 
45:391-405. 
Coss D, Jacobs SB, Bender CE, Mellon PL. 2004. A novel AP-1 site is critical for maximal induction of 
the follicle-stimulating hormone beta gene by gonadotropin-releasing hormone. J Biol Chem 
279(1):152-162. 
Crowder ME, Nett TM. 1984. Pituitary content of gonadotropins and receptors for gonadotropin-
releasing hormone (GnRH) and hypothalamic content of GnRH during the periovulatory period 
of the ewe. Endocrinology 114(1):234-239. 
Croxtall JD, Choudhury Q, Flower RJ. 2000. Glucocorticoids act within minutes to inhibit recruitment of 
signalling factors to activated EGF receptors through a receptor-dependent, transcription-
independent mechanism. Br J Pharmacol 130(2):289-298. 
Curtin D, Jenkins S, Farmer N, Anderson AC, Haisenleder DJ, Rissman E, Wilson EM, Shupnik MA. 
2001. Androgen suppression of GnRH-stimulated rat LHbeta gene transcription occurs 
through Sp1 sites in the distal GnRH-responsive promoter region. Mol Endocrinol 
15(11):1906-1917. 
U
ive
rsi
ty 
of 
Ca
pe
 To
wn
 163 
Da Silva JA, Peers SH, Perretti M, Willoughby DA. 1993. Sex steroids affect glucocorticoid response 
to chronic inflammation and to interleukin-1. J Endocrinol 136(3):389-397. 
D'Agostino J, Valadka RJ, Schwartz NB. 1990. Differential effects of in vitro glucocorticoids on 
luteinizing hormone and follicle-stimulating hormone secretion: dependence on sex of pituitary 
donor. Endocrinology 127(2):891-899. 
Dahlman-Wright K, Baumann H, McEwan IJ, Almlof T, Wright AP, Gustafsson JA, Hard T. 1995. 
Structural characterization of a minimal functional transactivation domain from the human 
glucocorticoid receptor. Proc Natl Acad Sci U S A 92(5):1699-1703. 
Dahlman-Wright K, Wright A, Gustafsson JA, Carlstedt-Duke J. 1991. Interaction of the glucocorticoid 
receptor DNA-binding domain with DNA as a dimer is mediated by a short segment of five 
amino acids. J Biol Chem 266(5):3107-3112. 
Daley CA, Macfarlane MS, Sakurai H, Adams TE. 1999. Effect of stress-like concentrations of cortisol 
on follicular development and the preovulatory surge of LH in sheep. J Reprod Fertil 
117(1):11-16. 
De Bosscher K, Schmitz ML, Vanden Berghe W, Plaisance S, Fiers W, Haegeman G. 1997. 
Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves 
direct interference with transactivation. Proc Natl Acad Sci U S A 94(25):13504-13509. 
De Cesare D, Vallone D, Caracciolo A, Sassone-Corsi P, Nerlov C, Verde P. 1995. Heterodimerization 
of c-Jun with ATF-2 and c-Fos is required for positive and negative regulation of the human 
urokinase enhancer. Oncogene 11(2):365-376. 
De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. 1998. Brain corticosteroid receptor balance in health 
and disease. Endocr Rev 19(3):269-301. 
De Martino MU, Bhattachryya N, Alesci S, Ichijo T, Chrousos GP, Kino T. 2004. The glucocorticoid 
receptor and the orphan nuclear receptor chicken ovalbumin upstream promoter-transcription 
factor II interact with and mutually affect each other's transcriptional activities: implications for 
intermediary metabolism. Mol Endocrinol 18(4):820-833. 
de Weerd WF, Leeb-Lundberg LM. 1997. Bradykinin sequesters B2 bradykinin receptors and the 
receptor-coupled Galpha subunits Galphaq and Galphai in caveolae in DDT1 MF-2 smooth 
muscle cells. J Biol Chem 272(28):17858-17866. 
Un
ive
rsi
ty 
f C
pe
 To
wn
 164 
Di S, Tasker JG. 2004. Dehydration-induced synaptic plasticity in magnocellular neurons of the 
hypothalamic supraoptic nucleus. Endocrinology 145(11):5141-5149. 
Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR. 1990. Transcription factor interactions: 
selectors of positive or negative regulation from a single DNA element. Science 
249(4974):1266-1272. 
Dobkin-Bekman M, Naidich M, Pawson AJ, Millar RP, Seger R, Naor Z. 2006. Activation of mitogen-
activated protein kinase (MAPK) by GnRH is cell-context dependent. Mol Cell Endocrinol 
252(1-2):184-190. 
Dobkin-Bekman M, Naidich M, Rahamim L, Przedecki F, Almog T, Lim S, Melamed P, Liu P, Wohland 
T, Yao Z, Seger R, Naor Z. 2009. A Pre-formed Signaling Complex Mediates GnRH-Activated 
ERK-Phosphorylation of Paxillin and FAK at Focal Adhesions in L{beta}T2 Gonadotrope Cells. 
Mol Endocrinol. 
Dosiou C, Hamilton AE, Pang Y, Overgaard MT, Tulac S, Dong J, Thomas P, Giudice LC. 2008. 
Expression of membrane progesterone receptors on human T lymphocytes and Jurkat cells 
and activation of G-proteins by progesterone. J Endocrinol 196(1):67-77. 
Duval DL, Farris AR, Quirk CC, Nett TM, Hamernik DL, Clay CM. 2000. Responsiveness of the ovine 
gonadotropin-releasing hormone receptor gene to estradiol and gonadotropin-releasing 
hormone is not detectable in vitro but is revealed in transgenic mice. Endocrinology 
141(3):1001-1010. 
Duval DL, Nelson SE, Clay CM. 1997a. A binding site for steroidogenic factor-1 is part of a complex 
enhancer that mediates expression of the murine gonadotropin-releasing hormone receptor 
gene. Biol Reprod 56(1):160-168. 
Duval DL, Nelson SE, Clay CM. 1997b. The tripartite basal enhancer of the gonadotropin-releasing 
hormone (GnRH) receptor gene promoter regulates cell-specific expression through a novel 
GnRH receptor activating sequence. Mol Endocrinol 11(12):1814-1821. 
Eberharter A, Becker PB. 2002. Histone acetylation: a switch between repressive and permissive 
chromatin. Second in review series on chromatin dynamics. EMBO Rep 3(3):224-229. 
Edwards DP. 2000. The role of coactivators and corepressors in the biology and mechanism of action 
of steroid hormone receptors. J Mammary Gland Biol Neoplasia 5(3):307-324. 
Un
ive
rsi
ty 
of 
ap
e T
ow
n
 165 
Eertmans F, De Wever O, Dhooge W, Vanden Berghe W, Bogaert V, Bracke M, Haegeman G, 
Comhaire F, Kaufman JM. 2007. Estrogen receptor signaling is an unstable feature of the 
gonadotropic LbetaT2 cell line. Mol Cell Endocrinol 273(1-2):16-24. 
Eickelberg O, Roth M, Lorx R, Bruce V, Rudiger J, Johnson M, Block LH. 1999. Ligand-independent 
activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary 
human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 274(2):1005-1010. 
Eidne KA, Sellar RE, Couper G, Anderson L, Taylor PL. 1992. Molecular cloning and characterisation 
of the rat pituitary gonadotropin-releasing hormone (GnRH) receptor. Mol Cell Endocrinol 
90(1):R5-9. 
Elenkov IJ, Chrousos GP. 1999. Stress Hormones, Th1/Th2 patterns, Pro/Anti-inflammatory Cytokines 
and Susceptibility to Disease. Trends Endocrinol Metab 10(9):359-368. 
Ellsworth BS, Burns AT, Escudero KW, Duval DL, Nelson SE, Clay CM. 2003a. The gonadotropin 
releasing hormone (GnRH) receptor activating sequence (GRAS) is a composite regulatory 
element that interacts with multiple classes of transcription factors including Smads, AP-1 and 
a forkhead DNA binding protein. Mol Cell Endocrinol 206(1-2):93-111. 
Ellsworth BS, White BR, Burns AT, Cherrington BD, Otis AM, Clay CM. 2003b. c-Jun N-terminal 
kinase activation of activator protein-1 underlies homologous regulation of the gonadotropin-
releasing hormone receptor gene in alpha T3-1 cells. Endocrinology 144(3):839-849. 
El-Tanani MK, Green CD. 1997. Two separate mechanisms for ligand-independent activation of the 
estrogen receptor. Mol Endocrinol 11(7):928-937. 
Emons G, Pahwa GS, Brack C, Sturm R, Oberheuser F, Knuppen R. 1989. Gonadotropin releasing 
hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 
25(2):215-221. 
Endoh H, Maruyama K, Masuhiro Y, Kobayashi Y, Goto M, Tai H, Yanagisawa J, Metzger D, 
Hashimoto S, Kato S. 1999. Purification and identification of p68 RNA helicase acting as a 
transcriptional coactivator specific for the activation function 1 of human estrogen receptor 
alpha. Mol Cell Biol 19(8):5363-5372. 
Engblom D, Kornfeld JW, Schwake L, Tronche F, Reimann A, Beug H, Hennighausen L, Moriggl R, 
Schutz G. 2007. Direct glucocorticoid receptor-Stat5 interaction in hepatocytes controls body 
size and maturation-related gene expression. Genes Dev 21(10):1157-1162. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 166 
Engelbrecht Y, de Wet H, Horsch K, Langeveldt CR, Hough FS, Hulley PA. 2003. Glucocorticoids 
induce rapid up-regulation of mitogen-activated protein kinase phosphatase-1 and 
dephosphorylation of extracellular signal-regulated kinase and impair proliferation in human 
and mouse osteoblast cell lines. Endocrinology 144(2):412-422. 
Engelman JA, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz DS, Lisanti MP. 1998. Caveolin-
mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the 
caveolin-scaffolding domain. FEBS Lett 428(3):205-211. 
Evans JJ. 1999. Modulation of gonadotropin levels by peptides acting at the anterior pituitary gland. 
Endocr Rev 20(1):46-67. 
Evans RM. 1988. The steroid and thyroid hormone receptor superfamily. Science 240(4854):889-895. 
Evans SJ, Murray TF, Moore FL. 2000. Partial purification and biochemical characterization of a 
membrane glucocorticoid receptor from an amphibian brain. J Steroid Biochem Mol Biol 
72(5):209-221. 
Faivre EJ, Daniel AR, Hillard CJ, Lange CA. 2008. Progesterone receptor rapid signaling mediates 
serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Mol 
Endocrinol 22(4):823-837. 
Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M. 2000. Multiple actions of steroid 
hormones--a focus on rapid, nongenomic effects. Pharmacol Rev 52(4):513-556. 
Fan NC, Jeung EB, Peng C, Olofsson JI, Krisinger J, Leung PC. 1994. The human gonadotropin-
releasing hormone (GnRH) receptor gene: cloning, genomic organization and chromosomal 
assignment. Mol Cell Endocrinol 103(1-2):R1-6. 
Fan NC, Peng C, Krisinger J, Leung PC. 1995. The human gonadotropin-releasing hormone receptor 
gene: complete structure including multiple promoters, transcription initiation sites, and 
polyadenylation signals. Mol Cell Endocrinol 107(2):R1-8. 
Faus H, Haendler B. 2006. Post-translational modifications of steroid receptors. Biomed Pharmacother 
60(9):520-528. 
Fernandes SM. 2007. Transcriptional Regulation of the Gonadotropin-Releasing Hormone Receptor 
(GnRHR) gene by Glucocorticoids. MSc thesis University of Stellenbosch, Stellenbosch, 
South Africa. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 167 
Fernandez-Vazquez G, Kaiser UB, Albarracin CT, Chin WW. 1996. Transcriptional activation of the 
gonadotropin-releasing hormone receptor gene by activin A. Mol Endocrinol 10(4):356-366. 
Fink G. 1988. Gonadotropin secretion and its control. Knobil E, Neill J, eds The Physiology of 
Reproduction New York: Raven Press:p.1349-1377. 
Ford J, McEwan IJ, Wright AP, Gustafsson JA. 1997. Involvement of the transcription factor IID protein 
complex in gene activation by the N-terminal transactivation domain of the glucocorticoid 
receptor in vitro. Mol Endocrinol 11(10):1467-1475. 
Freedman ND, Yamamoto KR. 2004. Importin 7 and importin alpha/importin beta are nuclear import 
receptors for the glucocorticoid receptor. Mol Biol Cell 15(5):2276-2286. 
Freshney RI. 1987. Culture of animal cells: a manual of basic technique. New York: John Wiley and 
Sons:183-185. 
Fryer CJ, Archer TK. 1998. Chromatin remodelling by the glucocorticoid receptor requires the BRG1 
complex. Nature 393(6680):88-91. 
Galliher-Beckley AJ, Williams JG, Collins JB, Cidlowski JA. 2008. Glycogen synthase kinase 3beta-
mediated serine phosphorylation of the human glucocorticoid receptor redirects gene 
expression profiles. Mol Cell Biol 28(24):7309-7322. 
Gametchu B, Chen F, Sackey F, Powell C, Watson CS. 1999. Plasma membrane-resident 
glucocorticoid receptors in rodent lymphoma and human leukemia models. Steroids 64(1-
2):107-119. 
Gametchu B, Watson CS, Wu S. 1993. Use of receptor antibodies to demonstrate membrane 
glucocorticoid receptor in cells from human leukemic patients. Faseb J 7(13):1283-1292. 
Gburcik V, Bot N, Maggiolini M, Picard D. 2005. SPBP is a phosphoserine-specific repressor of 
estrogen receptor alpha. Mol Cell Biol 25(9):3421-3430. 
Gharib SD, Wierman ME, Shupnik MA, Chin WW. 1990. Molecular biology of the pituitary 
gonadotropins. Endocr Rev 11(1):177-199. 
Goel A, Janknecht R. 2004. Concerted activation of ETS protein ER81 by p160 coactivators, the 
acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J Biol Chem 
279(15):14909-14916. 
Gregg DW, Allen MC, Nett TM. 1990. Estradiol-induced increase in number of gonadotropin-releasing 
hormone receptors in cultured ovine pituitary cells. Biol Reprod 43(6):1032-1036. 
Un
ive
rsi
t  
of 
Ca
pe
 To
wn
 168 
Gregory SJ, Lacza CT, Detz AA, Xu S, Petrillo LA, Kaiser UB. 2005. Synergy between activin A and 
gonadotropin-releasing hormone in transcriptional activation of the rat follicle-stimulating 
hormone-beta gene. Mol Endocrinol 19(1):237-254. 
Griekspoor A, Zwart W, Neefjes J, Michalides R. 2007. Visualizing the action of steroid hormone 
receptors in living cells. Nucl Recept Signal 5:e003. 
Gronemeyer H, Gustafsson JA, Laudet V. 2004. Principles for modulation of the nuclear receptor 
superfamily. Nat Rev Drug Discov 3(11):950-964. 
Gross KL, Cidlowski JA. 2008. Tissue-specific glucocorticoid action: a family affair. Trends Endocrinol 
Metab 19(9):331-339. 
Gross KL, Lu NZ, Cidlowski JA. 2009. Molecular mechanisms regulating glucocorticoid sensitivity and 
resistance. Mol Cell Endocrinol 300(1-2):7-16. 
Grosse R, Schmid A, Schoneberg T, Herrlich A, Muhn P, Schultz G. 2000. Gonadotropin-releasing 
hormone receptor initiates multiple signaling pathways by exclusively coupling to G(q/11) 
proteins. J Biol Chem 275(13):9193-9200. 
Grundker C, Gunthert AR, Westphalen S, Emons G. 2002. Biology of the gonadotropin-releasing 
hormone system in gynecological cancers. Eur J Endocrinol 146(1):1-14. 
Grundker C, Schulz K, Gunthert AR, Emons G. 2000. Luteinizing hormone-releasing hormone induces 
nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cells. J Clin 
Endocrinol Metab 85(10):3815-3820. 
Grundker C, Volker P, Emons G. 2001. Antiproliferative signaling of luteinizing hormone-releasing 
hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated 
activation of phosphotyrosine phosphatase. Endocrinology 142(6):2369-2380. 
Guerrero HE, Stein P, Asch RH, de Fried EP, Tesone M. 1993. Effect of a gonadotropin-releasing 
hormone agonist on luteinizing hormone receptors and steroidogenesis in ovarian cells. Fertil 
Steril 59(4):803-808. 
Haasemann M, Cartaud J, Muller-Esterl W, Dunia I. 1998. Agonist-induced redistribution of bradykinin 
B2 receptor in caveolae. J Cell Sci 111 ( Pt 7):917-928. 
Hai T, Curran T. 1991. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters 
DNA binding specificity. Proc Natl Acad Sci U S A 88(9):3720-3724. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 169 
Hall RA, Lefkowitz RJ. 2002. Regulation of G protein-coupled receptor signaling by scaffold proteins. 
Circ Res 91(8):672-680. 
Hall-Jackson CA, Goedert M, Hedge P, Cohen P. 1999. Effect of SB 203580 on the activity of c-Raf in 
vitro and in vivo. Oncogene 18(12):2047-2054. 
Hamernik DL. 1995. Molecular biology of gonadotrophins. J Reprod Fertil Suppl 49:257-269. 
Hammes A, Andreassen TK, Spoelgen R, Raila J, Hubner N, Schulz H, Metzger J, Schweigert FJ, 
Luppa PB, Nykjaer A, Willnow TE. 2005. Role of endocytosis in cellular uptake of sex steroids. 
Cell 122(5):751-762. 
Hanson RW, Reshef L. 1997. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene 
expression. Annu Rev Biochem 66:581-611. 
Hapgood JP, Sadie H, van Biljon W, Ronacher K. 2005. Regulation of expression of mammalian 
gonadotrophin-releasing hormone receptor genes. J Neuroendocrinol 17(10):619-638. 
Harris D, Bonfil D, Chuderland D, Kraus S, Seger R, Naor Z. 2002. Activation of MAPK cascades by 
GnRH: ERK and Jun N-terminal kinase are involved in basal and GnRH-stimulated activity of 
the glycoprotein hormone LHbeta-subunit promoter. Endocrinology 143(3):1018-1025. 
Harris D, Reiss N, Naor Z. 1997. Differential activation of protein kinase C delta and epsilon gene 
expression by gonadotropin-releasing hormone in alphaT3-1 cells. Autoregulation by protein 
kinase C. J Biol Chem 272(21):13534-13540. 
Hawes BE, Barnes S, Conn PM. 1993. Cholera toxin and pertussis toxin provoke differential effects on 
luteinizing hormone release, inositol phosphate production, and gonadotropin-releasing 
hormone (GnRH) receptor binding in the gonadotrope: evidence for multiple guanyl nucleotide 
binding proteins in GnRH action. Endocrinology 132(5):2124-2130. 
Hayashi R, Wada H, Ito K, Adcock IM. 2004. Effects of glucocorticoids on gene transcription. Eur J 
Pharmacol 500(1-3):51-62. 
Heck S, Kullmann M, Gast A, Ponta H, Rahmsdorf HJ, Herrlich P, Cato AC. 1994. A distinct 
modulating domain in glucocorticoid receptor monomers in the repression of activity of the 
transcription factor AP-1. Embo J 13(17):4087-4095. 
Heery DM, Kalkhoven E, Hoare S, Parker MG. 1997. A signature motif in transcriptional co-activators 
mediates binding to nuclear receptors. Nature 387(6634):733-736. 
U
ive
rsi
ty 
f C
ap
e T
wn
 170 
Heitzer MD, Wolf IM, Sanchez ER, Witchel SF, DeFranco DB. 2007. Glucocorticoid receptor 
physiology. Rev Endocr Metab Disord 8(4):321-330. 
Herrlich P. 2001. Cross-talk between glucocorticoid receptor and AP-1. Oncogene 20(19):2465-2475. 
Hittelman AB, Burakov D, Iniguez-Lluhi JA, Freedman LP, Garabedian MJ. 1999. Differential 
regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins. 
Embo J 18(19):5380-5388. 
Hoeck W, Groner B. 1990. Hormone-dependent phosphorylation of the glucocorticoid receptor occurs 
mainly in the amino-terminal transactivation domain. J Biol Chem 265(10):5403-5408. 
Hoeppner MA, Mordacq JC, Linzer DI. 1995. Role of the composite glucocorticoid response element 
in proliferin gene expression. Gene Expr 5(2):133-141. 
Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, Thompson EB, Rosenfeld MG, 
Evans RM. 1985. Primary structure and expression of a functional human glucocorticoid 
receptor cDNA. Nature 318(6047):635-641. 
Horn F, Windle JJ, Barnhart KM, Mellon PL. 1992. Tissue-specific gene expression in the pituitary: the 
glycoprotein hormone alpha-subunit gene is regulated by a gonadotrope-specific protein. Mol 
Cell Biol 12(5):2143-2153. 
Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L. 1996. Nuclear receptor 
coactivators and corepressors. Mol Endocrinol 10(10):1167-1177. 
Housley PR, Pratt WB. 1983. Direct demonstration of glucocorticoid receptor phosphorylation by intact 
L-cells. J Biol Chem 258(7):4630-4635. 
Hsieh KP, Martin TF. 1992. Thyrotropin-releasing hormone and gonadotropin-releasing hormone 
receptors activate phospholipase C by coupling to the guanosine triphosphate-binding 
proteins Gq and G11. Mol Endocrinol 6(10):1673-1681. 
Hulley PA, Gordon F, Hough FS. 1998. Inhibition of mitogen-activated protein kinase activity and 
proliferation of an early osteoblast cell line (MBA 15.4) by dexamethasone: role of protein 
phosphatases. Endocrinology 139(5):2423-2431. 
Hur EM, Kim KT. 2002. G protein-coupled receptor signalling and cross-talk: achieving rapidity and 
specificity. Cell Signal 14(5):397-405. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
wn
 171 
Hyde CL, Childs G, Wahl LM, Naor Z, Catt KJ. 1982. Preparation of gonadotroph-enriched cell 
populations from adult rat anterior pituitary cells by centrifugal elutriation. Endocrinology 
111(4):1421-1423. 
Imai A, Ohno T, Iida K, Fuseya T, Furui T, Tamaya T. 1994. Gonadotropin-releasing hormone receptor 
in gynecologic tumors. Frequent expression in adenocarcinoma histologic types. Cancer 
74(9):2555-2561. 
Imai A, Tamaya T. 2000. GnRH receptor and apoptotic signaling. Vitam Horm 59:1-33. 
Imai E, Miner JN, Mitchell JA, Yamamoto KR, Granner DK. 1993. Glucocorticoid receptor-cAMP 
response element-binding protein interaction and the response of the phosphoenolpyruvate 
carboxykinase gene to glucocorticoids. J Biol Chem 268(8):5353-5356. 
Imasato A, Desbois-Mouthon C, Han J, Kai H, Cato AC, Akira S, Li JD. 2002. Inhibition of p38 MAPK 
by glucocorticoids via induction of MAPK phosphatase-1 enhances nontypeable Haemophilus 
influenzae-induced expression of toll-like receptor 2. J Biol Chem 277(49):47444-47450. 
Ismaili N, Blind R, Garabedian MJ. 2005. Stabilization of the unliganded glucocorticoid receptor by 
TSG101. J Biol Chem 280(12):11120-11126. 
Ismaili N, Garabedian MJ. 2004. Modulation of glucocorticoid receptor function via phosphorylation. 
Ann N Y Acad Sci 1024:86-101. 
Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ, Adcock IM. 2006. Histone 
deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB 
suppression. J Exp Med 203(1):7-13. 
Iwasaki Y, Aoki Y, Katahira M, Oiso Y, Saito H. 1997. Non-genomic mechanisms of glucocorticoid 
inhibition of adrenocorticotropin secretion: possible involvement of GTP-binding protein. 
Biochem Biophys Res Commun 235(2):295-299. 
Jacobson JD, Crofford LJ, Sun L, Wilder RL. 1998. Cyclical expression of GnRH and GnRH receptor 
mRNA in lymphoid organs. Neuroendocrinology 67(2):117-125. 
Jaffey P, Chan LN, Shao J, Schneider-Schaulies J, Chan TS. 1992. Retinoic acid inhibition of serum-
induced c-fos transcription in a fibrosarcoma cell line. Cancer Res 52(9):2384-2388. 
Jain S, Li Y, Kumar A, Sehgal PB. 2005. Transcriptional signaling from membrane raft-associated 
glucocorticoid receptor. Biochem Biophys Res Commun 336(1):3-8. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 172 
Jang BC, Lim KJ, Suh MH, Park JG, Suh SI. 2007. Dexamethasone suppresses interleukin-1beta-
induced human beta-defensin 2 mRNA expression: involvement of p38 MAPK, JNK, MKP-1, 
and NF-kappaB transcriptional factor in A549 cells. FEMS Immunol Med Microbiol 51(1):171-
184. 
Jeong KH, Chin WW, Kaiser UB. 2004. Essential role of the homeodomain for pituitary homeobox 1 
activation of mouse gonadotropin-releasing hormone receptor gene expression through 
interactions with c-Jun and DNA. Mol Cell Biol 24(14):6127-6139. 
Jiang Z, Gibson JP, Archibald AL, Haley CS. 2001. The porcine gonadotropin-releasing hormone 
receptor gene (GNRHR): genomic organization, polymorphisms, and association with the 
number of corpora lutea. Genome 44(1):7-12. 
Johnson GL, Lapadat R. 2002. Mitogen-activated protein kinase pathways mediated by ERK, JNK, 
and p38 protein kinases. Science 298(5600):1911-1912. 
Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, Herrlich P. 1990. Antitumor promotion 
and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. 
Cell 62(6):1189-1204. 
Kaiser UB, Conn PM, Chin WW. 1997. Studies of gonadotropin-releasing hormone (GnRH) action 
using GnRH receptor-expressing pituitary cell lines. Endocr Rev 18(1):46-70. 
Kaiser UB, Jakubowiak A, Steinberger A, Chin WW. 1993. Regulation of rat pituitary gonadotropin-
releasing hormone receptor mRNA levels in vivo and in vitro. Endocrinology 133(2):931-934. 
Kakar SS. 1997. Molecular structure of the human gonadotropin-releasing hormone receptor gene. 
Eur J Endocrinol 137(2):183-192. 
Kakar SS, Musgrove LC, Devor DC, Sellers JC, Neill JD. 1992. Cloning, sequencing, and expression 
of human gonadotropin releasing hormone (GnRH) receptor. Biochem Biophys Res Commun 
189(1):289-295. 
Kakar SS, Rahe CH, Neill JD. 1993. Molecular cloning, sequencing, and characterizing the bovine 
receptor for gonadotropin releasing hormone (GnRH). Domest Anim Endocrinol 10(4):335-
342. 
Kakar SS, Winters SJ, Zacharias W, Miller DM, Flynn S. 2003. Identification of distinct gene 
expression profiles associated with treatment of LbetaT2 cells with gonadotropin-releasing 
hormone agonist using microarray analysis. Gene 308:67-77. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 173 
Kam KY, Jeong KH, Norwitz ER, Jorgensen EM, Kaiser UB. 2005. Oct-1 and nuclear factor Y bind to 
the SURG-1 element to direct basal and gonadotropin-releasing hormone (GnRH)-stimulated 
mouse GnRH receptor gene transcription. Mol Endocrinol 19(1):148-162. 
Kamel F, Kubajak CL. 1987. Modulation of gonadotropin secretion by corticosterone: interaction with 
gonadal steroids and mechanism of action. Endocrinology 121(2):561-568. 
Kanasaki H MS, Harada T, Miyazaki K. 2006. Phosphatidylinositol 3-kinase is involved in the 
regulation of gonadotropin and FSH-subunit gene expressions. Program of the 88th Annual 
Meeting of The Endocrine Society, Boston, MA,:(Abstract P2-349). 
Kanasaki H, Yonehara T, Yamada Y, Takahashi K, Hata K, Fujiwaki R, Yamamoto H, Takeuchi Y, 
Fukunaga K, Miyamoto E, Miyazaki K. 2002. Regulation of gonadotropin alpha subunit gene 
expression by dopamine D(2) receptor agonist in clonal mouse gonadotroph alphaT3-1 cells. 
Biol Reprod 67(4):1218-1224. 
Kang J, Shi Y, Xiang B, Qu B, Su W, Zhu M, Zhang M, Bao G, Wang F, Zhang X, Yang R, Fan F, 
Chen X, Pei G, Ma L. 2005. A nuclear function of beta-arrestin1 in GPCR signaling: regulation 
of histone acetylation and gene transcription. Cell 123(5):833-847. 
Kassel O, Herrlich P. 2007. Crosstalk between the glucocorticoid receptor and other transcription 
factors: molecular aspects. Mol Cell Endocrinol 275(1-2):13-29. 
Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M, Cato AC. 2001. Glucocorticoids inhibit MAP 
kinase via increased expression and decreased degradation of MKP-1. Embo J 20(24):7108-
7116. 
Kassel O, Schneider S, Heilbock C, Litfin M, Gottlicher M, Herrlich P. 2004. A nuclear isoform of the 
focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1- 
and NF-kappaB-regulated promoters. Genes Dev 18(20):2518-2528. 
Kerppola TK, Luk D, Curran T. 1993. Fos is a preferential target of glucocorticoid receptor inhibition of 
AP-1 activity in vitro. Mol Cell Biol 13(6):3782-3791. 
Kilen SM, Szabo M, Strasser GA, McAndrews JM, Ringstrom SJ, Schwartz NB. 1996. Corticosterone 
selectively increases follicle-stimulating hormone beta-subunit messenger ribonucleic acid in 
primary anterior pituitary cell culture without affecting its half-life. Endocrinology 137(9):3802-
3807. 
Un
ive
rsi
ty 
f C
ap
e T
ow
n
 174 
Kim HP, Lee JY, Jeong JK, Bae SW, Lee HK, Jo I. 1999. Nongenomic stimulation of nitric oxide 
release by estrogen is mediated by estrogen receptor alpha localized in caveolae. Biochem 
Biophys Res Commun 263(1):257-262. 
Kim JH, Li H, Stallcup MR. 2003. CoCoA, a nuclear receptor coactivator which acts through an N-
terminal activation domain of p160 coactivators. Mol Cell 12(6):1537-1549. 
Kino T, Ichijo T, Amin ND, Kesavapany S, Wang Y, Kim N, Rao S, Player A, Zheng YL, Garabedian 
MJ, Kawasaki E, Pant HC, Chrousos GP. 2007. Cyclin-dependent kinase 5 differentially 
regulates the transcriptional activity of the glucocorticoid receptor through phosphorylation: 
clinical implications for the nervous system response to glucocorticoids and stress. Mol 
Endocrinol 21(7):1552-1568. 
Kino T, Tiulpakov A, Ichijo T, Chheng L, Kozasa T, Chrousos GP. 2005. G protein beta interacts with 
the glucocorticoid receptor and suppresses its transcriptional activity in the nucleus. J Cell Biol 
169(6):885-896. 
Kleiman A, Tuckermann JP. 2007. Glucocorticoid receptor action in beneficial and side effects of 
steroid therapy: lessons from conditional knockout mice. Mol Cell Endocrinol 275(1-2):98-108. 
Knollman PE, Conn PM. 2008. Multiple G proteins compete for binding with the human gonadotropin 
releasing hormone receptor. Arch Biochem Biophys 477(1):92-97. 
Konig H, Ponta H, Rahmsdorf HJ, Herrlich P. 1992. Interference between pathway-specific 
transcription factors: glucocorticoids antagonize phorbol ester-induced AP-1 activity without 
altering AP-1 site occupation in vivo. Embo J 11(6):2241-2246. 
Kouzarides T. 2000. Acetylation: a regulatory modification to rival phosphorylation? Embo J 
19(6):1176-1179. 
Kowase T, Walsh HE, Darling DS, Shupnik MA. 2007. Estrogen enhances gonadotropin-releasing 
hormone-stimulated transcription of the luteinizing hormone subunit promoters via altered 
expression of stimulatory and suppressive transcription factors. Endocrinology 148(12):6083-
6091. 
Kraus S, Naor Z, Seger R. 2001. Intracellular signaling pathways mediated by the gonadotropin-
releasing hormone (GnRH) receptor. Arch Med Res 32(6):499-509. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 175 
Krstic MD, Rogatsky I, Yamamoto KR, Garabedian MJ. 1997. Mitogen-activated and cyclin-dependent 
protein kinases selectively and differentially modulate transcriptional enhancement by the 
glucocorticoid receptor. Mol Cell Biol 17(7):3947-3954. 
Kumar R, Thompson EB. 2005. Gene regulation by the glucocorticoid receptor: structure:function 
relationship. J Steroid Biochem Mol Biol 94(5):383-394. 
Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P. 2000. Estrogen 
receptor pathways to AP-1. J Steroid Biochem Mol Biol 74(5):311-317. 
Kutoh E, Stromstedt PE, Poellinger L. 1992. Functional interference between the ubiquitous and 
constitutive octamer transcription factor 1 (OTF-1) and the glucocorticoid receptor by direct 
protein-protein interaction involving the homeo subdomain of OTF-1. Mol Cell Biol 
12(11):4960-4969. 
Lantin-Hermoso RL, Rosenfeld CR, Yuhanna IS, German Z, Chen Z, Shaul PW. 1997. Estrogen 
acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium. Am J 
Physiol 273(1 Pt 1):L119-126. 
Lariviere S, Garrel G, Simon V, Soh JW, Laverriere JN, Counis R, Cohen-Tannoudji J. 2007. 
Gonadotropin-releasing hormone couples to 3',5'-cyclic adenosine-5'-monophosphate 
pathway through novel protein kinase Cdelta and -epsilon in LbetaT2 gonadotrope cells. 
Endocrinology 148(3):1099-1107. 
Lasa M, Brook M, Saklatvala J, Clark AR. 2001. Dexamethasone destabilizes cyclooxygenase 2 
mRNA by inhibiting mitogen-activated protein kinase p38. Mol Cell Biol 21(3):771-780. 
Laws SC, Webster JC, Miller WL. 1990. Estradiol alters the effectiveness of gonadotropin-releasing 
hormone (GnRH) in ovine pituitary cultures: GnRH receptors versus responsiveness to GnRH. 
Endocrinology 127(1):381-386. 
Lawson MA, Li D, Glidewell-Kenney CA, Lopez FJ. 2001. Androgen responsiveness of the pituitary 
gonadotrope cell line LbetaT2. J Endocrinol 170(3):601-607. 
Le Douarin B, Nielsen AL, Garnier JM, Ichinose H, Jeanmougin F, Losson R, Chambon P. 1996. A 
possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by 
nuclear receptors. Embo J 15(23):6701-6715. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 176 
Leal AM, Blount AL, Donaldson CJ, Bilezikjian LM, Vale WW. 2003. Regulation of follicle-stimulating 
hormone secretion by the interactions of activin-A, dexamethasone and testosterone in 
anterior pituitary cell cultures of male rats. Neuroendocrinology 77(5):298-304. 
Lee YH, Campbell HD, Stallcup MR. 2004. Developmentally essential protein flightless I is a nuclear 
receptor coactivator with actin binding activity. Mol Cell Biol 24(5):2103-2117. 
Lee YH, Coonrod SA, Kraus WL, Jelinek MA, Stallcup MR. 2005. Regulation of coactivator complex 
assembly and function by protein arginine methylation and demethylimination. Proc Natl Acad 
Sci U S A 102(10):3611-3616. 
Lee YH, Koh SS, Zhang X, Cheng X, Stallcup MR. 2002. Synergy among nuclear receptor 
coactivators: selective requirement for protein methyltransferase and acetyltransferase 
activities. Mol Cell Biol 22(11):3621-3632. 
Lefkowitz RJ, Rajagopal K, Whalen EJ. 2006. New roles for beta-arrestins in cell signaling: not just for 
seven-transmembrane receptors. Mol Cell 24(5):643-652. 
Lerner L, Henriksen MA, Zhang X, Darnell JE, Jr. 2003. STAT3-dependent enhanceosome assembly 
and disassembly: synergy with GR for full transcriptional increase of the alpha 2-
macroglobulin gene. Genes Dev 17(20):2564-2577. 
Levi NL, Hanoch T, Benard O, Rozenblat M, Harris D, Reiss N, Naor Z, Seger R. 1998. Stimulation of 
Jun N-terminal kinase (JNK) by gonadotropin-releasing hormone in pituitary alpha T3-1 cell 
line is mediated by protein kinase C, c-Src, and CDC42. Mol Endocrinol 12(6):815-824. 
Li PS. 1994. Modulation by cortisol of luteinizing hormone secretion from cultured porcine anterior 
pituitary cells: effects on secretion induced by phospholipase C, phorbol ester and cAMP. 
Naunyn Schmiedebergs Arch Pharmacol 349(1):107-112. 
Li X, Qiu J, Wang J, Zhong Y, Zhu J, Chen Y. 2001. Corticosterone-induced rapid phosphorylation of 
p38 and JNK mitogen-activated protein kinases in PC12 cells. FEBS Lett 492(3):210-214. 
Liberman AC, Druker J, Perone MJ, Arzt E. 2007. Glucocorticoids in the regulation of transcription 
factors that control cytokine synthesis. Cytokine Growth Factor Rev 18(1-2):45-56. 
Liggett SB, Bouvier M, O'Dowd BF, Caron MG, Lefkowitz RJ, DeBlasi A. 1989. Substitution of an 
extracellular cysteine in the beta 2-adrenergic receptor enhances agonist-promoted 
phosphorylation and receptor desensitization. Biochem Biophys Res Commun 165(1):257-
263. 
Un
ive
rsi
ty 
of 
C
pe
 To
wn
 177 
Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA. 2006. Kinase-specific 
phosphorylation of the estrogen receptor changes receptor interactions with ligand, 
deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen 
activity. Mol Endocrinol 20(12):3120-3132. 
Limonta P, Moretti RM, Marelli MM, Motta M. 2003. The biology of gonadotropin hormone-releasing 
hormone: role in the control of tumor growth and progression in humans. Front 
Neuroendocrinol 24(4):279-295. 
Lisanti MP, Scherer PE, Tang Z, Sargiacomo M. 1994. Caveolae, caveolin and caveolin-rich 
membrane domains: a signalling hypothesis. Trends Cell Biol 4(7):231-235. 
Liu F, Austin DA, Mellon PL, Olefsky JM, Webster NJ, Gudermann T. 2002a. GnRH activates ERK1/2 
leading to the induction of c-fos and LHbeta protein expression in LbetaT2 cells. Mol 
Endocrinol 16(3):419-434. 
Liu F, Austin DA, Webster NJ. 2003. Gonadotropin-releasing hormone-desensitized LbetaT2 
gonadotrope cells are refractory to acute protein kinase C, cyclic AMP, and calcium-
dependent signaling. Endocrinology 144(10):4354-4365. 
Liu F, Usui I, Evans LG, Austin DA, Mellon PL, Olefsky JM, Webster NJ. 2002b. Involvement of both 
G(q/11) and G(s) proteins in gonadotropin-releasing hormone receptor-mediated signaling in L 
beta T2 cells. J Biol Chem 277(35):32099-32108. 
Liu JL, Papachristou DN, Patel YC. 1994. Glucocorticoids activate somatostatin gene transcription 
through co-operative interaction with the cyclic AMP signalling pathway. Biochem J 301 ( Pt 
3):863-869. 
Loumaye E, Catt KJ. 1982. Homologous regulation of gonadotropin-releasing hormone receptors in 
cultured pituitary cells. Science 215(4535):983-985. 
Loumaye E, Catt KJ. 1983. Agonist-induced regulation of pituitary receptors for gonadotropin-
releasing hormone. Dissociation of receptor recruitment from hormone release in cultured 
gonadotrophs. J Biol Chem 258(19):12002-12009. 
Lowenberg M, Stahn C, Hommes DW, Buttgereit F. 2008. Novel insights into mechanisms of 
glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids 
73(9-10):1025-1029. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 178 
Lowenberg M, Tuynman J, Bilderbeek J, Gaber T, Buttgereit F, van Deventer S, Peppelenbosch M, 
Hommes D. 2005. Rapid immunosuppressive effects of glucocorticoids mediated through Lck 
and Fyn. Blood 106(5):1703-1710. 
Lowenberg M, Tuynman J, Scheffer M, Verhaar A, Vermeulen L, van Deventer S, Hommes D, 
Peppelenbosch M. 2006a. Kinome analysis reveals nongenomic glucocorticoid receptor-
dependent inhibition of insulin signaling. Endocrinology 147(7):3555-3562. 
Lowenberg M, Verhaar AP, Bilderbeek J, Marle J, Buttgereit F, Peppelenbosch MP, van Deventer SJ, 
Hommes DW. 2006b. Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated 
protein complex containing LCK and FYN. EMBO Rep 7(10):1023-1029. 
Lu NZ, Cidlowski JA. 2005. Translational regulatory mechanisms generate N-terminal glucocorticoid 
receptor isoforms with unique transcriptional target genes. Mol Cell 18(3):331-342. 
Luisi BF, Xu WX, Otwinowski Z, Freedman LP, Yamamoto KR, Sigler PB. 1991. Crystallographic 
analysis of the interaction of the glucocorticoid receptor with DNA. Nature 352(6335):497-505. 
Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL, Lefkowitz RJ. 2001. Activation 
and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl 
Acad Sci U S A 98(5):2449-2454. 
Luttrell LM, van Biesen T, Hawes BE, Koch WJ, Touhara K, Lefkowitz RJ. 1995. G beta gamma 
subunits mediate mitogen-activated protein kinase activation by the tyrosine kinase insulin-like 
growth factor 1 receptor. J Biol Chem 270(28):16495-16498. 
Ma H, Shang Y, Lee DY, Stallcup MR. 2003. Study of nuclear receptor-induced transcription complex 
assembly and histone modification by chromatin immunoprecipitation assays. Methods 
Enzymol 364:284-296. 
Makara GB, Haller J. 2001. Non-genomic effects of glucocorticoids in the neural system. Evidence, 
mechanisms and implications. Prog Neurobiol 65(4):367-390. 
Malcher-Lopes R, Franco A, Tasker JG. 2008. Glucocorticoids shift arachidonic acid metabolism 
toward endocannabinoid synthesis: a non-genomic anti-inflammatory switch. Eur J Pharmacol 
583(2-3):322-339. 
Mandler RN, Seamer LC, Domalewski MD, Bankhurst AD. 1993. Progesterone but not estrogen 
depolarizes natural killer cells. Nat Immun 12(3):128-135. 
Un
ive
rsi
ty 
of 
C
pe
 To
wn
 179 
Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, 
Mark M, Chambon P, Evans RM. 1995. The nuclear receptor superfamily: the second decade. 
Cell 83(6):835-839. 
Marelli MM, Moretti RM, Dondi D, Motta M, Limonta P. 1999. Luteinizing hormone-releasing hormone 
agonists interfere with the mitogenic activity of the insulin-like growth factor system in 
androgen-independent prostate cancer cells. Endocrinology 140(1):329-334. 
Marian J, Cooper RL, Conn PM. 1981. Regulation of the rat pituitary gonadotropin-releasing hormone 
receptor. Mol Pharmacol 19(3):399-405. 
Marinissen MJ, Gutkind JS. 2001. G-protein-coupled receptors and signaling networks: emerging 
paradigms. Trends Pharmacol Sci 22(7):368-376. 
Marrero MB, Paxton WG, Schieffer B, Ling BN, Bernstein KE. 1996. Angiotensin II signalling events 
mediated by tyrosine phosphorylation. Cell Signal 8(1):21-26. 
Marrs RP, Kletzky OA, Mishell DR, Jr. 1981. Functional capacity of the gonadotrophs during 
pregnancy and the puerperium. Am J Obstet Gynecol 141(6):658-661. 
Mason SA, Housley PR. 1993. Site-directed mutagenesis of the phosphorylation sites in the mouse 
glucocorticoid receptor. J Biol Chem 268(29):21501-21504. 
Maudsley S, Davidson L, Pawson AJ, Freestone SH, Lopez de Maturana R, Thomson AA, Millar RP. 
2006. Gonadotropin-releasing hormone functionally antagonizes testosterone activation of the 
human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5. 
Neuroendocrinology 84(5):285-300. 
Maudsley S, Naor Z, Bonfil D, Davidson L, Karali D, Pawson AJ, Larder R, Pope C, Nelson N, Millar 
RP, Brown P. 2007. Proline-rich tyrosine kinase 2 mediates gonadotropin-releasing hormone 
signaling to a specific extracellularly regulated kinase-sensitive transcriptional locus in the 
luteinizing hormone beta-subunit gene. Mol Endocrinol 21(5):1216-1233. 
Maya-Nunez G, Conn PM. 2003. Transcriptional regulation of the GnRH receptor gene by 
glucocorticoids. Mol Cell Endocrinol 200(1-2):89-98. 
McAndrews JM, Ringstrom SJ, Dahl KD, Schwartz NB. 1994. Corticosterone in vivo increases pituitary 
follicle-stimulating hormone (FSH)-beta messenger ribonucleic acid content and serum FSH 
bioactivity selectively in female rats. Endocrinology 134(1):158-163. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 180 
McArdle CA, Franklin J, Green L, Hislop JN. 2002. Signalling, cycling and desensitisation of 
gonadotrophin-releasing hormone receptors. J Endocrinol 173(1):1-11. 
McArdle CA, Schomerus E, Groner I, Poch A. 1992. Estradiol regulates gonadotropin-releasing 
hormone receptor number, growth and inositol phosphate production in alpha T3-1 cells. Mol 
Cell Endocrinol 87(1-3):95-103. 
McDonald PH, Chow CW, Miller WE, Laporte SA, Field ME, Lin FT, Davis RJ, Lefkowitz RJ. 2000. 
Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 
290(5496):1574-1577. 
McEwan IJ, Wright AP, Dahlman-Wright K, Carlstedt-Duke J, Gustafsson JA. 1993. Direct interaction 
of the tau 1 transactivation domain of the human glucocorticoid receptor with the basal 
transcriptional machinery. Mol Cell Biol 13(1):399-407. 
McGillivray SM, Bailey JS, Ramezani R, Kirkwood BJ, Mellon PL. 2005. Mouse GnRH receptor gene 
expression is mediated by the LHX3 homeodomain protein. Endocrinology 146(5):2180-2185. 
McGillivray SM, Thackray VG, Coss D, Mellon PL. 2007. Activin and glucocorticoids synergistically 
activate follicle-stimulating hormone beta-subunit gene expression in the immortalized 
LbetaT2 gonadotrope cell line. Endocrinology 148(2):762-773. 
McKenna NJ, Lanz RB, O'Malley BW. 1999. Nuclear receptor coregulators: cellular and molecular 
biology. Endocr Rev 20(3):321-344. 
Miksicek R, Borgmeyer U, Nowock J. 1987. Interaction of the TGGCA-binding protein with upstream 
sequences is required for efficient transcription of mouse mammary tumor virus. Embo J 
6(5):1355-1360. 
Millar RP. 2003. GnRH II and type II GnRH receptors. Trends Endocrinol Metab 14(1):35-43. 
Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. 2004. Gonadotropin-releasing 
hormone receptors. Endocr Rev 25(2):235-275. 
Miller AL, Garza AS, Johnson BH, Thompson EB. 2007. Pathway interactions between MAPKs, 
mTOR, PKA, and the glucocorticoid receptor in lymphoid cells. Cancer Cell Int 7:3. 
Miller AL, Webb MS, Copik AJ, Wang Y, Johnson BH, Kumar R, Thompson EB. 2005. p38 Mitogen-
activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of p: 
correlation between p38 MAPK activation and site-specific phosphorylation of the human 
glucocorticoid receptor at serine 211. Mol Endocrinol 19(6):1569-1583. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
wn
 181 
Milligan G. 2001. Oligomerisation of G-protein-coupled receptors. J Cell Sci 114(Pt 7):1265-1271. 
Miner JN, Yamamoto KR. 1992. The basic region of AP-1 specifies glucocorticoid receptor activity at a 
composite response element. Genes Dev 6(12B):2491-2501. 
Mittelstadt PR, Ashwell JD. 2001. Inhibition of AP-1 by the glucocorticoid-inducible protein GILZ. J Biol 
Chem 276(31):29603-29610. 
Moffett S, Brown DA, Linder ME. 2000. Lipid-dependent targeting of G proteins into rafts. J Biol Chem 
275(3):2191-2198. 
Montagnani Marelli M, Moretti RM, Mai S, Procacci P, Limonta P. 2007. Gonadotropin-releasing 
hormone agonists reduce the migratory and the invasive behavior of androgen-independent 
prostate cancer cells by interfering with the activity of IGF-I. Int J Oncol 30(1):261-271. 
Monte D, DeWitte F, Hum DW. 1998. Regulation of the human P450scc gene by steroidogenic factor 
1 is mediated by CBP/p300. J Biol Chem 273(8):4585-4591. 
Moore FL, Orchinik M. 1994. Membrane receptors for corticosterone: a mechanism for rapid 
behavioral responses in an amphibian. Horm Behav 28(4):512-519. 
Moore FL, Orchinik M, Lowry C. 1995. Functional studies of corticosterone receptors in neuronal 
membranes. Receptor 5(1):21-28. 
Morales P. 1998. Gonadotropin-releasing hormone increases ability of the spermatozoa to bind to the 
human zona pellucida. Biol Reprod 59(2):426-430. 
Moretti RM, Marelli MM, Dondi D, Poletti A, Martini L, Motta M, Limonta P. 1996. Luteinizing hormone-
releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in 
human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab 81(11):3930-
3937. 
Morgan K, Conklin D, Pawson AJ, Sellar R, Ott TR, Millar RP. 2003. A transcriptionally active human 
type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the 
antisense orientation on chromosome 1q.12. Endocrinology 144(2):423-436. 
Morrill GA, Kostellow AB. 1999. Progesterone induces meiotic division in the amphibian oocyte by 
releasing lipid second messengers from the plasma membrane. Steroids 64(1-2):157-167. 
Moutsatsou P, Papavassiliou AG. 2008. The glucocorticoid receptor signalling in breast cancer. J Cell 
Mol Med 12(1):145-163. 
Un
ive
rsi
ty 
f C
ap
e T
ow
n
 182 
Mukaida N, Morita M, Ishikawa Y, Rice N, Okamoto S, Kasahara T, Matsushima K. 1994. Novel 
mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for 
glucocorticoid-mediated interleukin 8 gene repression. J Biol Chem 269(18):13289-13295. 
Mulvaney JM, Zhang T, Fewtrell C, Roberson MS. 1999. Calcium influx through L-type channels is 
required for selective activation of extracellular signal-regulated kinase by gonadotropin-
releasing hormone. J Biol Chem 274(42):29796-29804. 
Naor Z. 1990. Signal transduction mechanisms of Ca2+ mobilizing hormones: the case of 
gonadotropin-releasing hormone. Endocr Rev 11(2):326-353. 
Naor Z. 2009. Signaling by G-protein-coupled receptor (GPCR): studies on the GnRH receptor. Front 
Neuroendocrinol 30(1):10-29. 
Naor Z, Azrad A, Limor R, Zakut H, Lotan M. 1986. Gonadotropin-releasing hormone activates a rapid 
Ca2+-independent phosphodiester hydrolysis of polyphosphoinositides in pituitary 
gonadotrophs. J Biol Chem 261(27):12506-12512. 
Naor Z, Benard O, Seger R. 2000. Activation of MAPK cascades by G-protein-coupled receptors: the 
case of gonadotropin-releasing hormone receptor. Trends Endocrinol Metab 11(3):91-99. 
Naor Z, Jabbour HN, Naidich M, Pawson AJ, Morgan K, Battersby S, Millar MR, Brown P, Millar RP. 
2007. Reciprocal cross talk between gonadotropin-releasing hormone (GnRH) and 
prostaglandin receptors regulates GnRH receptor expression and differential gonadotropin 
secretion. Mol Endocrinol 21(2):524-537. 
Navratil AM, Bliss SP, Berghorn KA, Haughian JM, Farmerie TA, Graham JK, Clay CM, Roberson MS. 
2003. Constitutive localization of the gonadotropin-releasing hormone (GnRH) receptor to low 
density membrane microdomains is necessary for GnRH signaling to ERK. J Biol Chem 
278(34):31593-31602. 
Neill JD. 2002. GnRH and GnRH receptor genes in the human genome. Endocrinology 143(3):737-
743. 
Neves SR, Ram PT, Iyengar R. 2002. G protein pathways. Science 296(5573):1636-1639. 
Newton R, Holden NS. 2007. Separating transrepression and transactivation: a distressing divorce for 
the glucocorticoid receptor? Mol Pharmacol 72(4):799-809. 
U
ive
rsi
ty 
of 
Ca
pe
 To
wn
 183 
Nissen RM, Yamamoto KR. 2000. The glucocorticoid receptor inhibits NFkappaB by interfering with 
serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 
14(18):2314-2329. 
Nordeen SK, Suh BJ, Kuhnel B, Hutchison CA, 3rd. 1990. Structural determinants of a glucocorticoid 
receptor recognition element. Mol Endocrinol 4(12):1866-1873. 
Norwitz ER, Cardona GR, Jeong KH, Chin WW. 1999a. Identification and characterization of the 
gonadotropin-releasing hormone response elements in the mouse gonadotropin-releasing 
hormone receptor gene. J Biol Chem 274(2):867-880. 
Norwitz ER, Jeong KH, Chin WW. 1999b. Molecular mechanisms of gonadotropin-releasing hormone 
receptor gene regulation. J Soc Gynecol Investig 6(4):169-178. 
Norwitz ER, Xu S, Jeong KH, Bedecarrats GY, Winebrenner LD, Chin WW, Kaiser UB. 2002a. Activin 
A augments GnRH-mediated transcriptional activation of the mouse GnRH receptor gene. 
Endocrinology 143(3):985-997. 
Norwitz ER, Xu S, Xu J, Spiryda LB, Park JS, Jeong KH, McGee EA, Kaiser UB. 2002b. Direct binding 
of AP-1 (Fos/Jun) proteins to a SMAD binding element facilitates both gonadotropin-releasing 
hormone (GnRH)- and activin-mediated transcriptional activation of the mouse GnRH receptor 
gene. J Biol Chem 277(40):37469-37478. 
Orchinik M, Moore FL, Rose JD. 1994. Mechanistic and functional studies of rapid corticosteroid 
actions. Ann N Y Acad Sci 746:101-112; discussion 112-104. 
Orti E, Mendel DB, Smith LI, Munck A. 1989. Agonist-dependent phosphorylation and nuclear 
dephosphorylation of glucocorticoid receptors in intact cells. J Biol Chem 264(17):9728-9731. 
Ostrom RS, Post SR, Insel PA. 2000. Stoichiometry and compartmentation in G protein-coupled 
receptor signaling: implications for therapeutic interventions involving G(s). J Pharmacol Exp 
Ther 294(2):407-412. 
Overbergh L, Valckx D, Waer M, Mathieu C. 1999. Quantification of murine cytokine mRNAs using 
real time quantitative reverse transcriptase PCR. Cytokine 11(4):305-312. 
Padmanabhan V, Keech C, Convey EM. 1983. Cortisol inhibits and adrenocorticotropin has no effect 
on luteinizing hormone-releasing hormone-induced release of luteinizing hormone from bovine 
pituitary cells in vitro. Endocrinology 112(5):1782-1787. 
U
ive
rsi
ty 
of 
Ca
pe
 To
wn
 184 
Pawson AJ, Morgan K, Maudsley SR, Millar RP. 2003. Type II gonadotrophin-releasing hormone 
(GnRH-II) in reproductive biology. Reproduction 126(3):271-278. 
Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. 2001. Mitogen-
activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 
22(2):153-183. 
Pelaia G, Cuda G, Vatrella A, Grembiale RD, De Sarro G, Maselli R, Costanzo FS, Avvedimento VE, 
Rotiroti D, Marsico SA. 2001. Effects of glucocorticoids on activation of c-jun N-terminal, 
extracellular signal-regulated, and p38 MAP kinases in human pulmonary endothelial cells. 
Biochem Pharmacol 62(12):1719-1724. 
Perissi V, Rosenfeld MG. 2005. Controlling nuclear receptors: the circular logic of cofactor cycles. Nat 
Rev Mol Cell Biol 6(7):542-554. 
Pernasetti F, Vasilyev VV, Rosenberg SB, Bailey JS, Huang HJ, Miller WL, Mellon PL. 2001. Cell-
specific transcriptional regulation of follicle-stimulating hormone-beta by activin and 
gonadotropin-releasing hormone in the LbetaT2 pituitary gonadotrope cell model. 
Endocrinology 142(6):2284-2295. 
Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic 
Acids Res 29(9):e45. 
Picard D, Yamamoto KR. 1987. Two signals mediate hormone-dependent nuclear localization of the 
glucocorticoid receptor. Embo J 6(11):3333-3340. 
Pierson-Mullany LK, Lange CA. 2004. Phosphorylation of progesterone receptor serine 400 mediates 
ligand-independent transcriptional activity in response to activation of cyclin-dependent protein 
kinase 2. Mol Cell Biol 24(24):10542-10557. 
Pincas H, Amoyel K, Counis R, Laverriere JN. 2001. Proximal cis-acting elements, including 
steroidogenic factor 1, mediate the efficiency of a distal enhancer in the promoter of the rat 
gonadotropin-releasing hormone receptor gene. Mol Endocrinol 15(2):319-337. 
Powell CE, Watson CS, Gametchu B. 1999. Immunoaffinity isolation of native membrane 
glucocorticoid receptor from S-49++ lymphoma cells: biochemical characterization and 
interaction with Hsp 70 and Hsp 90. Endocrine 10(3):271-280. 
Pratt WB, Gehring U, Toft DO. 1996. Molecular chaperoning of steroid hormone receptors. Exs 77:79-
95. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 185 
Pratt WB, Toft DO. 1997. Steroid receptor interactions with heat shock protein and immunophilin 
chaperones. Endocr Rev 18(3):306-360. 
Qi AQ, Qiu J, Xiao L, Chen YZ. 2005. Rapid activation of JNK and p38 by glucocorticoids in primary 
cultured hippocampal cells. J Neurosci Res 80(4):510-517. 
Qiu J, Lou LG, Huang XY, Lou SJ, Pei G, Chen YZ. 1998. Nongenomic mechanisms of glucocorticoid 
inhibition of nicotine-induced calcium influx in PC12 cells: involvement of protein kinase C. 
Endocrinology 139(12):5103-5108. 
Raga F, Casan EM, Kruessel JS, Wen Y, Huang HY, Nezhat C, Polan ML. 1998. Quantitative 
gonadotropin-releasing hormone gene expression and immunohistochemical localization in 
human endometrium throughout the menstrual cycle. Biol Reprod 59(3):661-669. 
Rama S, Rao AJ. 2001. Embryo implantation and GnRH antagonists: the search for the human 
placental GnRH receptor. Hum Reprod 16(2):201-205. 
Rani CS, Elango N, Wang SS, Kobayashi K, Strong R. 2009. Identification of an activator protein-1-
like sequence as the glucocorticoid response element in the rat tyrosine hydroxylase gene. 
Mol Pharmacol 75(3):589-598. 
Ray A, LaForge KS, Sehgal PB. 1991. Repressor to activator switch by mutations in the first Zn finger 
of the glucocorticoid receptor: is direct DNA binding necessary? Proc Natl Acad Sci U S A 
88(16):7086-7090. 
Razandi M, Oh P, Pedram A, Schnitzer J, Levin ER. 2002. ERs associate with and regulate the 
production of caveolin: implications for signaling and cellular actions. Mol Endocrinol 
16(1):100-115. 
Razandi M, Pedram A, Greene GL, Levin ER. 1999. Cell membrane and nuclear estrogen receptors 
(ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese 
hamster ovary cells. Mol Endocrinol 13(2):307-319. 
Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich 
P, Angel P, Schutz G. 1998. DNA binding of the glucocorticoid receptor is not essential for 
survival. Cell 93(4):531-541. 
Reichardt HM, Tuckermann JP, Gottlicher M, Vujic M, Weih F, Angel P, Herrlich P, Schutz G. 2001. 
Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid 
receptor. Embo J 20(24):7168-7173. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 186 
Reinhart J, Mertz LM, Catt KJ. 1992. Molecular cloning and expression of cDNA encoding the murine 
gonadotropin-releasing hormone receptor. J Biol Chem 267(30):21281-21284. 
Reinhart J, Xiao S, Arora KK, Catt KJ. 1997. Structural organization and characterization of the 
promoter region of the rat gonadotropin-releasing hormone receptor gene. Mol Cell Endocrinol 
130(1-2):1-12. 
Reiss N, Llevi LN, Shacham S, Harris D, Seger R, Naor Z. 1997. Mechanism of mitogen-activated 
protein kinase activation by gonadotropin-releasing hormone in the pituitary of alphaT3-1 cell 
line: differential roles of calcium and protein kinase C. Endocrinology 138(4):1673-1682. 
Reyes FI, Winter JS, Faiman C. 1976. Pituitary gonadotropin function during human pregnancy: serum 
FSH and LH levels before and after LHRH administration. J Clin Endocrinol Metab 42(3):590-
592. 
Rhen T, Cidlowski JA. 2005. Antiinflammatory action of glucocorticoids--new mechanisms for old 
drugs. N Engl J Med 353(16):1711-1723. 
Rivier C, Rivest S. 1991. Effect of stress on the activity of the hypothalamic-pituitary-gonadal axis: 
peripheral and central mechanisms. Biol Reprod 45(4):523-532. 
Roberson MS, Bliss SP, Xie J, Navratil AM, Farmerie TA, Wolfe MW, Clay CM. 2005. Gonadotropin-
releasing hormone induction of extracellular-signal regulated kinase is blocked by inhibition of 
calmodulin. Mol Endocrinol 19(9):2412-2423. 
Roberson MS, Zhang T, Li HL, Mulvaney JM. 1999. Activation of the p38 mitogen-activated protein 
kinase pathway by gonadotropin-releasing hormone. Endocrinology 140(3):1310-1318. 
Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. 2000a. Receptors for dopamine 
and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 
288(5463):154-157. 
Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC. 2000b. Subtypes of the somatostatin 
receptor assemble as functional homo- and heterodimers. J Biol Chem 275(11):7862-7869. 
Rogatsky I, Logan SK, Garabedian MJ. 1998. Antagonism of glucocorticoid receptor transcriptional 
activation by the c-Jun N-terminal kinase. Proc Natl Acad Sci U S A 95(5):2050-2055. 
Rogatsky I, Luecke HF, Leitman DC, Yamamoto KR. 2002. Alternate surfaces of transcriptional 
coregulator GRIP1 function in different glucocorticoid receptor activation and repression 
contexts. Proc Natl Acad Sci U S A 99(26):16701-16706. 
U
ive
rsi
ty 
of 
Ca
pe
 To
wn
 187 
Rogatsky I, Wang JC, Derynck MK, Nonaka DF, Khodabakhsh DB, Haqq CM, Darimont BD, 
Garabedian MJ, Yamamoto KR. 2003. Target-specific utilization of transcriptional regulatory 
surfaces by the glucocorticoid receptor. Proc Natl Acad Sci U S A 100(24):13845-13850. 
Rogatsky I, Zarember KA, Yamamoto KR. 2001. Factor recruitment and TIF2/GRIP1 corepressor 
activity at a collagenase-3 response element that mediates regulation by phorbol esters and 
hormones. Embo J 20(21):6071-6083. 
Ronacher K, Hadley K, Avenant C, Stubsrud E, Simons SS, Jr., Louw A, Hapgood JP. 2009. Ligand-
selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor 
interaction. Mol Cell Endocrinol 299(2):219-231. 
Rosen H, Dalkin A, Haisenleder D, Friberg RD, Ortolano G, Barkan A. 1991. Dexamethasone alters 
responses of pituitary gonadotropin-releasing hormone (GnRH) receptors, gonadotropin 
subunit messenger ribonucleic acids, and gonadotropins to pulsatile GnRH in male rats. 
Endocrinology 128(2):654-660. 
Rosenfeld MG, Lunyak VV, Glass CK. 2006. Sensors and signals: a 
coactivator/corepressor/epigenetic code for integrating signal-dependent programs of 
transcriptional response. Genes Dev 20(11):1405-1428. 
Rubinstein LM, Parlow AF, Derzko C, Hershman J. 1978. Pituitary gonadotropin response to LHRH in 
human pregnancy. Obstet Gynecol 52(2):172-175. 
Rybin VO, Xu X, Lisanti MP, Steinberg SF. 2000. Differential targeting of beta -adrenergic receptor 
subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally 
regulate the cAMP signaling pathway. J Biol Chem 275(52):41447-41457. 
Sadie H. 2006. Transcriptional regulation of the mouse gonadotropin-releasing hormone receptor 
gene in pituitary gonadotrope cell lines. PhD thesis University of Stellenbosch, Stellenbosch, 
South Africa. 
Sadie H, Styger G, Hapgood J. 2003. Expression of the mouse gonadotropin-releasing hormone 
receptor gene in alpha T3-1 gonadotrope cells is stimulated by cyclic 3',5'-adenosine 
monophosphate and protein kinase A, and is modulated by Steroidogenic factor-1 and Nur77. 
Endocrinology 144(5):1958-1971. 
Sakamoto Y, Harada T, Horie S, Iba Y, Taniguchi F, Yoshida S, Iwabe T, Terakawa N. 2003. Tumor 
necrosis factor-alpha-induced interleukin-8 (IL-8) expression in endometriotic stromal cells, 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 188 
probably through nuclear factor-kappa B activation: gonadotropin-releasing hormone agonist 
treatment reduced IL-8 expression. J Clin Endocrinol Metab 88(2):730-735. 
Sakurai H, Adams BM, Adams TE. 1997. Concentration of GnRH receptor and GnRH receptor mRNA 
in pituitary tissue of orchidectomized sheep: effect of oestradiol, progesterone, and 
progesterone withdrawal. J Endocrinol 152(1):91-98. 
Salahpour A, Angers S, Bouvier M. 2000. Functional significance of oligomerization of G-protein-
coupled receptors. Trends Endocrinol Metab 11(5):163-168. 
Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular Cloning, a laboratory manual, 2nd edition. Cold 
Spring Harbor Laboratory Press. 
Santoso B, Kadonaga JT. 2006. Reconstitution of chromatin transcription with purified components 
reveals a chromatin-specific repressive activity of p300. Nat Struct Mol Biol 13(2):131-139. 
Sasson R, Luu SH, Thackray VG, Mellon PL. 2008. Glucocorticoids induce human glycoprotein 
hormone alpha-subunit gene expression in the gonadotrope. Endocrinology 149(7):3643-
3655. 
Sasson R, Shinder V, Dantes A, Land A, Amsterdam A. 2003. Activation of multiple signal 
transduction pathways by glucocorticoids: protection of ovarian follicular cells against 
apoptosis. Biochem Biophys Res Commun 311(4):1047-1056. 
Savkur RS, Burris TP. 2004. The coactivator LXXLL nuclear receptor recognition motif. J Pept Res 
63(3):207-212. 
Savoy-Moore RT, Schwartz NB, Duncan JA, Marshall JC. 1980. Pituitary gonadotropin-releasing 
hormone receptors during the rat estrous cycle. Science 209(4459):942-944. 
Sayeski PP, Ali MS, Frank SJ, Bernstein KE. 2001. The angiotensin II-dependent nuclear 
translocation of Stat1 is mediated by the Jak2 protein motif 231YRFRR. J Biol Chem 
276(13):10556-10563. 
Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS, Jr. 1995a. Role of transcriptional activation of I 
kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 
270(5234):283-286. 
Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS, Jr. 1995b. Characterization of 
mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. 
Mol Cell Biol 15(2):943-953. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 189 
Schreihofer DA, Stoler MH, Shupnik MA. 2000. Differential expression and regulation of estrogen 
receptors (ERs) in rat pituitary and cell lines: estrogen decreases ERalpha protein and 
estrogen responsiveness. Endocrinology 141(6):2174-2184. 
Schule R, Rangarajan P, Kliewer S, Ransone LJ, Bolado J, Yang N, Verma IM, Evans RM. 1990. 
Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 
62(6):1217-1226. 
Seminara SB, Hayes FJ, Crowley WF, Jr. 1998. Gonadotropin-releasing hormone deficiency in the 
human (idiopathic hypogonadotropic hypogonadism and Kallmann's syndrome): 
pathophysiological and genetic considerations. Endocr Rev 19(5):521-539. 
Shaul PW. 1999. Rapid activation of endothelial nitric oxide synthase by estrogen. Steroids 64(1-
2):28-34. 
Shaul PW, Anderson RG. 1998. Role of plasmalemmal caveolae in signal transduction. Am J Physiol 
275(5 Pt 1):L843-851. 
Shupnik MA. 1996. Gonadal hormone feedback on pituitary gonadotropin genes. Trends Endocrinol 
Metab 7(8):272-276. 
Sim PJ, Wolbers WB, Mitchell R. 1995. Activation of MAP kinase by the LHRH receptor through a dual 
mechanism involving protein kinase C and a pertussis toxin-sensitive G protein. Mol Cell 
Endocrinol 112(2):257-263. 
Singh VB, Moudgil VK. 1984. Protein kinase activity of purified rat liver glucocorticoid receptor. 
Biochem Biophys Res Commun 125(3):1067-1073. 
Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M. 1991. Oncogenic and transcriptional cooperation 
with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature 354(6353):494-
496. 
Smith CL, Onate SA, Tsai MJ, O'Malley BW. 1996. CREB binding protein acts synergistically with 
steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc Natl 
Acad Sci U S A 93(17):8884-8888. 
So AY, Chaivorapol C, Bolton EC, Li H, Yamamoto KR. 2007. Determinants of cell- and gene-specific 
transcriptional regulation by the glucocorticoid receptor. PLoS Genet 3(6):e94. 
Solito E, Mulla A, Morris JF, Christian HC, Flower RJ, Buckingham JC. 2003. Dexamethasone induces 
rapid serine-phosphorylation and membrane translocation of annexin 1 in a human 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 190 
folliculostellate cell line via a novel nongenomic mechanism involving the glucocorticoid 
receptor, protein kinase C, phosphatidylinositol 3-kinase, and mitogen-activated protein 
kinase. Endocrinology 144(4):1164-1174. 
Song CZ, Tian X, Gelehrter TD. 1999. Glucocorticoid receptor inhibits transforming growth factor-beta 
signaling by directly targeting the transcriptional activation function of Smad3. Proc Natl Acad 
Sci U S A 96(21):11776-11781. 
Song IH, Buttgereit F. 2006. Non-genomic glucocorticoid effects to provide the basis for new drug 
developments. Mol Cell Endocrinol 246(1-2):142-146. 
Sowers JR, Colantino M, Fayez J, Jonas H. 1978. Pituitary response to LHRH in midtrimester 
pregnancy. Obstet Gynecol 52(6):685-688. 
Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, 
Tsai MJ, O'Malley BW. 1997. Steroid receptor coactivator-1 is a histone acetyltransferase. 
Nature 389(6647):194-198. 
Spiegelman BM, Heinrich R. 2004. Biological control through regulated transcriptional coactivators. 
Cell 119(2):157-167. 
Stanislaus D, Ponder S, Ji TH, Conn PM. 1998. Gonadotropin-releasing hormone receptor couples to 
multiple G proteins in rat gonadotrophs and in GGH3 cells: evidence from palmitoylation and 
overexpression of G proteins. Biol Reprod 59(3):579-586. 
Stellato C. 2004. Post-transcriptional and nongenomic effects of glucocorticoids. Proc Am Thorac Soc 
1(3):255-263. 
Stephens LR, Eguinoa A, Erdjument-Bromage H, Lui M, Cooke F, Coadwell J, Smrcka AS, Thelen M, 
Cadwallader K, Tempst P, Hawkins PT. 1997. The G beta gamma sensitivity of a PI3K is 
dependent upon a tightly associated adaptor, p101. Cell 89(1):105-114. 
Sterner DE, Berger SL. 2000. Acetylation of histones and transcription-related factors. Microbiol Mol 
Biol Rev 64(2):435-459. 
Stoecklin E, Wissler M, Moriggl R, Groner B. 1997. Specific DNA binding of Stat5, but not of 
glucocorticoid receptor, is required for their functional cooperation in the regulation of gene 
transcription. Mol Cell Biol 17(11):6708-6716. 
Stojilkovic SS, Catt KJ. 1995. Novel aspects of GnRH-induced intracellular signaling and secretion in 
pituitary gonadotrophs. J Neuroendocrinol 7(10):739-757. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 191 
Stossi F, Madak-Erdogan Z, Katzenellenbogen BS. 2009. Estrogen receptor alpha represses 
transcription of early target genes via p300 and CtBP1. Mol Cell Biol 29(7):1749-1759. 
Strahle U, Klock G, Schutz G. 1987. A DNA sequence of 15 base pairs is sufficient to mediate both 
glucocorticoid and progesterone induction of gene expression. Proc Natl Acad Sci U S A 
84(22):7871-7875. 
Stromstedt PE, Poellinger L, Gustafsson JA, Carlstedt-Duke J. 1991. The glucocorticoid receptor 
binds to a sequence overlapping the TATA box of the human osteocalcin promoter: a potential 
mechanism for negative regulation. Mol Cell Biol 11(6):3379-3383. 
Sturgill TW, Ray LB, Erikson E, Maller JL. 1988. Insulin-stimulated MAP-2 kinase phosphorylates and 
activates ribosomal protein S6 kinase II. Nature 334(6184):715-718. 
Suh BC, Kim JS, Namgung U, Han S, Kim KT. 2001. Selective inhibition of beta(2)-adrenergic 
receptor-mediated cAMP generation by activation of the P2Y(2) receptor in mouse pineal 
gland tumor cells. J Neurochem 77(6):1475-1485. 
Sun Y, Cheng Z, Ma L, Pei G. 2002. Beta-arrestin2 is critically involved in CXCR4-mediated 
chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J Biol Chem 
277(51):49212-49219. 
Sundaresan S, Colin IM, Pestell RG, Jameson JL. 1996. Stimulation of mitogen-activated protein 
kinase by gonadotropin-releasing hormone: evidence for the involvement of protein kinase C. 
Endocrinology 137(1):304-311. 
Swantek JL, Cobb MH, Geppert TD. 1997. Jun N-terminal kinase/stress-activated protein kinase 
(JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha 
(TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. 
Mol Cell Biol 17(11):6274-6282. 
Tanaka H, Makino Y, Miura T, Hirano F, Okamoto K, Komura K, Sato Y, Makino I. 1996. Ligand-
independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of 
IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent 
pathway. J Immunol 156(4):1601-1608. 
Tasker JG, Di S, Malcher-Lopes R. 2006. Minireview: rapid glucocorticoid signaling via membrane-
associated receptors. Endocrinology 147(12):5549-5556. 
U
ive
rsi
ty 
of 
Ca
pe
 To
wn
 192 
Teurich S, Angel P. 1995. The glucocorticoid receptor synergizes with Jun homodimers to activate AP-
1-regulated promoters lacking GR binding sites. Chem Senses 20(2):251-255. 
Thackray VG, McGillivray SM, Mellon PL. 2006. Androgens, progestins, and glucocorticoids induce 
follicle-stimulating hormone beta-subunit gene expression at the level of the gonadotrope. Mol 
Endocrinol 20(9):2062-2079. 
Thomas P, Pang Y, Dong J, Groenen P, Kelder J, de Vlieg J, Zhu Y, Tubbs C. 2007. Steroid and G 
protein binding characteristics of the seatrout and human progestin membrane receptor alpha 
subtypes and their evolutionary origins. Endocrinology 148(2):705-718. 
Tibolt RE, Childs GV. 1985. Cytochemical and cytophysiological studies of gonadotropin-releasing 
hormone (GnRH) target cells in the male rat pituitary: differential effects of androgens and 
corticosterone on GnRH binding and gonadotropin release. Endocrinology 117(1):396-404. 
Tilbrook AJ, Turner AI, Clarke IJ. 2000. Effects of stress on reproduction in non-rodent mammals: the 
role of glucocorticoids and sex differences. Rev Reprod 5(2):105-113. 
Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG. 1997. The 
transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 
387(6634):677-684. 
Touray M, Ryan F, Jaggi R, Martin F. 1991. Characterisation of functional inhibition of the 
glucocorticoid receptor by Fos/Jun. Oncogene 6(7):1227-1234. 
Treisman R. 1995. Journey to the surface of the cell: Fos regulation and the SRE. Embo J 
14(20):4905-4913. 
Tsutsumi M, Laws SC, Rodic V, Sealfon SC. 1995. Translational regulation of the gonadotropin-
releasing hormone receptor in alpha T3-1 cells. Endocrinology 136(3):1128-1136. 
Tsutsumi M, Laws SC, Sealfon SC. 1993. Homologous up-regulation of the gonadotropin-releasing 
hormone receptor in alpha T3-1 cells is associated with unchanged receptor messenger RNA 
(mRNA) levels and altered mRNA activity. Mol Endocrinol 7(12):1625-1633. 
Tsutsumi M, Zhou W, Millar RP, Mellon PL, Roberts JL, Flanagan CA, Dong K, Gillo B, Sealfon SC. 
1992. Cloning and functional expression of a mouse gonadotropin-releasing hormone 
receptor. Mol Endocrinol 6(7):1163-1169. 
U
ive
rsi
ty 
of 
Ca
pe
 To
wn
 193 
Tuckermann JP, Reichardt HM, Arribas R, Richter KH, Schutz G, Angel P. 1999. The DNA binding-
independent function of the glucocorticoid receptor mediates repression of AP-1-dependent 
genes in skin. J Cell Biol 147(7):1365-1370. 
Turgeon JL, Kimura Y, Waring DW, Mellon PL. 1996. Steroid and pulsatile gonadotropin-releasing 
hormone (GnRH) regulation of luteinizing hormone and GnRH receptor in a novel 
gonadotrope cell line. Mol Endocrinol 10(4):439-450. 
Turgeon JL, Waring DW. 1994. Activation of the progesterone receptor by the gonadotropin-releasing 
hormone self-priming signaling pathway. Mol Endocrinol 8(7):860-869. 
Turner R, Tjian R. 1989. Leucine repeats and an adjacent DNA binding domain mediate the formation 
of functional cFos-cJun heterodimers. Science 243(4899):1689-1694. 
Urbach V, Walsh DE, Mainprice B, Bousquet J, Harvey BJ. 2002. Rapid non-genomic inhibition of 
ATP-induced Cl- secretion by dexamethasone in human bronchial epithelium. J Physiol 545(Pt 
3):869-878. 
van Biljon W. 2006. The Mammalian Type II Gonadotropin-releasing Hormone Receptor: Cloning, 
Distribution and Role in Gondotropin gene expression. PhD thesis University of Stellenbosch, 
Stellenbosch, South Africa. 
van Biljon W, Wykes S, Scherer S, Krawetz SA, Hapgood J. 2002. Type II gonadotropin-releasing 
hormone receptor transcripts in human sperm. Biol Reprod 67(6):1741-1749. 
Vo N, Goodman RH. 2001. CREB-binding protein and p300 in transcriptional regulation. J Biol Chem 
276(17):13505-13508. 
Voegel JJ, Heine MJ, Tini M, Vivat V, Chambon P, Gronemeyer H. 1998. The coactivator TIF2 
contains three nuclear receptor-binding motifs and mediates transactivation through CBP 
binding-dependent and -independent pathways. Embo J 17(2):507-519. 
von Boetticher S. 2008. Investigating the Mechanism of Transcriptional Regulation of the 
Gonadotropin-Releasing Hormone Receptor (GnRHR) gene by Dexamethasone. MSc thesis 
University of Stellenbosch, Stellenbosch, South Africa. 
Waldegger S, Beisse F, Apfel H, Breit S, Kolb HA, Haussinger D, Lang F. 1995. Electrophysiological 
effects of progesterone on hepatocytes. Biochim Biophys Acta 1266(2):186-190. 
Wallace AD, Cidlowski JA. 2001. Proteasome-mediated glucocorticoid receptor degradation restricts 
transcriptional signaling by glucocorticoids. J Biol Chem 276(46):42714-42721. 
U
ive
rsi
ty 
of 
Ca
pe
 To
wn
 194 
Wang Y, Fortin J, Lamba P, Bonomi M, Persani L, Roberson MS, Bernard DJ. 2008. Activator protein-
1 and smad proteins synergistically regulate human follicle-stimulating hormone beta-promoter 
activity. Endocrinology 149(11):5577-5591. 
Wang Y, Tang Y, Teng L, Wu Y, Zhao X, Pei G. 2006. Association of beta-arrestin and TRAF6 
negatively regulates Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 7(2):139-
147. 
Wang Z, Chen W, Kono E, Dang T, Garabedian MJ. 2007. Modulation of glucocorticoid receptor 
phosphorylation and transcriptional activity by a C-terminal-associated protein phosphatase. 
Mol Endocrinol 21(3):625-634. 
Wang Z, Frederick J, Garabedian MJ. 2002. Deciphering the phosphorylation "code" of the 
glucocorticoid receptor in vivo. J Biol Chem 277(29):26573-26580. 
Webster JC, Jewell CM, Bodwell JE, Munck A, Sar M, Cidlowski JA. 1997. Mouse glucocorticoid 
receptor phosphorylation status influences multiple functions of the receptor protein. J Biol 
Chem 272(14):9287-9293. 
Weesner GD, Matteri RL. 1994. Rapid communication: nucleotide sequence of luteinizing hormone-
releasing hormone (LHRH) receptor cDNA in the pig pituitary. J Anim Sci 72(7):1911. 
Weigel NL, Moore NL. 2007. Steroid receptor phosphorylation: a key modulator of multiple receptor 
functions. Mol Endocrinol 21(10):2311-2319. 
White BR, Duval DL, Mulvaney JM, Roberson MS, Clay CM. 1999. Homologous regulation of the 
gonadotropin-releasing hormone receptor gene is partially mediated by protein kinase C 
activation of an activator protein-1 element. Mol Endocrinol 13(4):566-577. 
Wiegers GJ, Reul JM. 1998. Induction of cytokine receptors by glucocorticoids: functional and 
pathological significance. Trends Pharmacol Sci 19(8):317-321. 
Wieland S, Dobbeling U, Rusconi S. 1991. Interference and synergism of glucocorticoid receptor and 
octamer factors. Embo J 10(9):2513-2521. 
Windle JJ, Weiner RI, Mellon PL. 1990. Cell lines of the pituitary gonadotrope lineage derived by 
targeted oncogenesis in transgenic mice. Mol Endocrinol 4(4):597-603. 
Wissink S, van Heerde EC, Schmitz ML, Kalkhoven E, van der Burg B, Baeuerle PA, van der Saag 
PT. 1997. Distinct domains of the RelA NF-kappaB subunit are required for negative cross-talk 
and direct interaction with the glucocorticoid receptor. J Biol Chem 272(35):22278-22284. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 195 
Witherow DS, Garrison TR, Miller WE, Lefkowitz RJ. 2004. beta-Arrestin inhibits NF-kappaB activity by 
means of its interaction with the NF-kappaB inhibitor IkappaBalpha. Proc Natl Acad Sci U S A 
101(23):8603-8607. 
Wu JC, Sealfon SC, Miller WL. 1994. Gonadal hormones and gonadotropin-releasing hormone 
(GnRH) alter messenger ribonucleic acid levels for GnRH receptors in sheep. Endocrinology 
134(4):1846-1850. 
Wurmbach E, Yuen T, Ebersole BJ, Sealfon SC. 2001. Gonadotropin-releasing hormone receptor-
coupled gene network organization. J Biol Chem 276(50):47195-47201. 
Xu J, O'Malley BW. 2002. Molecular mechanisms and cellular biology of the steroid receptor 
coactivator (SRC) family in steroid receptor function. Rev Endocr Metab Disord 3(3):185-192. 
Yamamoto KR, Darimont BD, Wagner RL, Iniguez-Lluhi JA. 1998. Building transcriptional regulatory 
complexes: signals and surfaces. Cold Spring Harb Symp Quant Biol 63:587-598. 
Yang-Yen HF, Chambard JC, Sun YL, Smeal T, Schmidt TJ, Drouin J, Karin M. 1990. Transcriptional 
interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding 
due to direct protein-protein interaction. Cell 62(6):1205-1215. 
Yasin M, Dalkin AC, Haisenleder DJ, Kerrigan JR, Marshall JC. 1995. Gonadotropin-releasing 
hormone (GnRH) pulse pattern regulates GnRH receptor gene expression: augmentation by 
estradiol. Endocrinology 136(4):1559-1564. 
Yokoi T, Ohmichi M, Tasaka K, Kimura A, Kanda Y, Hayakawa J, Tahara M, Hisamoto K, Kurachi H, 
Murata Y. 2000. Activation of the luteinizing hormone beta promoter by gonadotropin-
releasing hormone requires c-Jun NH2-terminal protein kinase. J Biol Chem 275(28):21639-
21647. 
Yoon S, Seger R. 2006. The extracellular signal-regulated kinase: multiple substrates regulate diverse 
cellular functions. Growth Factors 24(1):21-44. 
Young LS, Naik SI, Clayton RN. 1984. Adenosine 3',5'-monophosphate derivatives increase 
gonadotropin-releasing hormone receptors in cultured pituitary cells. Endocrinology 
114(6):2114-2122. 
Zapatero-Caballero H, Sanchez-Franco F, Guerra-Perez N, Fernandez-Mendez C, Fernandez-
Vazquez G. 2003. Gonadotropin-releasing hormone receptor gene expression during pubertal 
development of male rats. Biol Reprod 68(5):1764-1770. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
wn
 196 
Zerial M, Toschi L, Ryseck RP, Schuermann M, Muller R, Bravo R. 1989. The product of a novel 
growth factor activated gene, fos B, interacts with JUN proteins enhancing their DNA binding 
activity. Embo J 8(3):805-813. 
Zhang JP, Wong CK, Lam CW. 2000. Role of caspases in dexamethasone-induced apoptosis and 
activation of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase in human 
eosinophils. Clin Exp Immunol 122(1):20-27. 
Zhou J, Cidlowski JA. 2005. The human glucocorticoid receptor: one gene, multiple proteins and 
diverse responses. Steroids 70(5-7):407-417. 
Zhou W, Sealfon SC. 1994. Structure of the mouse gonadotropin-releasing hormone receptor gene: 
variant transcripts generated by alternative processing. DNA Cell Biol 13(6):605-614. 
Zhu Y, Bond J, Thomas P. 2003a. Identification, classification, and partial characterization of genes in 
humans and other vertebrates homologous to a fish membrane progestin receptor. Proc Natl 
Acad Sci U S A 100(5):2237-2242. 
Zhu Y, Rice CD, Pang Y, Pace M, Thomas P. 2003b. Cloning, expression, and characterization of a 
membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish 
oocytes. Proc Natl Acad Sci U S A 100(5):2231-2236. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 T
wn
